rapport annuel - les annexes

Transcription

RAPPORT ANNUEL - LES ANNEXES
SOMMAIRE
03 ÉQUIPES DE RECHERCHE DE GUSTAVE ROUSSY
05 PUBLICATIONS À IMPACT FACTOR THOMSON REUTERS 2013 SUPÉRIEUR À 20
(51 PUBLICATIONS)
10 PUBLICATIONS À IMPACT FACTOR THOMSON REUTERS 2013 COMPRIS ENTRE 10 ET 20
(102 PUBLICATIONS)
19 PUBLICATIONS À IMPACT FACTOR THOMSON REUTERS 2014 COMPRIS ENTRE 5 ET 10
(324 PUBLICATIONS)
3
/ ÉQUIPES DE RECHERCHE
• TLS Polymérases et Cancer
Responsable : Patricia Kannouche
CNRS UMR 8200 - Stabilité génétique et oncogenèse,
Patricia Kannouche
• Protéomique et épigénétique
Responsable : Vasily Ogryzko
CNRS UMR 8126 - Signalisation, Noyaux et Innovations en
oncologie, Joëlle Wiels / Marc Lipinski
• Les voies de signalisation FANC/BRCA
et Cancers
Responsable : Filippo ROSSELLI
Patricia Kannouche
• Organisation nucléaire et modèles pathologiques
Responsables : Yegor Vassetzky / Marc Lipinski
• Recombination / Réparation et Cancer
Responsable : Bernard Lopez
Patricia Kannouche
• Oncogenèses et résistance à l’apoptose
dans les lymphomes B
Responsable : Joëlle Wiels
• Réparation de l’ADN
Responsable : Murat Saparbaev
Patricia Kannouche
• Intégrité du génome et microscopie moléculaire
Responsable : Éric Le Cam
• Division cellulaire et stabilité génomique
Responsable : Olivier Gavet
Patricia Kannouche
• Microenvironnement tumoral, exosomes
et microARN dans les tumeurs solides
Responsable : Pierre Busson
• Vectorologie des Acides Nucléiques
et des Médicaments Anticancéreux
Responsables : Lluis Mir / K. Benihoud
CNRS UMR 8203 - Laboratoire de Vectorologie et
Thérapeutiques anticancéreuses, Lluis Mir et K. Benihoud
• Nouvelles Thérapies Anticancéreuses
Responsable : Liliane Massade
CNRS UMR 8203 - Laboratoire de Vectorologie et
Thérapeutiques anticancéreuses, Lluis Mir et K. Benihoud
• Physiologie et Pathologie Moléculaires
des Rétrovirus Endogènes et Infectieux
Responsable : Thierry Heidmann
CNRS UMR 9196
• Trafic intracellulaire, complexes
macromoléculaires et cancer
Responsable : Svetlana Dokudovskaya
• Imagerie multimodale en cancérologie
Responsable : Nathalie Lassau
CNRS UMR 8081 - Imagerie par Résonance Magnétique Médicale
et Multi-Modalités (IR4M), Luc Darrasse et Nathalie Lassau
• Stades précoces de la transformation
hématopoïétique
Responsables : Olivier Bernard / Virginie Penardlacronique
Inserm UMR 1170 - Hématopoïèse normale et pathologique,
Olivier Bernard
• Des cellules souches hématopoïétiques
aux mégacoryocytes
Responsable : Hana Raslova
Olivier Bernard
• Génétique et modélisation des tumeurs malignes
pédiatriques
Responsable : Thomas Mercher
Olivier Bernard
4
• Des cellules souches hématopoïétiques aux monocytes
Responsables : Eric Solary / Françoise Porteu
Inserm UMR 1170 - Hématopoïèse normale et
pathologique, Olivier Bernard
• Biomarqueurs prédictifs
et nouvelles stratégies thérapeutiques en oncologie
Responsable : Fabrice André
Inserm UMR 981
• Stress réplicatif, instabilité génomique et mitose
Responsable : Valéria Naim
Patricia Kannouche
• Immunologie des tumeurs et immunothérapie
Responsable : Laurence Zitvogel
Inserm UMR 1015
• Méthodologie et épidémiologie clinique pour l’oncologie
moléculaire (équipe 2)
Responsable : Stephan Michiels
Centre de recherche en épidémiologie et en santé des
populations, Jean Bouyet
• Radiothérapie moléculaire
Responsables : Eric Deutsch et Jean-Luc Perfettini
Inserm UMR 1030
• Immunologie intégrative des tumeurs
Responsable : Fathia Mami-Chouaib / Salem CHOUAIB
Inserm UMR 1186
• Réparation des cassures double brin
et intégrité du génome
Responsable : Gérard Mazon - Equipe ATIP-AVENIR
Patricia Kannouche
• Invasion collective et morphogenèse épithéliale
Responsable : Fanny Jaulin - Equipe ATIP-AVENIR
CNRS UMR 8126 - Signalisation, Noyaux et Innovation en
oncologie, Joëlle Wiels
• Endocytose, cytosquelette et migration cellulaire
Responsable : Guillaume Montagnac - Equipe ATIPAVENIR
Inserm UMR 1170 - Hématopoïèse normale et
• Cellules souches hématopoïétiques normales et
cancéreuses : contrôles génétique et épigénétique
Responsable : Camille Lobry - Equipe ATIP-AVENIR
Inserm UMR 1170 - Hématopoïèse normale
• Rôle de la traduction d’ARNm dans la présentation
antigénique
Responsable : Sébastien Apcher - Equipe ATIP-AVENIR
Inserm UMR 1015 - Immunologie des tumeurs et
immunothérapie, Laurence Zitvogel
et
• Oncogenèse et progression tumorale du mélanome
Responsable : Medhi Khaled - Equipe ATIP-AVENIR
Inserm UMR 1186 - Immunologie intégrative des tumeurs,
Fathia Mami-Chouaib
• Epidémiologie des radiations, épidémiologie clinique
des cancers et survie (équipe 3)
Responsable : Florent de Vathaire
• Mode de vie, génétique et santé : études intégratives
et trans-générationnelles (équipe 9)
Responsable Marie-Christine Boutron-Ruault
• Management des organisations de santé
Responsable : Etienne Minvielle
EHESP - EA 7348
• Apoptose, cancer et immunité
Responsable : Guido Kroemer
Inserm / CNRS UMRS1138 Université Paris-Descartes
- Centre de Recherche des Cordeliers, Pascale Ferre /
Guido Kroemer
5
/ PUBLICATIONS INTERNATIONALES
GUSTAVE ROUSSY 2014
À IMPACT FACTOR THOMSON REUTERS 2013 SUPÉRIEUR À 20 (51 PUBLICATIONS)
1. André F., Bachelot T., Commo F., Campone M., Arnedos
M., Dieras V., Lacroix-Triki M., Lacroix L., Cohen P.,
Gentien D., Adélaide J., Dalenc F., Goncalves A., Levy
C., Ferrero J.M., Bonneterre J., Lefeuvre C., Jimenez
M., Filleron T., and Bonnefoi H. Comparative genomic
hybridisation array and DNA sequencing to direct
treatment of metastatic breast cancer : A multicentre,
prospective trial (SAFIR01/UNICANCER). [2014]
Lancet Oncology (15) 3 : 267-274. Impact factor :
24.725
2. André F., O’Regan R., Ozguroglu M., Toi M., Xu B.,
Jerusalem G., Masuda N., Wilks S., Arena F., Isaacs
C., Yap Y.S., Papai Z., Lang I., Armstrong A., Lerzo G.,
White M., Shen K., Litton J., Chen D., Zhang Y., Ali S.,
Taran T., and Gianni L. Everolimus for women with
trastuzumab-resistant, HER2-positive, advanced
breast cancer (BOLERO-3) : a randomised, doubleblind, placebo-controlled phase 3 trial. [2014]
24.725
3. André F., Gianni L., and Investigators B.O.L.E.
BOLERO-3 results : pharmacological activity or
pharmacokinetic effect? Reply. [2014] Lancet
Oncology (15) 8 : E304-E305. Impact factor : 24.725
4. Assie G., Letouze E., Fassnacht M., Jouinot A., Luscap
W., Barreau O., Omeiri H., Rodriguez S., Perlemoine
K., Rene-Corail F., Elarouci N., Sbiera S., Kroiss M.,
Allolio B., Waldmann J., Quinkler M., Mannelli M.,
Mantero F., Papathomas T., De Krijger R., Tabarin A.,
Kerlan V., Baudin E., Tissier F., Dousset B., Groussin
L., Amar L., Clauser E., Bertagna X., Ragazzon
B., Beuschlein F., Libe R., de Reynies A., and
Bertherat J. Integrated genomic characterization of
adrenocortical carcinoma. [2014] Nature Genetics
(46) 6 : 607-612. Impact factor : 29.648
5. Beelen R., Raaschou-Nielsen O., Stafoggia M.,
Andersen Z.J., Weinmayr G., Hoffmann B., Wolf K.,
Samoli E., Fischer P., Nieuwenhuijsen M., Vineis P.,
Xun W.W., Katsouyanni K., Dimakopoulou K., Oudin
A., Forsberg B., Modig L., Havulinna A.-S., Lanki T.,
Turunen A., Oftedal B., Nystad W., Nafstad P., De
Faire U., Pedersen N.-L., Östenson C.-G., Fratiglioni
L., Penell J., Korek M., Pershagen G., Eriksen K.T.,
Overvad K., Ellermann T., Eeftens M., Peeters P.H.,
Meliefste K., Wang M., Bueno-de-Mesquita B., Sugiri
D., Krämer U., Heinrich J.a., De Hoogh K., Key T.a.,
Peters A., Hampel R., Concin H.a., Nagel G., Ineichen
A.a.a., Schaffner E.a.a., Probst-Hensch N.a.a.,
Künzli N.a.a., Schindler C.a.a., Schikowski T.a.a.,
Adam M.a.a., Phuleria H.a.a., Vilier A.a.a.a., ClavelChapelon F.a.a.a., Declercq C.a., Grioni S.a., Krogh
V.a., Tsai M.Y., Ricceri F.a., Sacerdote C.a., Galassi
C.a., Migliore E.a., Ranzi A.a., Cesaroni G., Badaloni
C., Forastiere F., Tamayo I., Amiano P., Dorronsoro
M., Katsoulis M.a., Trichopoulou A.a., Brunekreef B.,
and Hoek G. Effects of long-term exposure to air
pollution on natural-cause mortality : An analysis
of 22 European cohorts within the multicentre
ESCAPE project. [2014] Lancet (383) 9919 : 785-795.
Impact factor : 39.207
6. Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y.,
Sternberg C.N., Higano C.S., Iversen P., Bhattacharya
S., Carles J., Chowdhury S., Davis I.D., de Bono J.S.,
Evans C.P., Fizazi K., Joshua A.M., Kim C.S., Kimura
G., Mainwaring P., Mansbach H., Miller K., Noonberg
S.B., Perabo F., Phung D., Saad F., Scher H.I., Taplin
M.E., Venner P.M., and Tombal B. Enzalutamide in
Metastatic Prostate Cancer before Chemotherapy.
[2014] The New England journal of medicine (371)
5 : 424-433. Impact factor : 54.420
7. Bidard F.C., Peeters D.J., Fehm T., Nolé F., GisbertCriado R., Mavroudis D., Grisanti S., Generali D.,
Garcia-Saenz J.A., Stebbing J., Caldas C., Gazzaniga
P., Manso L., Zamarchi R., de Lascoiti A.F., De MattosArruda L., Ignatiadis M., Lebofsky R., van Laere
S.J., Meier-Stiegen F., Sandri M.T., Vidal-Martinez
J., Politaki E., Consoli F., Bottini A., Diaz-Rubio E.,
Krell J., Dawson S.J., Raimondi C., Rutten A., Janni
W., Munzone E., Caranana V., Agelaki S., Almici C.,
Dirix L., Solomayer E.F., Zorzino L., Johannes H.,
Reis-Filho J.S., Pantel K., Pierga J.Y., and Michiels
S. Clinical validity of circulating tumour cells in
patients with metastatic breast cancer : a pooled
analysis of individual patient data. [2014] Lancet
Oncology (15) 4 : 406-414. Impact factor : 24.725
8. Boussemart L., Malka-Mahieu H., Girault I., Allard
D., Hemmingsson O., Tomasic G., Thomas M.,
Basmadjian C., Ribeiro N., Thuaud F., Mateus C.,
Routier E., Kamsu-Kom N., Agoussi S., Eggermont
A.M., Désaubry L., Robert C., and Vagner S. eIF4F
is a nexus of resistance to anti-BRAF and anti-MEK
cancer therapies. [2014] Nature (513) 7516 : 105105. Impact factor : 42.351
9. Brose M.S., Nutting C.M., Jarzab B., Elisei R.,
Siena S., Bastholt L., De La Fouchardiere C., Pacini
F., Paschke R., Shong Y.K., Sherman S.I., Smit
J.W.A., Chung J., Kappeler C., Pena C., Molnar
I., Schlumberger M.J., and Investigators D.E.C.I.
Sorafenib in radioactive iodine-refractory, locally
advanced or metastatic differentiated thyroid
cancer : a randomised, double-blind, phase 3 trial.
[2014] Lancet (384) 9940 : 319-328. Impact factor :
39.207
10. Burdett S., Rydzewska L.H.M., Tierney J.F., Auperin
A., Pignon J.P., Le Pechoux C., Le Chevalier T., and
Van Meerbeeck J. Preoperative chemotherapy for
6
non-small-cell lung cancer - Authors’ reply. [2014]
Lancet (384) 9939 : 233-233. Impact factor : 39.207
11. Burdett S., Rydzewska L.H.M., Tierney J.F., Auperin
A., Le Pechoux C., Le Chevalier T., Pignon J.P., and
Grp N.M.-A.C. Preoperative chemotherapy for nonsmall-cell lung cancer : a systematic review and
meta-analysis of individual participant data. [2014]
Lancet (383) 9928 : 1561-1571. Impact factor :
39.207
12. Caplin M.E., Pavel M., Cwikla J.B., Phan A.T., Raderer
M., Sedlackova E., Cadiot G., Wolin E.M., Capdevila J.,
Wall L., Rindi G., Langley A., Martinez S., Blumberg
J., and Ruszniewski P. Lanreotide in metastatic
enteropancreatic neuroendocrine tumors. [2014]
New England journal of medicine (371) 3 : 224-233.
13. Conroy T., Galais M.P., Raoul J.L., Bouche O.,
Gourgou-Bourgade S., Douillard J.Y., Étienne
P.L., Boige V., Martel-Lafay I., Michel P., LlacerMoscardo C., Francois E., Crehange G., Ben
Abdelghani M., Juzyna B., Bedenne L., and Adenis
A. Definitive chemoradiotherapy with FOLFOX
versus fluorouracil and cisplatin in patients with
oesophageal cancer (PRODIGE5/ACCORD17) : final
results of a randomised, phase 2/3 trial. [2014]
24.725
14. De Meerleer G., Khoo V., Escudier B., Joniau S., Bossi
A., Ost P., Briganti A., Fonteyne V., Van Vulpen M.,
Lumen N., Spahn M., and Mareel M. Radiotherapy for
renal-cell carcinoma. [2014] Lancet Oncology (15) 4 :
E170-E177. Impact factor : 24.725
15. De Ruysscher D., Faivre-Finn C., Le Pechoux
C., Peeters S., and Belderbos J. High-dose reirradiation following radical radiotherapy for nonsmall-cell lung cancer. [2014] Lancet Oncology (15)
13 : e620-e624. Impact factor : 24.725
16. Eggermont A.M.M., Spatz A., and Robert C.
Cutaneous melanoma. [2014] Lancet (383) 9919 :
816-827. Impact factor : 39.207
17. Fizazi K., Scher H.I., Miller K., Basch E., Sternberg
C.N., Cella D., Forer D., Hirmand M., and de Bono
J.S. Effect of enzalutamide on time to first skeletalrelated event, pain, and quality of life in men with
castration-resistant prostate cancer : results from
the randomised, phase 3 AFFIRM trial. [2014] Lancet
18. Fizazi K., Pagliaro L., Laplanche A., Fléchon A.,
Mardiak J., Geoffrois L., Kerbrat P., Chevreau C.,
Delva R., Rolland F., Theodore C., Roubaud G., Gravis
G., Eymard J.C., Malhaire J.P., Linassier C., Habibian
M., Martin A.L., Journeau F., Reckova M., Logothetis
C., and Culine S. Personalised chemotherapy based
on tumour marker decline in poor prognosis germcell tumours (GETUG 13) : a phase 3, multicentre,
randomised trial. [2014] Lancet Oncology (15) 13 :
1442-1450. Impact factor : 24.725
19. Fizazi K., Massard C., Bono P., Jones R., Kataja
V., James N., Garcia J.A., Protheroe A., Tammela
T.L., Elliott T., Mattila L., Aspegren J., Vuorela A.,
Langmuir P., Mustonen M., and Grp A.S. Activity
and safety of ODM-201 in patients with progressive
metastatic castration-resistant prostate cancer
(ARADES) : an open-label phase 1 dose-escalation
and randomised phase 2 dose expansion trial.
[2014] Lancet Oncology (15) 9 : 975-985. Impact
factor : 24.725
20. Flaherty K.T., Hennig M., Lee S.J., Ascierto P.A.,
Dummer R., Eggermont A.M.M., Hauschild A.,
Kefford R., Kirkwood J.M., Long G.V., Lorigan P.,
Mackensen A., McArthur G., O’Day S., Patel P.M.,
Robert C., and Schadendorf D. Surrogate endpoints
for overall survival in metastatic melanoma : a
meta-analysis of randomised controlled trials.
[2014] Lancet Oncology (15) 3 : 297-304. Impact
factor : 24.725
21. Galluzzi L., Pietrocola F., Levine B., and Kroemer G.
Metabolic Control of Autophagy. [2014] Cell (159) 6 :
1263-1276. Impact factor : 33.116
22. Galluzzi L., Pedro J.M.B.-S., and Kroemer G.
Organelle-specific initiation of cell death. [2014]
Nature CELL BIOLOGY (16) 8 : 728-736. Impact
factor : 20.058
23. Green D.R., Galluzzi L., and Kroemer G. Metabolic
control of cell death. [2014] Science (345) 6203 :
1250256-1250256. Impact factor : 31.477
24. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D.,
Hamid O., Gordon M.S., Sosman J.A., McDermott D.F.,
Powderly J.D., Gettinger S.N., Kohrt H.E.K., Horn L.,
Lawrence D.P., Rost S., Leabman M., Xiao Y., Mokatrin
A., Koeppen H., Hegde P.S., Mellman I., Chen D.S.,
and Hodi F.S. Predictive correlates of response to the
anti-PD-L1 antibody MPDL3280A in cancer patients.
[2014] Nature (515) 7528 : 563-567. Impact factor :
42.351
25. Hescot S., Vignaux O., and Goldwasser F. Pancreatic
atrophy from sorafenib. [2014] New England journal
of medicine (370) 2 : 186-186. Impact factor : 54.420
26. Kool M., Jones D.T.W., Jaeger N., Northcott P.A., Pugh
T.J., Hovestadt V., Piro R.M., Esparza L.A., Markant S.L.,
Remke M., Milde T., Bourdeaut F., Ryzhova M., Sturm
D., Pfaff E., Stark S., Hutter S., Seker-Cin H., Johann P.,
Bender S., Schmidt C., Rausch T., Shih D., Reimand J.,
Sieber L., Wittmann A., Linke L., Witt H., Weber U.D.,
7
Zapatka M., Koenig R., Beroukhim R., Bergthold G., van
Sluis P., Volckmann R., Koster J., Versteeg R., Schmidt
S., Wolf S., Lawerenz C., Bartholomae C.C., von Kalle
C., Unterberg A., Herold-Mende C., Hofer S., Kulozik
A.E., von Deimling A., Scheurlen W., Felsberg J.,
Reifenberger G., Hasselblatt M., Crawford J.R., Grant
G.A., Jabado N., Perry A., Cowdrey C., Croul S., Zadeh
G., Korbel J.O., Doz F., Delattre O., Bader G.D., McCabe
M.G., Collins V.P., Kieran M.W., Cho Y.J., Pomeroy S.L.,
Witt O., Brors B., Taylor M.D., Schueller U., Korshunov
A., Eils R., Wechsler-Reya R.J., Lichter P., and Pfister
S.M. Genome Sequencing of SHH Medulloblastoma
Predicts Genotype-Related Response to Smoothened
Inhibition. [2014] Cancer Cell (25) 3 : 393-405. Impact
factor : 23.893
27. Kwon E.D., Drake C.G., Scher H.I., Fizazi K., Bossi A.,
den Eertwegh A.J.M., Krainer M., Houede N., Santos
R., Mahammedi H., Ng S., Maio M., Franke F.A.,
Sundar S., Agarwal N., Bergman A.M., Ciuleanu T.E.,
Korbenfeld E., Sengeløv L., Hansen S., Logothetis
C., Beer T.M., McHenry M.B., Gagnier P., Liu D., and
Gerritsen W.R. Ipilimumab versus placebo after
radiotherapy in patients with metastatic castrationresistant prostate cancer that had progressed
after docetaxel chemotherapy (CA184-043) : A
multicentre, randomised, double-blind, phase
3 trial. [2014] Lancet Oncology (15) 7 : 700-712.
28. Lane A.A., Chapuy B., Lin C.Y., Tivey T., Li H.,
Townsend E.C., van Bodegom D., Day T.A., Wu S.C.,
Liu H., Yoda A., Alexe G., Schinzel A.C., Sullivan
T.J., Malinge S.Ã., Taylor J.E., Stegmaier K., Jaffe
J.D., Bustin M., te Kronnie G., Izraeli S., Harris
M.H., Stevenson K.E., Neuberg D., Silverman L.B.,
Sallan S.E., Bradner J.E., Hahn W.C., Crispino J.D.,
Pellman D., and Weinstock D.M. Triplication of a
21q22 region contributes to B cell transformation
through HMGN1 overexpression and loss of histone
H3 Lys27 trimethylation. [2014] Nature Genetics
(46) 6 : 618-623. Impact factor : 29.648
29. Lawler M., Le Chevalier T., Banks I., Conte P., De
Lorenzo F., Meunier F., Pinedo H.M., Selby P., Murphy
M.J., and Johnston P.G. A Bill of Rights for patients
with cancer in Europe. [2014] Lancet Oncology (15)
3 : 258-260. Impact factor : 24.725
30. Long G.V., Stroyakovskiy D., Gogas H.H., Levchenko
E.E., De Braud F.F., Larkin J., Garbe C.C., Jouary
T., Hauschild A., Grob J.J., Chiarion Sileni V.V.,
Lebbe C.C., Mandala M., Millward M., Arance A.A.,
Bondarenko I., Haanen J.B.A.G., Hansson J.J.,
Utikal J.J., Ferraresi V., Kovalenko N.N., Mohr P.,
Probachai V., Schadendorf D.D., Nathan P.P., Robert
C.C., Ribas A., DeMarini D.J., Irani J.G., Casey M.,
Ouellet D., Martin A.M., Le N., Patel K., and Flaherty
K. Combined BRAF and MEK inhibition versus BRAF
inhibition alone in melanoma. [2014] New England
journal of medicine (371) 20 : 1877-1888. Impact
factor : 54.420
31. Madeo F., Pietrocola F., Eisenberg T., and Kroemer G.
Caloric restriction mimetics : towards a molecular
definition. [2014] Nature reviews Drug discovery
(13) 10 : 727-740. Impact factor : 37.231
32. Malka D., Cervera P., Foulon S., Trarbach T., De
La Fouchardière C., Boucher E., Fartoux L., Faivre
S., Blanc J.F., Viret F., Assenat E., Seufferlein T.,
Herrmann T., Grenier J., Hammel P., Dollinger
M., Andre T., Hahn P., Heinemann V., Rousseau V.,
Ducreux M., Pignon J.P., Wendum D., Rosmorduc
O., and Greten T.F. Gemcitabine and oxaliplatin
with or without cetuximab in advanced biliary-tract
cancer (BINGO) : a randomised, open-label, noncomparative phase 2 trial. [2014] Lancet Oncology
(15) 8 : 819-828. Impact factor : 24.725
33. Marino G., Niso-Santano M., Baehrecke E.H., Kroemer
G.G., and Marino G. Self-consumption : the interplay
of autophagy and apoptosis. [2014] Nature Reviews
Molecular Cell Biology (15) 2 : 81-94. Impact factor :
36.458
34. McArthur G.A., Chapman P.B., Robert C., Larkin J.,
Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid
O., Ascierto P.A., Garbe C., Testori A., Maio M., Lorigan
P., Lebbé C., Jouary T., Schadendorf D., O’Day S.J.,
Kirkwood J.M., Eggermont A.M., Dréno B., Sosman
J.A., Flaherty K.T., Yin M., Caro I., Cheng S., Trunzer K.,
and Hauschild A.a. Safety and efficacy of vemurafenib
in BRAFV600E and BRAFV600K mutation-positive
melanoma (BRIM-3) : Extended follow-up of a phase
3, randomised, open-label study. [2014] Lancet
35. McGale P., Taylor C., Correa C., Cutter D., Duane F.,
Ewertz M., Gray R., Mannu G., Peto R., Whelan T.,
Wang Y., Wang Z., and Darby S. Effect of radiotherapy
after mastectomy and axillary surgery on 10-year
recurrence and 20-year breast cancer mortality :
meta-analysis of individual patient data for 8135
women in 22 randomised trials. [2014] Lancet (383)
9935 : 2127-2135. Impact factor : 39.207
36. Monk B.J., Poveda A., Vergote I., Raspagliesi F.,
Fujiwara K., Bae D.S., Oaknin A., Ray-Coquard
I., Provencher D.M., Karlan B.Y., Lhomme C.,
Richardson G., Rincon D.G., Coleman R.L., Herzog
T.J., Marth C., Brize A., Fabbro M., Redondo A.,
Bamias A., Tassoudji M., Navale L., Warner D.J., and
Oza A.M. Anti-angiopoietin therapy with trebananib
for recurrent ovarian cancer (TRINOVA-1) : a
randomised, multicentre, double-blind, placebocontrolled phase 3 trial. [2014] Lancet Oncology
8
(15) 8 : 799-808. Impact factor : 24.725
37. Motzer R.J., Porta C., Vogelzang N.J., Sternberg
C.N., Szczylik C., Zolnierek J., Kollmannsberger
C., Rha S.Y., Bjarnason G.A., Melichar B., De Giorgi
U., Grunwald V., Davis I.D., Lee J.L., Esteban E.,
Urbanowitz G., Cai C., Squires M., Marker M., Shi
M.M., and Escudier B. Dovitinib versus sorafenib
for third-line targeted treatment of patients with
metastatic renal cell carcinoma : An open-label,
randomised phase 3 trial. [2014] Lancet Oncology
(15) 3 : 286-296. Impact factor : 24.725
38. Palomero T., Couronné L., Khiabanian H., Kim M.Y.,
Ambesi-Impiombato A., Perez-Garcia A., Carpenter
Z., Abate F., Allegretta M., Haydu J.E., Jiang X., Lossos
I.S., Nicolas C., Balbin M., Bastard C., Bhagat G.,
Piris M.A., Campo E., Bernard O.A., Rabadan R., and
Ferrando A.A. Recurrent mutations in epigenetic
regulators, RHOA and FYN kinase in peripheral T cell
lymphomas. [2014] Nature Genetics (46) 2 : 166-170.
39. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y.,
Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng
S.l., Shen X., Boyd Z., Hegde P.S., Chen D.S., and
Vogelzang N.J. MPDL3280A (anti-PD-L1) treatment
leads to clinical activity in metastatic bladder
cancer. [2014] Nature (515) 7528 : 558-562. Impact
factor : 42.351
40. Robert C., Long G.V., Brady B., Dutriaux C., Maio
M., Mortier L., Hassel J.C., Rutkowski P., McNeil C.,
Kalinka-Warzocha E., Savage K.J., Hernberg M.M.,
Lebbé C., Charles J., Mihalcioiu C., Chiarion-Sileni
V., Mauch C., Cognetti F., Arance A., Schmidt H.,
Schadendorf D., Gogas H., Lundgren-Eriksson L.,
Horak C., Sharkey B., Waxman I.M., Atkinson V.,
and Ascierto P. Nivolumab in Previously Untreated
Melanoma without BRAF Mutation. [2014] New
England journal of medicine : 141116004513004141116004513004. Impact factor : 54.420
41. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid
O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J.,
Gangadhar T.C., Patnaik A., Dronca R., Zarour H.,
Joseph R.W., Boasberg P., Chmielowski B., Mateus
C., Postow M.A., Gergich K., Elassaiss-Schaap J.,
Li X.N., Iannone R., Ebbinghaus S.W., Kang S.P.,
and Daud A. Anti-programmed-death-receptor-1
treatment with pembrolizumab in ipilimumabrefractory advanced melanoma : a randomised
dose-comparison cohort of a phase 1 trial. [2014]
Lancet (384) 9948 : 1109-1117. Impact factor :
39.207
42. Shi J., Yang X.R., Ballew B., Rotunno M., Calista D.,
Fargnoli M.C., Ghiorzo P., Bressac-de Paillerets B.,
Nagore E., Avril M.F., Caporaso N.E., McMaster M.L.,
Cullen M., Wang Z., Zhang X., Bruno W., Pastorino
L., Queirolo P., Banuls-Roca J., Garcia-Casado Z.,
Vaysse A., Mohamdi H., Riazalhosseini Y., Foglio M.,
Jouenne F., Hua X., Hyland P.L., Yin J., Vallabhaneni
H., Chai W., Minghetti P., Pellegrini C., Ravichandran
S., Eggermont A., Lathrop M., Peris K., Scarra G.B.,
Landi G., Savage S.A., Sampson J.N., He J., Yeager
M., Goldin L.R., Demenais F., Chanock S.J., Tucker
M.A., Goldstein A.M., Liu Y., and Landi M.T. Rare
missense variants in POT1 predispose to familial
cutaneous malignant melanoma. [2014] Nature
Genetics (46) 5 : 482-486. Impact factor : 29.648
43. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot
D.P., Adam J., Vitale I., Goubar A., Baracco E.E.,
Remédios C., Fend L., Hannani D., Aymeric L., Ma
Y., Niso-Santano M., Kepp O., Schultze J.L., Tüting
T., Belardelli F., Bracci L., La Sorsa V., Ziccheddu G.,
Sestili P., Urbani F., Delorenzi M., Lacroix-Triki M.,
Quidville V., Conforti R., Spano J.P., Pusztai L., PoirierColame V., Delaloge S., Penault-Llorca F., Ladoire S.,
Arnould L., Cyrta J., Dessoliers M.C., Eggermont A.,
Bianchi M.E., Pittet M., Engblom C., Pfirschke C.,
Préville X., Uzè G., Schreiber R.D., Chow M.T., Smyth
M.J., Proietti E., André F., Kroemer G., and Zitvogel
L. Cancer cell-autonomous contribution of type I
interferon signaling to the efficacy of chemotherapy.
[2014] Nature medicine (20) 11 : 1301-1309. Impact
factor : 28.054
44. Sturm D., Bender S., Jones D.T.W., Lichter P., Grill
J., Becher O., Hawkins C., Majewski J., Jones C.,
Costello J.F., Iavarone A., Aldape K., Brennan C.W.,
Jabado N., and Pfister S.M. Paediatric and adult
glioblastoma : Multiform (epi)genomic culprits
emerge. [2014] Nature Reviews Cancer (14) 2 : 92107. Impact factor : 37.912
45. Sun C., Wang L., Huang S., Heynen G.J.J.E.,
Prahallad A., Robert C., Haanen J., Blank C.,
Wesseling J., Willems S.M., Zecchin D., Hobor
S., Bajpe P.K., Lieftink C., Mateus C., Vagner S.,
Grernrum W., Hofland I., Schlicker A., Wessels L.F.A.,
Beijersbergen R.L., Bardelli A., Di Nicolantonio F.,
Eggermont A.M.M., and Bernards R. Reversible and
adaptive resistance to BRAF(V600E) inhibition in
melanoma. [2014] Nature (508) 1 : 118-122. Impact
factor : 42.351
46. Taieb J., Tabernero J., Mini E., Subtil F., Folprecht G.,
van Laethem J.L., Thaler J., Bridgewater J., Petersen
L.N., Blons H., Collette L., Van Cutsem E., Rougier
P., Salazar R., Bedenne L., Emile J.F., Laurent-Puig
P., and Lepage C. Oxaliplatin, fluorouracil, and
leucovorin with or without cetuximab in patients
with resected stage III colon cancer (PETACC-8) : an
open-label, randomised phase 3 trial. [2014] Lancet
9
47. Taylor K.R., Mackay A., Truffaux N., Butterfield Y.S.,
Morozova O., Philippe C., Castel D., Grasso C.S., Vinci
M., Carvalho D., Carcaboso A.M., de Torres C., Cruz
O., Mora J., Entz-Werle N., Ingram W.J., Monje M.,
Hargrave D., Bullock A.N., Puget S., Yip S., Jones C.,
and Grill J. Recurrent activating ACVR1 mutations
in diffuse intrinsic pontine glioma. [2014] Nature
48. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku
I.P., Taylor E.J.M., Robert L., Chmielowski B., Spasic
M., Henry G., Ciobanu V., West A.N., Carmona M.,
Kivork C., Seja E., Cherry G., Gutierrez A.J., Grogan
T.R., Mateus C., Tomasic G., Glaspy J.A., Emerson
R.O., Robins H., Pierce R.H., Elashoff D.A., Robert
C., and Ribas A. PD-1 blockade induces responses
by inhibiting adaptive immune resistance. [2014]
Nature (515) 7528 : 568-571. Impact factor : 42.351
49. Wang Y., McKay J.D., Rafnar T., Wang Z., Timofeeva
M.N., Broderick P., Zong X., Laplana M., Wei Y., Han Y.,
Lloyd A., Delahaye-Sourdeix M., Chubb D., Gaborieau
V., Wheeler W., Chatterjee N., Thorleifsson G., Sulem
P., Liu G., Kaaks R., Henrion M., Kinnersley B., Vallée
M., Lecalvez-Kelm F., Stevens V.L., Gapstur S.M., Chen
W.V., Zaridze D., Szeszenia-Dabrowska N., Lissowska
J., Rudnai P., Fabianova E., Mates D., Bencko V.,
Foretova L., Janout V., Krokan H.E., Gabrielsen M.E.,
Skorpen F., Vatten L., Njolstad I., Chen C., Goodman G.,
Benhamou S., Vooder T., Välk K., Nelis M., Metspalu A.,
Lener M., Lubinski J., Johansson M., Vineis P., Agudo
A., Clavel-Chapelon F., Bueno-de-Mesquita H.B.,
Trichopoulos D., Khaw K.T., Johansson M., Weiderpass
E., Tjonneland A., Riboli E., Lathrop M., Scelo G.,
Albanes D., Caporaso N.E., Ye Y., Gu J., Wu X., Spitz
M.R., Dienemann H., Rosenberger A., Su L., Matakidou
A., Eisen T., Stefansson K., Risch A., Chanock S.J.,
Christiani D.C., Hung R.J., Brennan P., Landi M.T.,
Houlston R.S., and Amos C.I. Rare variants of large
effect in BRCA2 and CHEK2 affect risk of lung cancer.
[2014] Nature Genetics (46) 7 : 736-741. Impact
factor : 29.648
50. Wolpin B.M., Rizzato C., Kraft P., Kooperberg C.,
Petersen G.M., Wang Z., Arslan A.A., Beane-Freeman
L., Bracci P.M., Buring J., Canzian F., Duell E.J.,
Gallinger S., Giles G.G., Goodman G.E., Goodman P.J.,
Jacobs E.J., Kamineni A., Klein A.P., Kolonel L.N.,
Kulke M.H., Li D., Malats N., Olson S.H., Risch H.A.,
Sesso H.D., Visvanathan K., White E., Zheng W., Abnet
C.C., Albanes D., Andreotti G., Austin M.A., Barfield R.,
Basso D., Berndt S.I., Boutron-Ruault M.C., Brotzman
M., Büchler M.W., Bueno-de-Mesquita H.B., Bugert
P., Burdette L., Campa D., Caporaso N.E., Capurso G.,
Chung C., Cotterchio M., Costello E., Elena J., Funel
N., Gaziano J.M., Giese N.A., Giovannucci E.L., Goggins
M., Gorman M.J., Gross M., Haiman C.A., Hassan M.,
Helzlsouer K.J., Henderson B.E., Holly E.A., Hu N.,
Hunter D.J., Innocenti F., Jenab M., Kaaks R., Key
T.J., Khaw K.T., Klein E.A., Kogevinas M., Krogh V.,
Kupcinskas J., Kurtz R.C., LaCroix A., Landi M.T.,
Landi S., Le Marchand L., Mambrini A., Mannisto S.,
Milne R.L., Nakamura Y., Oberg A.L., Owzar K., Patel
A.V., Peeters P.H.M., Peters U., Pezzilli R., Piepoli A.,
Porta M., Real F.X., Riboli E., Rothman N., Scarpa A.,
Shu X.O., Silverman D.T., Soucek P., Sund M., TalarWojnarowska R., Taylor P.R., Theodoropoulos G.E.,
Thornquist M., Tjonneland A., Tobias G.S., Trichopoulos
D., Vodicka P., Wactawski-Wende J., Wentzensen N.,
Wu C., Yu H., Yu K., Zeleniuch-Jacquotte A., Hoover
R., Hartge P., Fuchs C., Chanock S.J., StolzenbergSolomon R.S., and Amundadottir L.T. Genome-wide
association study identifies multiple susceptibility loci
for pancreatic cancer. [2014] Nature Genetics (46) 9 :
994-1000. Impact factor : 29.648
51. Zitvogel L. and Kroemer G. CD103+ Dendritic
Cells Producing Interleukin-12 in Anticancer
Immunosurveillance. [2014] Cancer Cell (26) 5 :
591-593. Impact factor : 23.893
10
/ PUBLICATIONS INTERNATIONALES
GUSTAVE ROUSSY 2014
À IMPACT FACTOR THOMSON REUTERS 2013 COMPRIS ENTRE 10 ET 20 (102 PUBLICATIONS)
1. Aleksandrova K., Boeing H., Nöthlings U., Jenab M.,
Fedirko V., Kaaks R., Lukanova A., Trichopoulou A.,
Trichopoulos D., Boffetta P., Trepo E., Westhpal S.,
Duarte-Salles T., Stepien M., Overvad K., Tjonneland
A., Halkjaer J., Boutron-Ruault M.C., Dossus L., Racine
A., Lagiou P., Bamia C., Benetou V., Agnoli C., Palli D.,
Panico S., Tumino R., Vineis P., Bueno-de-Mesquita B.,
Peeters P.H., Gram I.T., Lund E., Weiderpass E., Quiros
J.R., Agudo A., Sanchez M.J., Gavrila D., Barricarte A.,
Dorronsoro M., Ohlsson B., Lindkvist B., Johansson
A., Sund M., Khaw K.T., Wareham N., Travis R.C.,
Riboli E., and Pischon T. Inflammatory and metabolic
biomarkers and risk of liver and biliary tract cancer.
[2014] Hepatology (60) 3 : 858-871. Impact factor :
11.190
2. Angelergues A., Maillet D., Flechon A., Ozguroglu M.,
Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc
P., Massard C., Rouge T.d.L.M., Delanoy N., Elaidi R.T.,
and Oudard S. Duration of response to androgendeprivation therapy (ADT) and efficacy of secondary
hormone therapy, docetaxel (D), and cabazitaxel (C)
in metastatic castration-resistant prostate cancer
(mCRPC). [2014] Journal of Clinical Oncology (32) 4
Suppl.. Impact factor : 17.879
3. Barthelemy P., Escudier B., Joly F., Geoffrois L.,
Laguerre B., Houede N., Gross-Goupil M., YannAlexandre V., Lucidarme O., Bidault F., Kelkouli N., and
Oudard S. Long-term responders to everolimus: A
subgroup analysis of the sector study. [2014] Journal
of Clinical Oncology (32) 4 Suppl.. Impact factor :
17.879
4. Beer T.M., Logothetis C., Gerritsen W.R., Kwon E.D.,
Scher H.I., Bossi A., van den Eertwegh A.J.M., Drake
C.G., McHenry B., Liu D., and Fizazi K. Characterization
of immune-related adverse events (irAEs) in a phase
3 trial of ipilimumab (Ipi) versus placebo (Pbo) in postdocetaxel mCRPC. [2014] Journal of Clinical Oncology
(32) 4 Suppl.. Impact factor : 17.879
5. Beer T.M., Hotte S.J., De Bono J.S., Beuzeboc P., Gabrail
N.Y., Cain D., Jacobs C., and Fizazi K. Pain palliation
as an oncology label indication: Lessons learned in
custirsen phase III development. [2014] Journal of
Clinical Oncology (32) 4 Suppl.. Impact factor : 17.879
6. Beer T.M., Armstrong A.J., Sternberg C.N., Higano
C.S., Iversen P., Loriot Y., Rathkopf D.E., Bhattacharya
S., Carles J., de Bono J.S., Evans C.P., Joshua A.M.,
Kim C.S., Kimura G., Mainwaring P.N., Mansbach H.H.,
Miller K., Noonberg S.B., Venner P.M., and Tombal
B. Enzalutamide in men with chemotherapy-naive
metastatic prostate cancer (mCRPC): Results of phase
III PREVAIL study. [2014] Journal of Clinical Oncology
7. Berruti A., Fassnacht M., Haak H., Else T., Baudin
E., Sperone P., Kroiss M., Kerkhofs T., Williams A.R.,
Ardito A., Leboulleux S., Volante M., Deutschbein T.,
Feelders R., Ronchi C., Grisanti S., Gelderblom H.,
Porpiglia F., Papotti M., Hammer G.D., Allolio B., and
Terzolo M. Prognostic role of overt hypercortisolism
in completely operated patients with adrenocortical
cancer. [2014] European Urology (65) 4 : 832-838.
8. Bex A., Fournier L., Lassau N., Mulders P., Nathan P.,
Oyen W.J.G., and Powles T. Assessing the response to
targeted therapies in renal cell carcinoma: Technical
insights and practical considerations. [2014] European
Urology (65) 4 : 766-777. Impact factor : 12.480
9. Blanchard P., Pignon J.P., and Bourhis J. Reply to D.
Tural et al. [2014] Journal of Clinical Oncology (32) 3 :
259-260. Impact factor : 17.879
10. Blanchard P., Bourhis J., and Pignon J.P. Is TaxaneCisplatin-Fluorouracil Superior to CisplatinFluorouracil As Induction Chemotherapy in Outcome
in Locally Advanced Head and Neck Cancers? Reply.
[2014] Journal of Clinical Oncology (32) 3 : 259-260.
11. Bluteau D., Balduini A., Balayn N., Currao M., Nurden
P., Deswarte C., Leverger G., Noris P., Perrotta
S., Solary E., Vainchenker W., Debili N., Favier R.,
and Raslova H. Thrombocytopenia-associated
mutations in the ANKRD26 regulatory region induce
MAPK hyperactivation. [2014] Journal of Clinical
Investigation (124) 2 : 580-591. Impact factor : 13.765
12. Bonastre J., Marguet S., Lueza B., Michiels S., Delaloge
S., and Saghatchian M. Cost effectiveness of molecular
profiling for adjuvant decision making in patients
with node-negative breast cancer. [2014] Journal of
Clinical Oncology (32) 31 : 3513-3519. Impact factor :
17.879
13. Brasme J.F., Chalumeau M., Oberlin O., ValteauCouanet D., and Gaspar N. Time to diagnosis of ewing
tumors in children and adolescents is not associated
with metastasis or survival: A prospective multicenter
study of 436 patients. [2014] Journal of Clinical
14. Brasme J.F., Chalumeau M., Oberlin O., ValteauCouanet D., and Gaspar N. Reply to L. Alonso et al.
[2014] Journal of Clinical Oncology (32) 35 : 40204021. Impact factor : 17.879
11
15. Chouaid C., Borget I., and Vergnenegre A. Targeted
therapies in non-small-cell lung cancer management:
no cost-effective strategies? [2014] Journal of Clinical
16. Damm F., Mylonas E., Cosson A., Yoshida K., Della Valle
V., Mouly E., Diop M., Scourzic L., Shiraishi Y., Chiba
K., Tanaka H., Miyano S., Kikushige Y., Davi F., Lambert
J., Gautheret D., Merle-Béral H., Sutton L., Dessen
P., Solary E., Akashi K., Vainchenker W., Mercher T.,
Droin N., Ogawa S., Nguyen-Khac F., and Bernard O.A.
Acquired initiating mutations in early hematopoietic
cells of CLL patients. [2014] Cancer Discovery (4) 9 :
1088-1101. Impact factor : 15.929
17. Denkert C., von Minckwitz G., Brase J.C., Sinn B.V., Gade
S., Kronenwett R., Pfitzner B.M., Salat C., Loi S., Schmitt
W.D., Schem C., Fisch K., Darb-Esfahani S., Mehta K.,
Sotiriou C., Wienert S., Klare P., Andre F., Klauschen
F., Blohmer J.U., Krappmann K., Schmidt M., Tesch H.,
Kummel S., Sinn P., Jackisch C., Dietel M., Reimer T.,
Untch M., and Loibl S. Tumor-Infiltrating Lymphocytes
and Response to Neoadjuvant Chemotherapy With
or Without Carboplatin in Human Epidermal Growth
Factor Receptor 2-Positive and Triple-Negative
Primary Breast Cancers. [2014] Journal of Clinical
Oncology. Impact factor : 17.879
18. Dimakopoulou K., Samoli E., Beelen R., Stafoggia M.,
Andersen Z.J., Hoffmann B., Fischer P., Nieuwenhuijsen
M., Vineis P., Xun W., Hoek G., Raaschou-Nielsen O.,
Oudin A., Forsberg B., Modig L., Jousilahti P., Lanki T.,
Turunen A., Oftedal B., Nafstad P., Schwarze P.E., Penell
J., Fratiglioni L., Andersson N., Pedersen N., Korek M.,
De Faire U., Eriksen K.T., Tjonneland A., Becker T.,
Wang M., Bueno-de-Mesquita B., Tsai M.Y., Eeftens
M., Peeters P.H., Meliefste K., Marcon A., Kramer U.,
Kuhlbusch T.A.J., Vossoughi M., Key T., de Hoogh K.,
Hampel R., Peters A., Heinrich J., Weinmayr G., Concin
H., Nagel G., Ineichen A., Jacquemin B., Stempfelet M.,
Vilier A., Ricceri F., Sacerdote C., Pedeli X., Katsoulis
M., Trichopoulou A., Brunekreef B., and Katsouyanni K.
Air Pollution and Nonmalignant Respiratory Mortality
in 16 Cohorts within the ESCAPE Project. [2014]
American Journal of Respiratory and Critical Care
Medicine (189) 6 : 684-696. Impact factor : 11.986
19. Drake C.G., Kwon E.D., Fizazi K., Bossi A., van den
Eertwegh A.J.M., Logothetis C., Scher H.I., Beer T.M.,
McHenry B., Liu D., and Gerritsen W.R. Results of
subset analyses on overall survival (OS) from study
CA184-043: Ipilimumab (Ipi) versus placebo (Pbo)
in post-docetaxel metastatic castration-resistant
prostate cancer (mCRPC). [2014] Journal of Clinical
Oncology (32) 4 S2. Impact factor : 17.879
20. Dreicer R., Jones R., Oudard S., Efstathiou E., Saad
F., De Wit R., De Bono J.S., Shi Y., Tejura B., Agus
D.B., Borgstein N.G., Bellmunt J., and Fizazi K.
Results from a phase 3, randomized, double-blind,
multicenter, placebo-controlled trial of orteronel
(TAK-700) plus prednisone in patients with metastatic
castration-resistant prostate cancer (mCRPC) that
has progressed during or following docetaxel-based.
[2014] Journal of Clinical Oncology (32) 4 S2. Impact
factor : 17.879
21. Eggermont A.M.M. and Robert C. MELANOMA Smart
therapeutic strategies in immuno-oncology. [2014]
Nature Reviews Clinical Oncology (11) 4 : 181-182.
22. Eisenberg T., Schroeder S., Buttner S., CarmonaGutierrez D., Pendl T., Andryushkova A., Marino G.,
Pietrocola F., Harger A., Zimmermann A., Magnes C.,
Sinner F., Sedej S., Pieber T.R., Dengjel J., Sigrist S.,
Kroemer G., and Madeo F. A histone point mutation
that switches on autophagy. [2014] Autophagy (10) 6 :
1143-1145. Impact factor : 11.423
23. Eisenberg T., Schroeder S., Andryushkova A., Pendl T.,
Kuttner V., Bhukel A., Marino G., Pietrocola F., Harger
A., Zimmermann A., Moustafa T., Sprenger A., Jany
E., Buttner S., Carmona-Gutierrez D., Ruckenstuhl C.,
Ring J., Reichelt W., Schimmel K., Leeb T., Moser C.,
Schatz S., Kamolz L.P., Magnes C., Sinner F., Sedej S.,
Fröhlich K.U., uhasz G., ieber T.R., engjel J., igrist S.J.,
roemer G., and adeo F. Nucleocytosolic depletion of
the energy metabolite acetyl-coenzyme A stimulates
autophagy and prolongs lifespan. [2014] Cell
Metabolism (19) 3 : 431-444. Impact factor : 16.747
24. Escudier B., Porta C., Bono P., Powles T., Eisen T.,
Sternberg C.N., Gschwend J.E., De Giorgi U., Parikh
O., Hawkins R., Sevin E., Négrier S., Khan S., Diaz
J., Redhu S., Mehmud F., and Cella D. Randomized,
controlled, double-blind, cross-over trial assessing
treatment preference for pazopanib versus sunitinib
in patients with metastatic renal cell carcinoma:
PISCES study. [2014] Journal of Clinical Oncology (32)
14 : 1412-1418. Impact factor : 17.879
25. Escudier B., Porta C., Powles T., Eisen T., Sternberg
C.N., Mehmud F., and Cella D. Reply to S. Barni et Al
and M. Sun et Al. [2014] Journal of Clinical Oncology
(32) 33 : 3783-3784. Impact factor : 17.879
26. Escudier B.J., Porta C., Squires M., Szczylik C.,
Kollmannsberger C.K., Melichar B., Rha S.Y., Esteban
E., Bjarnason G.A., Vogelzang N.J., Sternberg C.N.,
Shi M., Marker M., and Motzer R.J. Biomarker
12
analysis from a phase III trial (GOLD) of dovitinib
(Dov) versus sorafenib (Sor) in patients with
metastatic renal cell carcinoma after one prior
VEGF pathway-targeted therapy and one prior
mTOR inhibitor therapy. [2014] Journal of Clinical
Oncology (32) 4 Suppl.. Impact factor : 17.879
Laplanche A. A risk-adapted study of cisplatin
and etoposide, with or without ifosfamide, in
patients with metastatic seminoma: Results of
the GETUG S99 multicenter prospective study.
[2014] European Urology (65) 2 : 381-386. Impact
factor : 12.480
27. Escudier B.J., Bracarda S., Rey J.P.M., Szczylik
C., Nathan P.D., Negrier S., Cattaneo A., Weiss
C., Porta C., and Gruenwald V. Open-label, phase
II raptor study of everolimus (EVE) for papillary
mRCC: Efficacy in type 1 and type 2 histology.
[2014] Journal of Clinical Oncology (32) 4 S2.
32. Fizazi K., Flaig T.W., Ohlmann C.H., Scher H.I., De
Bono J.S., Rathkopf D.E., Ryan C.J., Kheoh T.S., Li
J., Todd M.B., Griffin T.W., Molina A., and Stoeckle
M. Does Gleason score (GS) predict efficacy of
abiraterone acetate (AA) therapy in patients (pts)
with metastatic castration-resistant prostate
cancer (mCRPC)? An analysis of AA phase 3 trials.
[2014] Journal of Clinical Oncology (32) 4 Suppl..
28. Favaudon V., Caplier L., Monceau V., Pouzoulet
F., Sayarath M., Fouillade C., Poupon M.F., Brito
I., Hupe P., Bourhis J., Hall J., Fontaine J.J.,
and Vozenin M.C. Ultrahigh dose-rate FLASH
irradiation increases the differential response
between normal and tumor tissue in mice. [2014]
Science Translational Medicine (6) 245 : 245ra93245ra93. Impact factor : 14.414
29. Fe d i r k o V. , D u a r t e - S a l le s T. , B a m i a C . ,
Trichopoulou A., Aleksandrova K., Trichopoulos
D., Trepo E., Tjonneland A., Olsen A., Overvad K.,
Boutron-Ruault M.C., Clavel-Chapelon F., Kvaskoff
M., Kuehn T., Lukanova A., Boeing H., Buijsse B.,
Klinaki E., Tsimakidi C., Naccarati A., Tagliabue G.,
Panico S., Tumino R., Palli D., Bueno-de-Mesquita
H.B., Siersema P.D., Peters P.H., Lund E., Brustad
M., Olsen K.S., Weiderpass E., Zamora-Ros R.,
Sanchez M.J., Ardanaz E., Amiano P., Navarro C.,
Ramon Quiros J., Werner M., Sund M., Lindkvist
B., Malm J., Travis R.C., Khaw K.T., Stepien M.,
Scalbert A., Romieu I., Lagiou P., Riboli E., and
Jenab M. Prediagnostic Circulating Vitamin D
Levels and Risk of Hepatocellular Carcinoma in
European Populations: A Nested Case-Control
Study. [2014] Hepatology (60) 4 : 1222-1230.
30. Ferté C., Koscielny S., Albiges L., Rocher L., Soria
J.C., Iacovelli R., Loriot Y., Fizazi K., and Escudier B.
Tumor Growth Rate Provides Useful Information
to Evaluate Sorafenib and Everolimus Treatment
in Metastatic Renal Cell Carcinoma Patients: An
Integrated Analysis of the TARGET and RECORD
Phase 3 Trial Data. [2014] European Urology (65)
4 : 713-720. Impact factor : 12.480
31. Fizazi K., Delva R., Caty A., Chevreau C., Kerbrat P.,
Rolland F., Priou F., Geoffrois L., Rixe O., Beuzeboc
P., Malhaire J.P., Culine S., Aubelle M.S., and
33. Galluzzi L., Kepp O., and Kroemer G. MLKL
regulates necrotic plasma membrane
permeabilization. [2014] Cell research (24) 2 :
139-140. Impact factor : 11.981
34. Gandhi L., Bahleda R., Tolaney S.M., Kwak E.L.,
Cleary J.M., Pandya S.S., Hollebecque A., Abbas R.,
Ananthakrishnan R., Berkenblit A., Krygowski M.,
Liang Y., Turnbull K.W., Shapiro G.I., and Soria J.C.
Phase I Study of Neratinib in Combination With
Temsirolimus in Patients With Human Epidermal
Growth Factor Receptor 2-Dependent and Other
Solid Tumors. [2014] Journal of Clinical Oncology
(32) 2 : 68-+. Impact factor : 17.879
35. Garcia J.A., Kataja V.V., James N.D., Jones R.H.,
Protheroe A., Massard C., Mattila L., Mustonen
M.V.J., Aspegren J., and Fizazi K. Bone and soft
tissue response from a phase I/II study with ODM201 in metastatic castration-resistant prostate
cancer (mCRPC). [2014] Journal of Clinical
Oncology (32) S4. Impact factor : 17.879
36. Garlipp B., De Baere T., Damm R., Irmscher R.,
van Buskirk M., Stübs P., Deschamps F., Meyer F.,
Seidensticker R., Mohnike K., Pech M., Amthauer
H., Lippert H., Ricke J., and Seidensticker M. Leftliver hypertrophy after therapeutic right-liver
radioembolization is substantial but less than
after portal vein embolization. [2014] Hepatology
(59) 5 : 1864-1873. Impact factor : 11.190
37. Gartrell B.A., Coleman R.E., Fizazi K., Miller K.,
Saad F., Sternberg C.N., and Galsky M.D. Toxicities
Following Treatment with Bisphosphonates and
Receptor Activator of Nuclear Factor-kappa
B Ligand Inhibitors in Patients with Advanced
Prostate Cancer. [2014] European Urology (65) 2 :
13
278-286. Impact factor : 12.480
38. Gibert B., Delloye-Bourgeois C., Gattolliat C.H.,
Meurette O., Le Guernevel S., Fombonne J.,
Ducarouge B., Lavial F., Bouhallier F., Creveaux
M., Negulescu A.M., Bénard J., Janoueix-Lerosey
I., Harel-Bellan A., Delattre O., and Mehlen P.
Regulation by miR181 family of the dependence
receptor CDON tumor suppressive activity in
neuroblastoma. [2014] Jnci-Journal of the
National Cancer Institute (106) 11. Impact factor :
15.161
39. Gravis G., Boher J.M., Fizazi K., Joly F., Priou
F., Marino P., Latorzeff I., Delva R., Krakowski
I., Laguerre B., Walz J., Rolland F., Théodore
C., Deplanque G., Ferrero J.M., Pouessel D.,
Mourey L., Beuzeboc P., Zanetta S., Habibian M.,
Berdah J.F., Dauba J., Baciuchka M., Platini C.,
Linassier C., Labourey J.L., Machiels J.P., Kouri
C.E., Ravaud A., Suc E., Eymard J.C., Hasbini A.,
Bousquet G., Soulie M., and Oudard S. Prognostic
Factors for Survival in Noncastrate Metastatic
Prostate Cancer: Validation of the Glass Model
and Development of a Novel Simplified Prognostic
Model. [2014] European Urology. Impact factor :
12.480
40. Grill J. and Dufour C. Neuro-oncology : Stability
of medulloblastoma subgroups at tumour
recurrence. [2014] Nature Reviews Neurology
(10) 1 : 5-6. Impact factor : 14.103
41. Guinney J., Dienstmann R., Ferté C., Friend S., and
McCormick F. Social interactomes for enabling
research communities. [2014] Cancer Discovery
(4) 11 : 1265-1268. Impact factor : 15.929
42. Halabi S., Lin C.Y., Kelly W.K., Fizazi K.S., Moul
J.W., Kaplan E.B., Morris M.J., and Small E.J.
Updated Prognostic Model for Predicting Overall
Survival in First-Line Chemotherapy for Patients
With Metastatic Castration-Resistant Prostate
Cancer. [2014] Journal of Clinical Oncology (32)
7 : 671-+. Impact factor : 17.879
43. Hoster E., Klapper W., Hermine O., KluinNelemans H.C., Walewski J., Van Hoof A., Trneny
M., Geisler C.H., Raimondo F.D., Szymczyk M.,
Stilgenbauer S., Thieblemont C., Hallek M.,
Forstpointner R., Pott C., Ribrag V., Doorduijn
J., Hiddemann W., Dreyling M.H., and Unterhalt
M. Confirmation of the mantle-cell lymphoma
International Prognostic Index in randomized
trials of the European Mantle-Cell Lymphoma
Network. [2014] Journal of Clinical Oncology (32)
13 : 1338-1346. Impact factor : 17.879
44. Hutson T.E., Escudier B., Esteban E., Bjarnason
G . A . , L i m H . Y. , P i t t m a n K . B . , S e n i co P. ,
Niethammer A., Lu D.R., Hariharan S., and Motzer
R.J. Randomized phase III trial of temsirolimus
versus sorafenib as second-line therapy after
sunitinib in patients with metastatic renal cell
carcinoma. [2014] Journal of Clinical Oncology
(32) 8 : 760-767. Impact factor : 17.879
45. Iacovelli R., Massari F., Albiges L., Loriot Y.,
Massard C., Fizazi K., and Escudier B. Evidence
and Clinical Relevance of Tumor Flare in Patients
Who Discontinue Tyrosine Kinase Inhibitors for
Treatment of Metastatic Renal Cell Carcinoma.
[2014] European Urology. Impact factor : 12.480
46. Iacovelli R., Massari F., Albiges L., and Escudier
B. Prognostic value of flare-up phenomenon after
discontinuation of sunitinib (SU) or pazopanib
(PA) in metastatic renal cell carcinoma (mRCC).
[2014] Journal of Clinical Oncology (32) 4 Suppl..
47. Jaafoura S., de Goër de Herve M.G., HernandezVargas E.A., Hendel-Chavez H., Abdoh M., Mateo
M.C., Krzysiek R., Merad M., Seng R., Tardieu
M., Delfraissy J.F., Goujard C., and Taoufik Y.
Progressive contraction of the latent HIV reservoir
around a core of less-differentiated CD4+ memory
T Cells. [2014] Nature communications (5) : 54075407. Impact factor : 10.742
48. Janin M., Mylonas E., Saada V., Micol J.B.,
Renneville A., Quivoron C., Koscielny S., Scourzic
L., Forget S., Pautas C., Caillot D., Preudhomme
C., Dombret H., Berthon C., Barouki R., Rabier D.,
Auger N., Griscelli F., Chachaty E., Leclercq E.,
Courtier M.H., Bennaceur-Griscelli A., Solary E.,
Bernard O.A., Penard-Lacronique V., Ottolenghi
C., and De Botton S. Serum 2-hydroxyglutarate
production in IDH1- And IDH2-mutated de novo
acute myeloid leukemia: A study by the acute
leukemia french association group. [2014]
Journal of Clinical Oncology (32) 4 : 297-305.
49. Kroemer G. and Perfettini J.L. Entosis, a key player
in cancer cell competition. [2014] Cell research
(24) 11 : 1280-1281. Impact factor : 11.981
50. Kvaskoff M., Bijon A., Mesrine S., Vilier A., Baglietto
L., Fournier A., Clavel-Chapelon F., Dossus L.,
and Boutron-Ruault M.C. Association between
Melanocytic Nevi and Risk of Breast Diseases:
The French E3N Prospective Cohort. [2014] PLOS
MEDICINE (11) 6 : e1001660-e1001660. Impact
factor : 14.000
14
51. Kyro C., Olsen A., Landberg R., Skeie G., Loft S.,
Aman P., Leenders M., Dik V.K., Siersema P.D.,
Pischon T., Christensen J., Overvad K., BoutronRuault M.C., Fagherazzi G., Cottet V., Kuehn T.,
Chang-Claude J., Boeing H., Trichopoulou A.,
Bamia C., Trichopoulos D., Palli D., Krogh V.,
Tumino R., Vineis P., Panico S., Peeters P.H.,
Weiderpass E., Bakken T., Asli L.A., Argueelles M.,
Jakszyn P., Sanchez M.J., Amiano P., Huerta J.M.,
Barricarte A., Ljuslinder I., Palmqvist R., Khaw
K.T., Wareham N., Key T.J., Travis R.C., Ferrari P.,
Freisling H., Jenab M., Gunter M.J., Murphy N.,
Riboli E., Tjonneland A., and Bueno-de-Mesquita
H.B. Plasma Alkylresorcinols, Biomarkers of
Whole-Grain Wheat and Rye Intake, and Incidence
of Colorectal Cancer. [2014] Jnci-Journal of the
National Cancer Institute (106) 1 : djt352-djt352.
52. Langenberg C., Sharp S.J., Franks P.W., Scott
R.A., Deloukas P., Forouhi N.G., Froguel P., Groop
L.C., Hansen T., Palla L., Pedersen O., Schulze
M.B., Tormo M.J., Wheeler E., Agnoli C., Arriola
L., Barricarte A., Boeing H., Clarke G.M., ClavelChapelon F., Duell E.J., Fagherazzi G., Kaaks
R., Kerrison N.D., Key T.J., Khaw K.T., Kroger
J., Lajous M., Morris A.P., Navarro C., Nilsson
P.M., Overvad K., Palli D., Panico S., Quiros J.R.,
Rolandsson O., Sacerdote C., Sanchez M.J.,
Slimani N., Spijkerman A.M.W., Tumino R., van
d.A., van der Schouw Y.T., Barroso I., McCarthy
M.I., Riboli E., and Wareham N.J. Gene-lifestyle
interaction and type 2 diabetes: the EPIC interact
case-cohort study. [2014] PLOS MEDICINE (11) 5 :
e1001647-e1001647. Impact factor : 14.000
53. Lassau N., Koscielny S., Taieb S., Lacroix J., Aziza
R., Joly F., Chevreau C., Negrier S., Gravis G., and
Escudier B.J. Validation of imaging biomarker in a
multicentric study to predict PFS in mRCC treated
with TKI. [2014] Journal of Clinical Oncology (32)
4 Suppl.. Impact factor : 17.879
54. Le Deley M.C., Paulussen M., Lewis I., Brennan
B., Ranft A., Whelan J., Le Teuff G., Michon J.,
Ladenstein R., Marec-Bérard P., van den Berg H.,
Hjorth L., Wheatley K., Judson I., Juergens H., Craft
A., Oberlin O., and Dirksen U. Cyclophosphamide
compared with ifosfamide in consolidation
treatment of standard-risk Ewing sarcoma:
results of the randomized noninferiority EuroEWING99-R1 trial. [2014] Journal of Clinical
Oncology (32) 23 : 2440-2448. Impact factor :
17.879
55. Levy A., Rivera S., del Campo E.R., Chargari
C., and Arriagada R. Individualizing Adjuvant
Radiotherapy in Patients With Breast Cancer:
Let’s Not Get Ahead of Ourselves. [2014] Journal
of Clinical Oncology (32) 29 : 3339-3339. Impact
factor : 17.879
56. Lhommé C., Leary A., Uzan C., Pautier P., Gouy S.,
and Morice P. Adjuvant chemotherapy in stage I
ovarian germ cell tumors: should indications and
treatment modalities be different in young girls
and adults? [2014] Journal of Clinical Oncology
(32) 25 : 2815-2816. Impact factor : 17.879
57. Loibl S., von Minckwitz G., Schneeweiss A., Paepke
S., Lehmann A., Rezai M., Zahm D.M., Sinn P.,
Khandan F., Eidtmann H., Dohnal K., Heinrichs
C., Huober J., Pfitzner B., Fasching P.A., Andre F.,
Lindner J.L., Sotiriou C., Dykgers A., Guo S., Gade
S., Nekljudova V., Loi S., Untch M., and Denkert
C. PIK3CA mutations are associated with lower
rates of pathologic complete response to antihuman epidermal growth factor receptor 2 (her2)
therapy in primary HER2-overexpressing breast
cancer. [2014] Journal of Clinical Oncology (32)
29 : 3212-3220. Impact factor : 17.879
58. Loriot Y., Pagliaro L.C., Flechon A., Mardiak J.,
Geoffrois L., Kerbrat P., Chevreau C., Delva R.,
Rolland F., Theodore C., Bui B., Gravis G., Eymard
J.C., Malhaire J.P., Linassier C., Habibian M.,
Logothetis C., Culine S., Laplanche A., and Fizazi
K. Patterns of relapse in poor-prognosis germ
cell tumors in the GETUG 13 trial: Implications for
assessment of brain progression. [2014] Journal
of Clinical Oncology (32) S4. Impact factor : 17.879
59. Loriot Y., Massard C., and Fizazi K. One Size Does
Not Fit All: Can We Choose the Best Sequence of
Treatment in Asymptomatic Castration-resistant
Prostate Cancer Patients? [2014] European
Urology (66) 4 : 653-654. Impact factor : 12.480
60. Loriot Y. and Fizazi K. Towards random sequencing
or precision medicine in castration-resistant
prostate cancer? [2014] European Urology (65)
1 : 37-38. Impact factor : 12.480
61. Malouf G.G., Job S., Paradis V., Fabre M.,
Brugieres L., Saintigny P., Vescovo L., Belghiti
J., Branchereau S., Faivre S., De Reyniès A., and
Raymond E. Transcriptional profiling of pure
fibrolamellar hepatocellular carcinoma reveals
an endocrine signature. [2014] Hepatology (59)
6 : 2228-2237. Impact factor : 11.190
62. Mariño G., Pietrocola F., Eisenberg T., Kong Y.,
Malik S.A., Andryushkova A., Schroeder S., Pendl
15
T., Harger A., Niso-Santano M., Zamzami N.,
Scoazec M., Durand S.r., Enot D.P., Fernández ÁF.,
Martins I., Kepp O., Senovilla L., Bauvy C., Morselli
E., Vacchelli E., Bennetzen M., Magnes C., Sinner
F., Pieber T., López-Otín C., Maiuri M.C., Codogno
P., Andersen J.S., Hill J.A., Madeo F., and Kroemer
G. Regulation of autophagy by cytosolic acetylcoenzyme A. [2014] Molecular cell (53) 5 : 710725. Impact factor : 14.464
63. Mariette C., Dahan L., Mornex F.o., Maillard E.,
Thomas P.A., Meunier B., Boige V.r., Pezet D., Robb
W.B., Le Brun-Ly V.r., Bosset J.F.o., Mabrut J.Y.,
Triboulet J.P., Bedenne L., and Seitz J.F.o. Surgery
alone versus chemoradiotherapy followed by
surgery for stage I and II esophageal cancer: final
analysis of randomized controlled phase III trial
FFCD 9901. [2014] Journal of Clinical Oncology
(32) 23 : 2416-2422. Impact factor : 17.879
64. Marino G., Pietrocola F., Kong Y., Eisenberg T., Hill
J.A., Madeo F., and Kroemer G. Dimethyl alphaketoglutarate inhibits maladaptive autophagy
in pressure overload-induced cardiomyopathy.
[2014] Autophagy (10) 5 : 930-932. Impact factor :
11.423
65. Massard C., Tammela T.L.J., Vjaters E., Lietuvietis
V., Bono P., Penttinen H., Nykanen P., Snapir A.,
Mattila L., and Fizazi K. A study of two ODM201 formulations with a safety and tolerability
extension phase in patients with metastatic
c h e m o t h e r a p y - n a i v e c a s t r a t i o n - re s i s t a n t
prostate cancer (CRPC). [2014] Journal of Clinical
66. Miller K.D., Diéras V., Harbeck N., Andre F.,
Mahtani R.L., Gianni L., Albain K.S., Crivellari D.,
Fang L., Michelson G., De Haas S.L., and Burris
H.A. Phase IIa trial of trastuzumab emtansine
with pertuzumab for patients with human
epidermal growth factor receptor 2-positive,
locally advanced, or metastatic breast cancer.
67. Molina T.J., Canioni D., Copie-Bergman C., Recher
C., Brière J., Haioun C., Berger F., Fermé C., Copin
M.C., Casasnovas O., Thieblemont C., Petrella
T., Leroy K., Salles G., Fabiani B., Morschauser
F., Mounier N., Coiffier B., Jardin F., Gaulard P.,
Jais J.P., and Tilly H. Young patients with nongerminal center B-cell-like diffuse large B-cell
lymphoma benefit from intensified chemotherapy
with ACVBP plus rituximab compared with CHOP
plus rituximab: analysis of data from the Groupe
d’Etudes des Lymphomes de l’Adulte/lympho.
68. Morice P., Gouy S., Querleu D., and Leblanc E.
Using Positron Emission Tomography Imaging for
Maximum Benefit in Locally Advanced Cervical
Cancer Reply. [2014] Journal of Clinical Oncology
(32) 4 : 358-359. Impact factor : 17.879
69. Morice P., Gouy S., Querleu D., and Leblanc E.
Reply to m.s. Rajagopalan et Al and p.g. Rose.
70. Mulders P.F.A., Molina A., Marberger M., Saad F.,
Higano C.S., Chi K.N., Li J., Kheoh T., Haqq C.M.,
and Fizazi K. Efficacy and Safety of Abiraterone
Acetate in an Elderly Patient Subgroup (Aged
75 and Older) with Metastatic Castrationresistant Prostate Cancer After Docetaxel-based
Chemotherapy. [2014] European Urology (65) 5 :
875-883. Impact factor : 12.480
71. Nassif M., Valenzuela V., Rojas-Rivera D., Vidal R.,
Matus S., Castillo K., Fuentealba Y., Kroemer G.,
Levine B., and Hetz C. Pathogenic role of BECN1/
Beclin 1 in the development of amyotrophic
lateral sclerosis. [2014] Autophagy (10) 7 : 12561271. Impact factor : 11.423
72. Naudin C., Sirvent A., Leroy C., Larive R., Simon V.,
Pannequin J., Bourgaux J.F., Pierre J., Robert B.,
Hollande F., and Roche S. SLAP displays tumour
suppressor functions in colorectal cancer via
destabilization of the SRC substrate EPHA2.
[2014] Nature communications (5) : 3159-3159.
73. Nguyen T.V., Riou L., Aoufouchi S., and Rosselli
F. Fanca deficiency reduces A/T transitions in
somatic hypermutation and alters class switch
recombination junctions in mouse B cells. [2014]
Journal of Experimental Medicine (211) 6 : 10111018. Impact factor : 13.912
74. Noman M.Z., Desantis G., Janji B., Hasmim M.,
Karray S., Dessen P., Bronte V., and Chouaib S.
PD-L1 is a novel direct target of HIF-1&, and
its blockade under hypoxia enhanced MDSCmediated T cell activation. [2014] Journal of
Experimental Medicine (211) 5 : 781-790. Impact
factor : 13.912
75. Oudard S., Joly F., Geoffrois L., Laguerre B.,
16
Houede N., Barthelemy P., Gross-Goupil M., YannAlexandre V., Lucidarme O., Bidault F., Kelkouli
N., and Escudier B. Retrospective evaluation of
tyrosine kinase inhibitor (TKI)-everolimus (eve)
and/or TKI-eve-TKI sequences in metastatic renal
cell carcinoma (mRCC): A French survey-The
sector study. [2014] Journal of Clinical Oncology
Novatchkova M., Nitsch R., Sykacek P., Frank L.,
Schramek D., Komnenovic V., Sigl V., Aumayr K.,
Schmauss G., Fellner N., Handschuh S., Glösmann
M., Pasierbek P., Schlederer M., Resch G.P., Ma
Y., Yang H., Popper H., Kenner L., Kroemer G.,
and Penninger J.M. A dual role for autophagy in
a murine model of lung cancer. [2014] Nature
communications (5). Impact factor : 10.742
76. Oudard S., Kheoh T.S., Yu M.K., Smith M.R., Small
E.J., Mulders P.F.A., Fizazi K., Rathkopf D.E., Saad
F., Scher H.I., Bellmunt J., Taplin M.E., Davis
I.D., Schrijvers D.L., Protheroe A., Molina A.,
Griffin T.W., De Bono J.S., and Ryan C.J. Impact
of prior endocrine therapy on radiographic
progression-free survival (rPFS) in patients (pts)
with chemotherapy-naive metastatic castrationresistant prostate cancer (mCRPC): Results from
COU-AA-302. [2014] Journal of Clinical Oncology
81. Rao S., Yang H., Penninger J.M., and Kroemer G.
Autophagy in non- small cell lung carcinogenesis.
[2014] Autophagy (10) 3 : 529-531. Impact factor :
11.423
77. Peeters M., Oliner K.S., Price T.J., Cervantes A.,
Sobrero A.F., Ducreux M., Hotko Y., Andre T., Chan
E., Lordick F., Punt C.J.A., Strickland A., Wilson G.,
Ciuleanu T.E., Roman L., Van Cutsem E., Tian Y.,
Jung A.S., Sidhu R., and Patterson S.D. Analysis
of KRAS/NRAS mutations in phase 3 study
20050181 of panitumumab (pmab) plus FOLFIRI
versus FOLFIRI for second-line treatment (tx)
of metastatic colorectal cancer (mCRC). [2014]
Journal of Clinical Oncology (32) 3 Suppl.. Impact
factor : 17.879
78. Pinton P. and Kroemer G. Cancer therapy: Altering
mitochondrial properties. [2014] Nature chemical
biology (10) 2 : 89-90. Impact factor : 13.217
79. Raemaekers J.M.M., André M.P.E., Federico
M., Girinsky T., Oumedaly R., Brusamolino E.,
Brice P., Fermé C., Van Der Maazen R., Gotti M.,
Bouabdallah R., Sebban C.J., Lievens Y., Re A.,
Stamatoullas A., Morschhauser F., Lugtenburg
P.J., Abruzzese E., Olivier P., Casasnovas R.O.,
Van Imhoff G., Raveloarivahy T., Bellei M., Van
Der Borght T., Bardet S., Versari A., Hutchings M.,
Meignan M., and Fortpied C. Omitting Radiotherapy
in early positron emission tomography-negative
stage I/II Hodgkin lymphoma is associated with
an increased risk of early relapse: Clinical
results of the preplanned interim analysis of the
randomized EORTC/LYSA/FIL H10 trial. [2014]
80. Rao S., Tortola L., Perlot T., Wirnsberger G.,
82. Rathkopf D.E., Smith M.R., de Bono J.S., Logothetis
C.J., Shore N.D., de Souza P., Fizazi K., Mulders
P.F.A., Mainwaring P., Hainsworth J.D., Beer T.M.,
North S., Fradet Y., Van Poppel H., Carles J., Flaig
T.W., Efstathiou E., Yu E.Y., Higano C.S., Taplin M.E.,
Griffin T.W., Todd M.B., Yu M.K., Park Y.C., Kheoh
T., Small E.J., Scher H.I., Molina A., Ryan C.J.,
and Saad F. Updated Interim Efficacy Analysis
and Long-term Safety of Abiraterone Acetate in
Metastatic Castration-resistant Prostate Cancer
Patients Without Prior Chemotherapy (COUAA-302). [2014] European Urology (66) 5 : 815825. Impact factor : 12.480
83. Rebouissou S., Bernard-Pierrot I., De Reyniès
A., Lepage M.L., Krucker C., Chapeaublanc E.,
Hérault A., Kamoun A., Caillault A., Letouzé E.,
Elarouci N., Neuzillet Y., Denoux Y., Molinié V.,
Vordos D., Laplanche A., Maillé P., Soyeux P.,
Ofualuka K., Reyal F., Biton A., Sibony M., Paoletti
X., Southgate J., Benhamou S., Lebret T., Allory Y.,
and Radvanyi F. EGFR as a potential therapeutic
target for a subset of muscle-invasive bladder
cancers presenting a basal-like phenotype.
[2014] Science Translational Medicine (6) 244 :
244ra91-244ra91. Impact factor : 14.414
84. Rinaldi S., Plummer M., Biessy C., Tsilidis K.K.,
Ostergaard J.N., Overvad K., Tjonneland A.,
Halkjaer J., Boutron-Ruault M.C., Clavel-Chapelon
F., Dossus L., Kaaks R., Lukanova A., Boeing H.,
Trichopoulou A., Lagiou P., Trichopoulos D., Palli
D., Agnoli C., Tumino R., Vineis P., Panico S.,
De-Mesquita H.B.B., Peeters P.H., Weiderpass
E., Lund E., Quiros J.R., Agudo A., Molina E.,
Larranaga N., Navarro C., Ardanaz E., Manjer J.,
Almquist M., Sandström M., Hennings J., Khaw
K.T., Schmidt J., Travis R.C., Byrnes G., Scalbert
A., Romieu I., Gunter M., Riboli E., and Franceschi
S. Thyroid-stimulating hormone, thyroglobulin,
and thyroid hormones and risk of differentiated
17
thyroid carcinoma: The EPIC study. [2014] JnciJournal of the National Cancer Institute (106) 6 :
dju097-dju097. Impact factor : 15.161
85. Rini B.I., Bellmunt J., Clancy J., Wang K.,
Niethammer A.G., Hariharan S., and Escudier
B. Randomized phase III trial of temsirolimus
and bevacizumab versus interferon alfa and
bevacizumab in metastatic renal cell carcinoma:
INTORACT trial. [2014] Journal of Clinical
86. Rosmarin D., Palles C., Church D., Domingo E.,
Jones A., Johnstone E., Wang H., Love S., Julier
P., Scudder C., Nicholson G., Gonzalez-Neira
A., Martin M., Sargent D., Green E., McLeod H.,
Zanger U.M., Schwab M., Braun M., Seymour M.,
Thompson L., Lacas B., Boige V., Ribelles N., Afzal
S., Enghusen H., Jensen S.A., Etienne-Grimaldi
M.C., Milano G., Wadelius M., Glimelius B., Garmo
H., Gusella M., Lecomte T., Laurent-Puig P.,
Martinez-Balibrea E., Sharma R., Garcia-Foncillas
J., Kleibl Z., Morel A., Pignon J.P., Midgley R., Kerr
D., and Tomlinson I. Genetic markers of toxicity
from capecitabine and other fluorouracil-based
regimens: Investigation in the QUASAR2 study,
systematic review, and meta-analysis. [2014]
87. Saad F., de Bono J., Shore N., Fizazi K., Loriot Y.,
Hirmand M., Franks B., Haas G.P., and Scher H.I.
Efficacy Outcomes by Baseline Prostate-specific
Antigen Quartile in the AFFIRM Trial. [2014]
European Urology. Impact factor : 12.480
88. Schroeder S., Pendl T., Zimmermann A., Eisenberg
T., Carmona-Gutierrez D., Ruckenstuhl C., Marino
G., Pietrocola F., Harger A., Magnes C., Sinner F.,
Pieber T.R., Dengjel J., Sigrist S.J., Kroemer G.,
and Madeo F. Acetyl-coenzyme A: A metabolic
master regulator of autophagy and longevity.
[2014] Autophagy (10) 7 : 1335-1337. Impact
factor : 11.423
89. Shore N.D., Bono P., Massard C., Snapir A.,
Sarapohja T., and Fizazi K. ODM-201 and the CNS:
A clinical perspective. [2014] Journal of Clinical
90. Sieri S., Chiodini P., Agnoli C., Pala V., Berrino
F., Trichopoulou A., Benetou V., Vasilopoulou E.,
Sanchez M.J., Chirlaque M.D., Amiano P., Ramon
Quiros J., Ardanaz E., Buckland G., Masala
G., Panico S., Grioni S., Sacerdote C., Tumino
R., Boutron-Ruault M.C., Clavel-Chapelon F.,
Fagherazzi G., Peeters P.H.M., van Gils C.H.,
Bueno-de-Mesquita H.B., van Kranen H.J., Key
T.J., Travis R.C., Khaw K.T., Wareham N.J., Kaaks
R., Lukanova A., Boeing H., Schuetze M., Sonestedt
E., Wirfaelt E., Sund M., Andersson A., Chajes V.,
Rinaldi S., Romieu I., Weiderpass E., Skeie G.,
Dagrun E., Tjonneland A., Halkjaer J., Overvard
K., Merritt M.A., Cox D., Riboli E., and Krogh V.
Dietary Fat Intake and Development of Specific
Breast Cancer Subtypes. [2014] Jnci-Journal of
the National Cancer Institute (106) 5 : dju068dju068. Impact factor : 15.161
91. Smith M.R., Coleman R.E., Klotz L., Pittman K.B.,
Milecki P., Wei R., Balakumaran A., and Fizazi K.
Denosumab for the prevention of symptomatic
skeletal events in patients with castrationresistant advanced prostate cancer: A comparison
with skeletal-related events. [2014] Journal of
Clinical Oncology (32) 4 Suppl.. Impact factor :
17.879
92. Smith M.R., Matheny S., Saad F., Rathkopf D.E.,
Mulders P.F.A., De Bono J.S., Small E.J., Shore
N.D., Fizazi K., Kheoh T.S., Li J., Todd M.B., Griffin
T.W., Yu M.K., and Ryan C.J. Response to androgen
signaling (AS)-directed therapy after treatment
with abiraterone acetate (AA) in patients (pts)
cancer (mCRPC): Post hoc analysis of study COUAA-302. [2014] Journal of Clinical Oncology (32) 4
Suppl.. Impact factor : 17.879
93. Sonpavde G., Sudarshan S., and Escudier B.
Do the sites of metastases provide additional
information regarding prognosis and biology in
renal cell carcinoma? [2014] European Urology
(65) 3 : 585-586. Impact factor : 12.480
94. Veccia A., Ortega C., Di Lorenzo G., La Russa F.,
Burgio S.L., Facchini G., Messina C., Sacco C.,
Spizzo G., Aieta M., Lodde M., Mansueto G., Zucali
P.A., D’Angelo A., Iacovelli R., Massari F., Morelli
F., Procopio G., Ruatta F., and Caffo O. Clinical
outcomes of patients (pts) age 60 or younger
treated with docetaxel (DOC) for castrationresistant prostate cancer (CRPC): Results of an
Italian multicenter retrospective study (CYCLOP
study). [2014] Journal of Clinical Oncology (32)
S4. Impact factor : 17.879
95. Viprey V.F., Gregory W.M., Corrias M.V., Tchirkov A.,
Swerts K., Vicha A., Dallorso S., Brock P., Luksch
R., Valteau-Couanet D., Papadakis V., Laureys
18
G., Pearson A.D., Ladenstein R., and Burchill
S.A. Neuroblastoma mRNAs predict outcome in
children with stage 4 neuroblastoma: A European
HR-NBL1/SIOPEN study. [2014] Journal of
Clinical Oncology (32) 10 : 1074-1083. Impact
factor : 17.879
96. Viry E., Baginska J., Berchem G., Noman M.Z.,
Medves S., Chouaib S., and Janji B. Autophagic
degradation of GZMB/granzyme B : a new
mechanism of hypoxic tumor cell escape from
natural killer cell-mediated lysis. [2014]
Autophagy (10) 1 : 173-175. Impact factor : 11.423
97. Wislez M., Barlesi F., Besse B., Mazieres J., Merle
P., Cadranel J., Audigier-Valette C., Moro-Sibilot
D., Gautier-Felizot L., Goupil F., Renault A., Quoix
E., Souquet P.J., Madroszyck A., Corre R., Perol D.,
Morin F., Zalcman G., and Soria J.C. Customized
adjuvant phase II trial in patients with nonsmall-cell lung cancer: IFCT-0801 TASTE. [2014]
98. Wu C., Kraft P., Stolzenberg-Solomon R., Steplowski
E., Brotzman M., Xu M., Mudgal P., Amundadottir
5., Arslan A.A., Bueno-de-Mesquita H.B., Gross
M., Helzlsouer K., Jacobs E.J., Kooperberg C.,
Petersen G.M., Zheng W., Albanes D., BoutronRuault M.C., Buring J.E., Canzian F., Cao G., Duell
E.J., Elena J.W., Gaziano J.M., Giovannucci E.L.,
Hallmans G., Hutchinson A., Hunter D.J., Jenab M.,
Jiang G., Khaw K.T., LaCroix A., Li Z., Mendelsohn
J.B., Panico S., Patel A.V., Qian Z.R., Riboli E.,
Sesso H., Shen H., Shu Z.O., Tjonneland A., Tobias
G.S., Trichopoulos D., Virtamo J., Visvanathan K.,
Wactawski-Wende J., Wang C., Yu K., ZeleniuchJacquotte A., Chanock S., Hoover R., Hartge P.,
Fuchs C.S., Lin D., and Wolpin B.M. Genome-wide
association study of survival in patients with
pancreatic adenocarcinoma. [2014] Gut. Impact
factor : 13.319
99. Yamada O., Mahfoudhi E., Plo I., Ozaki K.,
Nakatake M., Akiyama M., Yamada H., Kawauchi
K., and Vainchenker W. Emergence of a BCR-ABL
Translocation in a Patient With the JAK2V617F
Mutation: Evidence for Secondary Acquisition of
BCR-ABL in the JAK2V617F Clone. [2014] Journal
of Clinical Oncology (32) 21 : E76-E79. Impact
factor : 17.879
100. Yu E.Y., Saad F., Londhe A., Shore N.D., Van
Poppel H., Rathkopf D.E., Smith M.R., Logothetis
C., De Souza P.L., Fizazi K., Mulders P.F.A.,
Mainwaring P.N., Hainsworth J.D., Beer T.M., North
S.A., Small E.J., Scher H.I., Griffin T.W., Yu M.K.,
and Ryan C.J. Association of alkaline phosphatase
(ALP) with clinical outcomes in chemotherapynaive patients (pts) with metastatic castrationresistant prostate cancer (mCRPC): Results from
COU-AA-302. [2014] Journal of Clinical Oncology
101. Zitvogel L. and Kroemer G. Cytokines reinstate
NK cell-mediated cancer immunosurveillance.
[2014] Journal of Clinical Investigation (124) 11 :
4687-4689. Impact factor : 13.765
102. Zitvogel L. and Kroemer G. Targeting foxp1
for reinstating anticancer immunosurveillance.
[2014] Immunity (41) 3 : 345-347. Impact factor :
19.748
19
/ PUBLICATIONS INTERNATIONALES (TOUS TYPES)
GUSTAVE ROUSSY 2014
A IMPACT FACTOR THOMSON REUTERS 2014 COMPRIS ENTRE 5 ET 10 (324 PUBLICATIONS)
1. A
apro M., Andre F., Blackwell K., Calvo E., Jahanzeb
M., Papazisis K., Porta C., Pritchard K., and Ravaud A.
Adverse event management in patients with advanced
cancer receiving oral everolimus: Focus on breast
cancer. [2014] Annals of Oncology (25) 4 : 763-773.
2. A
denis A., Blay J.Y., Bui-Nguyen B., Bouché O., Bertucci
F., Isambert N., Bompas E., Chaigneau L., Domont
J., Ray-Coquard I., Blésius A., Van tine B.A., Bulusu
V.R., Dubreuil P., Mansfield C.D., Acin Y., Moussy A.,
Hermine O., and Le Cesne A. Masitinib in advanced
gastrointestinal stromal tumor (GIST) after failure of
imatinib: A randomized controlled open-label trial.
[2014] Annals of Oncology (25) 9 : 1762-1769. Impact
factor : 7.040
3. A
ftimos PG. Phase i/iia study with CNS-targeted
liposomal Doxorubicin (2b3-101) in patients with brain
metastases (bm) from breast cancer (bc) and other
brain. [2014] Annals of Oncology (25) S1 : i25-i25.
4. A
gresta S., Stein E.M., Tallman M.S., Levine R.L., Yua
H., Yen K., Fan B., Flinn I.W., Fathi A.T., Stone R.M.,
DeAngelo D.J., DeBotton S., and Pollyea D.A. A Phase
I Study of AG-221, A First in Class, Potent Inhibitor
of the IDH2-Mutant Protein, in Patients with IDH2
Mutant Positive Advanced Hematologic Malignancies.
[2014] Haematologica (99) S1 : 789-789. Impact factor
: 5.814
5. A
hmed M., Solbiati L., Brace C.L., Breen D.J., Callstrom
M.R., Charboneau J.W., Chen M.H., Choi B.I., de Baere
T., Dodd III G.D., Dupuy D.E., Gervais D.A., Gianfelice
D., Gillams A.R., Lee J., Leen E., Lencioni R., Littrup
P.J., Livraghi T., Lu D.S., McGahan J.P., Meloni M.F.,
Nikolic B., Pereira P.L., Liang P., Rhim H., Rose S.C.,
Salem R., Sofocleous C.T., Solomon S.B., Soulen M.C.,
Tanaka M., Vogl T.J., Wood B.J., Goldberg S.N., Tumor
I.W.G.I.-G., Front I.O.S., Radiology S.I., and Radiolog
C.I. Image-guided Tumor Ablation: Standardization
of Terminology and Reporting Criteria-A 10-Year
Update. [2014] Radiology (273) 1 : 241-260. Impact
factor : 6.867
6. A
kalay I., Tan T.Z., Kumar P., Janji B., Mami-Chouaib F.,
Charpy C., Vielh P., Larsen A.K., Thiery J.P., Sabbah M.,
and Chouaib S. Targeting WNT1-inducible signaling
pathway protein 2 alters human breast cancer cell
susceptibility to specific lysis through regulation
of KLF-4 and miR-7 expression. [2014] Oncogene.
7. A
l Nakouzi N., Cotteret S., Commo F., Gaudin C., Rajpar
S., Dessen P., Vielh P., Fizazi K., Chauchereau A., and
Nakouzi N.A. Targeting CDC25C, PLK1 and CHEK1
to overcome Docetaxel resistance induced by loss of
LZTS1 in prostate cancer. [2014] Oncotarget (5) 3 :
667-678. Impact factor : 6.359
8. A
lapetite C., Ruffier-Loubiere A., De Marzi L., Bolle S.,
Claude L., Habrand J.L., Brisse H., Frappaz D., Doz F.,
Bourdeaut F., Dendale R., Mazal A., and Fournier-Bidoz
N. Protontherapy for whole Ventricular Irradiation in
Localized Intracranial Germinoma: which Benefit.
The French Experience. [2014] Neuro-Oncology (16)
Suppl.1 : i36-i36. Impact factor : 5.562
9. A
lbiges L., Guegan J., Le Formal A., Verkarre V., RiouxLeclercq N., Sibony M., Bernhard J.C., Camparo P.,
Merabet Z., Molinie V., Allory Y., Orear C., Couvé S.,
Gad S., Patard J.J., and Escudier B. MET Is a potential
target across all papillary renal cell carcinomas:
Result from a large molecular study of pRCC with
CGH array and matching gene expression array.
[2014] Clinical Cancer Research (20) 13 : 3411-3421.
10. A
leksandrova K., Jenab M., Bueno-de-Mesquita H.B.,
Fedirko V., Kaaks R., Lukanova A., van Duijnhoven
F.J.B., Jansen E., Rinaldi S., Romieu I., Ferrari P.,
Murphy N., Gunter M.J., Riboli E., Westhpal S.,
Overvad K., Tjonneland A., Halkjaer J., BoutronRuault M.C., Dossus L., Racine A., Trichopoulou
A., Bamia C., Orfanos P., Agnoli C., Palli D., Panico
S., Tumino R., Vineis P., Peeters P.H., Duell E.J.,
Molina-Montes E., Ramon Quiros J., Dorronsoro M.,
Chirlaque M.D., Barricarte A., Ljuslinder I., Palmqvist
R., Travis R.C., Khaw K.T., Wareham N., Pischon T.,
and Boeing H. Biomarker patterns of inflammatory
and metabolic pathways are associated with risk
of colorectal cancer: results from the European
Prospective Investigation into Cancer and Nutrition
({EPIC}). [2014] European Journal of Epidemiology
(29) 4 : 261-275. Impact factor : 5.339
20
11. A
leksandrova K., Drogan D., Boeing H., Jenab M.,
Bueno-de-Mesquita H.B., Jansen E., van Duijnhoven
F.J.B., Rinaldi S., Fedirko V., Romieu I., Kaaks R., Riboli
E., Gunter M.J., Romaguera D., Westhpal S., Overvad
K., Tjonneland A., Halkjaer J., Boutron-Ruault M.C.,
Clavel-Chapelon F., Lukanova A., Trichopoulou A.,
Trichopoulos D., Vidalis P., Panico S., Agnoli C., Palli
D., Tumino R., Vineis P., Buckland G., Sanchez-Cruz
J.J., Dorronsoro M., Tormo Diaz M.J., Barricarte A.,
Ramon Quiros J., Peeters P.H., May A.M., Hallmans
G., Palmqvist R., Crowe F.L., Khaw K.T., Wareham N.,
and Pischon T. Adiposity, mediating biomarkers and
risk of colon cancer in the European Prospective
Investigation into Cancer and Nutrition Study. [2014]
International Journal of Cancer (134) 3 : 612-621.
12. A
leksandrova K., Pischon T., Jenab M., Buenode-Mesquita H., Fedirko V., Norat T., Romaguera
D., Knuppel S., Boutron-Ruault M.C., Dossus L.,
Dartois L., Kaaks R., Li K., Tjonneland A., Overvad K.,
Quiros J., Buckland G., Sanchez M., Dorronsoro M.,
Chirlaque M.D., Barricarte A., Khaw K.T., Wareham
N.J., Bradbury K.E., Trichopoulou A., Lagiou P.,
Trichopoulos D., Palli D., Krogh V., Tumino R.,
Naccarati A., Panico S., Siersema P.D., Peeters P.,
Ljuslinder I., Johansson I., Ericson U., Ohlsson B.,
Weiderpass E., Skeie G., Borch K., Rinaldi S., Romieu
I., Kong J., Gunter M.J., Ward H.A., Riboli E., and
Boeing H. Combined impact of healthy lifestyle
factors on colorectal cancer: a large European
cohort study. [2014] BMC Medicine (12) 1 : 168-168.
13. A
lgret R., Fernandez-Martinez J., Shi Y., Kim S.J.,
Pellarin R., Cimermancic P., Cochet E., Sali A., Chait
B.T., Rout M.P., and Dokudovskaya S. Molecular
architecture and function of the SEA complex, a
modulator of the TORC1 pathway. [2014] Molecular
& cellular proteomics (MCP) (13) 11 : 2855-2870.
14. A
mabille M.I., Mazouni C., Mesnard C., Sarfati B.,
Leymarie N., Bentivegna E., Garbay J., and Rimareix
F. Predictive factors of failure and complications of
oncoplastic breast surgery. [2014] European Journal
of Cancer (50) S2 : S158-S159. Impact factor : 5.417
15. A
nantharaman D., Gheit T., Waterboer T., Halec G.,
Carreira C., Abedi-Ardekani B., McKay-Chopin S.,
Zaridze D., Mukeria A., Szeszenia-Dabrowska N.,
Lissowska J., Mates D., Janout V., Foretova L., Bencko
V., Rudnai P., Fabianova E., Tjonneland A., Travis R.C.,
Boeing H., Quiros J.R., Johansson M., Krogh V., Buenode-Mesquita H.B., Kotanidou A., Clavel-Chapelon F.,
Weiderpass E., Johansson M., Pawlita M., Scelo G.,
Tommasino M., and Brennan P. No Causal Association
Identified for Human Papillomavirus Infections in
Lung Cancer. [2014] Cancer research (74) 13 : 35253534. Impact factor : 9.329
16. A
ndré F. Overcoming Implementation Challenges
of Personalized Cancer Therapy in Patients with
Breast Cancer. [2014] Annals of Oncology (25) supp
4 : 146IN. Impact factor : 7.040
17. A
ndré F. Current limitations of precision medicine
in the breast cancer field. [2014] European Journal
18. A
ndré F. Predictive biomarkers. [2014] European Journal
19. A
ndré F. Reproducible, innovative, global and
balanced: The pillars for manuscript acceptance at
annals of oncology. [2014] Annals of Oncology (25) 4
: 759-760. Impact factor : 7.040
20. A
ngelergues A., Maillet D., Flechon A., Ozguroglu M.,
Mercier F., Guillot A., Le Moulec S., Gravis G., Beuzeboc
P., Massard C., Fizazi K., Rouge T.d.L.M., Delanoy N.,
Elaidi R.T., and Oudard S. Prostate-specific antigen
flare induced by cabazitaxel-based chemotherapy
in patients with metastatic castration-resistant
prostate cancer. [2014] European Journal of Cancer
(50) 9 : 1602-1609. Impact factor : 5.417
21. A
ngevin E., Tabernero J., Elez E., Cohen S.J., Bahleda
R., Van Laethem J.L., Ottensmeier C., Lopez-Martin
J.A., Clive S., Joly F., Ray-Coquard I., Dirix L., Machiels
J.P., Steven N., Reddy M., Hall B., Puchalski T.A.,
Bandekar R., Van De Velde H., Tromp B., Vermeulen
J., and Kurzrock R. A Phase I/II, multiple-dose, doseescalation study of siltuximab, an anti-interleukin-6
monoclonal antibody, in patients with advanced
21
solid tumors. [2014] Clinical Cancer Research (20) 8
: 2192-2204. Impact factor : 8.722
22. A
randa F., Bloy N., Pesquet J., Petit B., Chaba K.,
Sauvat A., Kepp O., Khadra N., Enot D., Pfirschke
C., Pittet M., Zitvogel L., Kroemer G., and Senovilla
L. Immune-dependent antineoplastic effects of
cisplatin plus pyridoxine in non-small-cell lung
cancer. [2014] Oncogene. Impact factor : 8.459
23. A
randa F., Vacchelli E., Eggermont A., Galon J., Fridman
W.H., Zitvogel L., Kroemer G., and Galluzzi L. Trial
watch : Immunostimulatory monoclonal antibodies
in cancer therapy. [2014] OncoImmunology (3) :
e27297-e27297. Impact factor : 6.266
24. A
randa F., Bloy N., Galluzzi L., Kroemer G.,
and Senovilla L. Vitamin B6 improves the
immunogenicity of cisplatin-induced cell death.
[2014] OncoImmunology (3) 9 : e955685-e955685.
25. A
randa F., Vacchelli E., Obrist F., Eggermont A., Galon
J., Fridman W.H., Cremer I., Tartour E., Zitvogel L.,
Kroemer G., and Galluzzi L. Trial Watch : Adoptive
cell transfer for anticancer immunotherapy. [2014]
OncoImmunology (3). Impact factor : 6.266
26. A
randa F., Vacchelli E., Obrist F., Eggermont A.,
Galon J., Sautès-Fridman C., Cremer I., Henrik Ter
Meulen J., Zitvogel L., Kroemer G., and Galluzzi
L. Trial Watch: Toll-like receptor agonists in
oncological indications. [2014] OncoImmunology (3)
: e29179-e29179. Impact factor : 6.266
27. A
rnedos M., Drury S., Afentakis M., A’Hern R.,
Hills M., Salter J., Smith I.E., Reis-Filho J.S., and
Dowsett M. Biomarker changes associated with the
development of resistance to aromatase inhibitors
(AIs) in estrogen receptor-positive breast cancer.
factor : 7.040
28. A
rnedos M., Soria J.C., Andre F., and Tursz T.
Personalized treatments of cancer patients: a
reality in daily practice, a costly dream or a shared
vision of the future from the oncology community?
[2014] Cancer Treatment Reviews (40) 10 : 11921198. Impact factor : 7.588
29. A
rnedos M., Vielh P., Soria J.C., and Andre F. The
genetic complexity of common cancers and the
promise of personalized medicine: is there any
hope? [2014] Journal of Pathology (232) 2 : 274-282.
30. A
rrondeau J., Ammari S., Besse B., and Soria
J.C. LDK378 compassionate use for treating
carcinomatous meningitis in an ALK translocated
non-small-cell lung cancer. [2014] Journal of
Thoracic Oncology (9) 8 : e62-e63. Impact factor :
5.282
31. A
rrondeau J., Le Pechoux C., Le Moulec S., Barlési F.,
Lesueur P., and Besse B. Bevacizumab Safety when
Combined with Whole-Brain Radiation Therapy
(WBRT). [2014] Journal of Thoracic Oncology (9) 4,
S1 : S49-S49. Impact factor : 5.282
32. B
abron M.C., Kazma R., Gaborieau V., McKay J.,
Brennan P., Sarasin A., and Benhamou S. Genetic
variants in DNA repair pathways and risk of upper
aerodigestive tract cancers: combined analysis of
data from two genome-wide association studies in
European populations. [2014] Carcinogenesis (35) 7
: 1523-1527. Impact factor : 5.334
33. B
ardin C., Veal G., Paci A., Chatelut E., Astier A.,
Levêque D., Widmer N., and Beijnen J. Therapeutic
drug monitoring in cancer--are we missing a trick?
[2014] European Journal of Cancer (50) 12 : 20052009. Impact factor : 5.417
34. B
arrdahl M., Canzian F., Joshi A.D., Travis R.C., ChangClaude J., Auer P.L., Gapstur S.M., Gaudet M., Diver
W.R., Henderson B.E., Haiman C.A., Schumacher
F.R., Le Marchand L., Berg C.D., Chanock S.J., Hoover
R.N., Rudolph A., Ziegler R.G., Giles G.G., Baglietto L.,
Severi G., Hankinson S.E., Lindstroem S., Willet W.,
Hunter D.J., Buring J.E., Lee I.M., Zhang S., Dossus
L., Cox D.G., Khaw K.T., Lund E., Naccarati A., Peeters
P.H., Ramon Quiros J., Riboli E., Sund M., Trichopoulos
D., Prentice R.L., Kraft P., Kaaks R., and Campa D.
Post-G WAS gene-environment interplay in breast
22
cancer: results from the Breast and Prostate Cancer
Cohort Consortium and a meta-analysis on 79 000
women. [2014] Human Molecular Genetics (23) 19 :
5260-5270. Impact factor : 6.393
35. B
arton O., Naumann S.C., Diemer-Biehs R., Kunzel
J., Steinlage M., Conrad S., Makharashvili N., Wang
J., Feng L., Lopez B.S., Paull T.T., Chen J., Jeggo P.A.,
and Löbrich M. Polo-like kinase 3 regulates CtIP
during DNA double-strand break repair in G1. [2014]
The Journal of cell biology (206) 7 : 877-894. Impact
factor : 9.834
36. B
eau-Faller M., Prim N., Ruppert A.M., NanniMetéllus I., Lacave R., Lacroix L., Escande F., Lizard
S., Pretet J.L., Rouquette I., De Cremoux P., Solassol
J., de Fraipont F., Bièche I., Cayre A., Favre-Guillevin
E., Tomasini P., Wislez M., Besse B., Legrain M.,
Voegeli A.C., Baudrin L., Morin F., Zalcman G., Quoix
E., Blons H., and Cadranel J. Rare EGFR exon 18 and
exon 20 mutations in non-small-cell lung cancer
on 10 117 patients: A multicentre observational
study by the French ERMETIC-IFCT network. [2014]
Annals of Oncology (25) 1 : 126-131. Impact factor :
7.040
37. B
eck C., Boehler C., Barbat J.G., Bonnet M.E., Illuzzi
G., Ronde P., Gauthier L.R., Magroun N., Rajendran A.,
Lopez B.S., Scully R., Boussin F.D., Schreiber V., and
Dantzer F. PARP3 affects the relative contribution
of homologous recombination and nonhomologous
end-joining pathways. [2014] Nucleic Acids
Research (42) 9 : 5616-5632. Impact factor : 9.112
38. B
eelen R., Stafoggia M., Raaschou-Nielsen
O., Andersen Z.J., Xun W.W., Katsouyanni K.,
Dimakopoulou K., Brunekreef B., Weinmayr G.,
Hoffmann B., Wolf K., Samoli E., Houthuijs D.,
Nieuwenhuijsen M., Oudin A., Forsberg B., Olsson D.,
Salomaa V., Lanki T., Yli-Tuomi T., Oftedal B., Aamodt
G., Nafstad P., De Faire U., Pedersen N.L., Ostenson
C.G., Fratiglioni L., Penell J., Korek M., Pyko A.,
Eriksen K.T., Tjonneland A., Becker T., Eeftens M.,
Bots M., Meliefste K., Wang M., Bueno-de-Mesquita
B., Sugiri D., Kraemer U., Heinrich J., de Hoogh
K., Key T., Peters A., Cyrys J., Concin H., Nagel G.,
Ineichen A., Schaffner E., Probst-Hensch N., Dratva
J., Ducret-Stich R., Vilier A., Clavel-Chapelon F.,
Stempfelet M., Grioni S., Krogh V., Tsai M.Y., Marcon A.,
Ricceri F., Sacerdote C., Galassi C., Migliore E., Ranzi
A., Cesaroni G., Badaloni C., Forastiere F., Tamayo I.,
Amiano P., Dorronsoro M., Katsoulis M., Trichopoulou
A., Vineis P., and Hoek G. Long-term Exposure to Air
Pollution and Cardiovascular Mortality An Analysis
of 22 European Cohorts. [2014] Epidemiology (25) 3 :
39. B
ento C., Percy M.J., Gardie B., Magalhaes Maia T.,
van Wijk R., Perrotta S., Della Ragione F., Almeida
H., Rossi C., Girodon F., Astrom M., Neumann D.,
Schnittger S., Landin B., Minkov M., Randi M.L.,
Richard S., Casadevall N., Vainchenker W., Rives
S., Hermouet S., Ribeiro M.L., McMullin M.F., and
Cario H. Genetic Basis of Congenital Erythrocytosis:
Mutation Update and Online Databases. [2014]
Human Mutation (35) 1 : 15-26. Impact factor : 5.144
40. B
ergthold G., Bandopadhayay P., Rich B., Chan
J., Santagata S., Hoshida Y., Ramkissoon S.,
Ramkissoon L., Golub T., Tabak B., Ferrer-Luna R.,
Weng P.Y., Stiles C., Grill J., Kieran M.W., Ligon K.L.,
and Beroukhim R. Gene Expression Analysis of 151
Pediatric Low-Grade Gliomas Reveals Underlying
Molecular Heterogeneity. [2014] Neuro-Oncology
(16) Suppl. 1 : i62-i62. Impact factor : 5.562
41. B
ertozzi A.I., Munzer C., Fouyssac F., Andre N., Boetto
S., Leblond P., Bourdeaut F., and Dufour C. Atypical
Teratoid Rhabdoid Tumours (ATRT): A French
Retrospective Study. [2014] Neuro-Oncology (16)
Suppl. 1 : i1-i1. Impact factor : 5.562
42. B
erveiller P., Selleret L., and Mir O. Drug selection
and dosing in pregnant cancer patients: insights
from clinical pharmacokinetics. [2014] Annals of
43. B
esse B., Adjei A., Baas P., Meldgaard P., Nicolson M.,
Paz-Ares L., Reck M., Smit E.F., Syrigos K., Stahel R.,
Felip E., Peters S., Stahel R., Peters S., Kerr K., Besse
B., Vansteenkiste J., Eberhardt W., Edelman M., Mok
T., O’Byrne K., Novello S., Bubendorf L., Marchetti A.,
Smit F.E., Crino L., Van Schil P., Senan S.a., FaivreFinn C., Rocco G.a., Veronesi G.a., Douillard J.Y., Lim
E.a., Dooms C., Weder W.a., de Ruysscher D., Le
23
Pechoux C.a., de Leyn P., and Westeel V.a. 2nd ESMO
Consensus Conference on Lung Cancer: Non-smallcell lung cancer first-line/second and further lines
in advanced disease. [2014] Annals of Oncology (25)
8 : 1475-1484. Impact factor : 7.040
in PROFILE 1007: A Randomized Trial of Crizotinib
Compared with Chemotherapy in Previously Treated
Patients with ALK-Positive Advanced Non-SmallCell Lung Cancer. [2014] Journal of Thoracic
44. B
esse B., Leighl N., Bennouna J., Papadimitrakopoulou
V.A., Blais N., Traynor A.M., Soria J.C., Gogov S., Miller N.,
Jehl V., and Johnson B.E. Phase II study of everolimuserlotinib in previously treated patients with advanced
non-small-cell lung cancer. [2014] Annals of Oncology
(25) 2 : 409-415. Impact factor : 7.040
50. B
loy N., Pol J., Manic G., Vitale I., Eggermont A.,
Galon J., Tartour E., Zitvogel L., Kroemer G., and
Galluzzi L. Trial Watch : Radioimmunotherapy for
oncological indications. [2014] OncoImmunology (3)
9 : e954929-e954929. Impact factor : 6.266
45. B
esse B., Heist R.S., Papadmitrakopoulou V.A.,
Camidge D.R., Beck J.T., Schmid P., Mulatero C.,
Miller N., Dimitrijevic S., Urva S., Pylvaenaeinen
I., Petrovic K., and Johnson B.E. A phase Ib doseescalation study of everolimus combined with
cisplatin and etoposide as first-line therapy in
patients with extensive-stage small-cell lung
cancer. [2014] Annals of Oncology (25) 2 : 505-511.
46. B
étermier M., Bertrand P., and Lopez B.S. Is nonhomologous end-joining really an inherently
error-prone process? [2014] PLoS genetics (10) 1 :
e1004086-e1004086. Impact factor : 7.528
47. B
inachon B., Dossus L., Danjou A.M.N., ClavelChapelon F., and Fervers B. Life in urban areas and
breast cancer risk in the French E3N cohort. [2014]
European Journal of Epidemiology (29) 10 : 743-751.
48. B
iton A., Bernard-Pierrot I., Lou Y., Krucker C.,
Chapeaublanc E., Rubio-Pérez C., Lopez-Bigas
N., Kamoun A., Neuzillet Y., Gestraud P., Grieco L.,
Rebouissou S., de Reyniès A., Benhamou S., Lebret
T., Southgate J., Barillot E., Allory Y., Zinovyev A.,
and Radvanyi F. Independent component analysis
uncovers the landscape of the bladder tumor
transcriptome and reveals insights into luminal
and basal subtypes. [2014] Cell reports (9) 4 : 12351245. Impact factor : 8.358
49. B
lackhall F., Kim D.W., Besse B., Nokihara H., Han J.Y.,
Wilner K.D., Reisman A., Iyer S., Hirsh V., and Shaw
A.T. Patient-Reported Outcomes and Quality of Life
51. B
loy N., Pol J., Aranda F., Eggermont A., Cremer
I., Fridman W.H., Fucikova J., Galon J., Tartour E.,
Spisek R., Dhodapkar M.V., Zitvogel L., Kroemer G.,
and Galluzzi L. Trial watch: Dendritic cell-based
anticancer therapy. [2014] OncoImmunology (3) 11 :
e963424-e963424. Impact factor : 6.266
52. B
onnetain F., Bonsing B., Conroy T., Dousseau
A., Glimelius B., Haustermans K., Lacaine F., van
Laethem J.L., Aparicio T., Aust D., Bassi C., Berger V.,
Chamorey E., Chibaudel B., Dahan L., De Gramont A.,
Delpero J.R., Dervenis C., Ducreux M., Gal J., Gerber
E., Ghaneh P., Hammel P., Hendlisz A., Jooste V.,
Labianca R., Latouche A., Lutz M., Macarulla T., Malka
D., Mauer M., Mitry E., Neoptolemos J., Pessaux P.,
Sauvanet A., Tabernero J., Taieb J., van Tienhoven
G., Gourgou-Bourgade S., Bellera C., MathoulinPélissier S., and Collette L. Guidelines for time-toevent end-point definitions in trials for pancreatic
cancer. Results of the DATECAN initiative (Definition
for the Assessment of Time-to-event End-points in
CANcer trials). [2014] European Journal of Cancer
(50) 17 : 2983-2993. Impact factor : 5.417
53. B
ouabdallah K., Gilleron A., Haioun C., Lahssen
H.O., Delarue R., and Ribrag V. Torisel in Mantle Cell
Lymphoma : Results of Restor Study (Non Interventional,
Longitudinal, Retrospective, Multicenter and National
Study on a Cohort of 93 Patients with Mantle Cell
Lymphoma. [2014] Haematologica (99) Suppl. 1 : 416416. Impact factor : 5.814
54. B
ounedjah O., Desforges B., u T.D., ioche-Durieu C.,
Marco S., Hamon L., urmi P.A., uerquin-Kern J.L.,
iétrement O., and astré D. Free mRNA in excess
24
upon polysome dissociation is a scaffold for protein
multimerization to form stress granules. [2014]
Nucleic Acids Research (42) 13 : 8678-8691. Impact
factor : 9.112
55. B
randsma D., Dieras V., Altintas S., Anders C.,
Arnedos M., Gelderblom H., Soetekouw P., Jager A.,
van Linde M., and Aftimos P. 2B3-101, Glutathione
Pegylated Liposomal Doxorubicin, in Patients with
Recurrent High Grade Gliomas and Breast Cancer
Metastases. [2014] Neuro-Oncology (16) Suppl. 2 :
ii50-ii51. Impact factor : 5.562
56. B
rasme J.F., Grill J., Gaspar N., Oberlin O., ValteauCouanet D., and Chalumeau M. Evidence of
increasing mortality with longer time to diagnosis
of cancer: Is there a paediatric exception? [2014]
European Journal of Cancer (50) 4 : 864-866. Impact
factor : 5.417
57. B
ressy C. and Benihoud K. Association of oncolytic
adenoviruses with chemotherapies: an overview and
future directions. [2014] Biochemical pharmacology
(90) 2 : 97-106. Impact factor : 5.009
58. B
roussais-Guillaumot F., Morschhauser F., Terriou
L., Kim W.S., Lim S.T., Egyed M., Coiffier B., Bachy
E., Dyer M.J., Illes A., Rosta A., Lemieux B., Wu K.L.,
Yoon S.S., Kim S., Gasztonyi Z., Jakucs J., Offner F.,
den Neste E., Ysebaert L., Wendtner C.M., Kloos I.,
Sarry A.L., Malasse S., and Ribrag V. Abexinostat
(S78454) a Histone Deacetylase Inhibitor, in Patients
with Refractory or Relapsed Hodgkin’s Lymphoma,
Non-Hodgkin Lymphoma and Chronic Lymphocytic
Leukaemia : Preliminary Phase II Results. [2014]
Haematologica (99) Suppl. 1 : 141-141. Impact factor
: 5.814
59. B
uckland G., Ros M.M., Roswall N., Bueno-deMesquita H.B., Travier N., Tjonneland A., Kiemeney
L.A., Sacerdote C., Tumino R., Ljungberg B., Gram
I.T., Weiderpass E., Skeie G., Malm J., Ehrnstrom
R., Chang-Claude J., Mattiello A., Agnoli C., Peeters
P.H., Boutron-Ruault M.C., Fagherazzi G., ClavelChapelon F., Nilsson L.M., Amiano P., Trichopoulou
A., Oikonomou E., Tsiotas K., Sanchez M.J., Overvad
K., Quiros J.R., Chirlaque M.D., Barricarte A., Key T.J.,
Allen N.E., Khaw K.T., Wareham N., Riboli E., Kaaks
R., Boeing H., Palli D., Romieu I., Romaguera D., and
Gonzalez C.A. Adherence to the Mediterranean diet
and risk of bladder cancer in the EPIC cohort study.
[2014] International Journal of Cancer (134) 10 :
2504-2511. Impact factor : 5.085
60. B
uczek M., Escudier B., Bartnik E., Szczylik C., and
Czarnecka A. Resistance to tyrosine kinase inhibitors
in clear cell renal cell carcinoma: From the patient’s
bed to molecular mechanisms. [2014] Biochimica et
Biophysica Acta - Reviews on Cancer (1845) 1 : 3141. Impact factor : 7.845
61. C
almon R., Grevent D., Blauwblomme T., Puget S.,
Sainte-Rose C., Varlet P., Dufour C., Grill J., Saitovich
A., Zilbovicius M., Brunelle F., and Boddaert N.
Multimodal Mr Imaging of Diffuse Intrinsic Pontine
Glioma (DIPG) : Detection of Pseudoprogression
after Radiotherapy as a Sign of Better Clinical
Outcome. [2014] Neuro-Oncology (16) Suppl. 1 :
i124-i124. Impact factor : 5.562
62. C
alvet C.Y., Thalmensi J., Pliquet E., Liard C., Bestetti
T., Demoyen P.L., Huet T., and Mir L.M. Optimization
of Intradermal Gene Electrotransfer Procedure for
Human Telomerase-Based DNA Vaccination. [2014]
Molecular Therapy (22) Suppl.1 : S246-S246. Impact
factor : 6.227
63. C
alvet C.Y., Famin D., Andre F.M., and Mir L.M.
Electrochemotherapy with bleomycin induces
hallmarks of immunogenic cell death in murine
colon cancer cells. [2014] OncoImmunology (3).
64. C
alvet C.Y., Andre F.M., and Mir L.M. Dual therapeutic
benefit of electroporation-mediated DNA vaccination
in vivo Enhanced gene transfer and adjuvant activity.
[2014] OncoImmunology (3). Impact factor : 6.266
65. C
amara-Clayette V., Lecluse Y., Schrader C., Klapper
W., Vainchenker W., Hermine O., and Ribrag V. The
NF-kB pathway is rarely spontaneously activated in
mantle cell lymphoma (MCL) cell lines and patient’s
samples. [2014] European Journal of Cancer (50) 1 :
25
66. C
amara-Costa H., Resch A., Lalande C., Kieffer V.,
Poggi G., Kennedy C., Bull K., Calaminus G., Grill
J., Doz F., Rutkowski S., Massimino M., Kortmann
R.D., Lannering B., Dellatolas G., and Chevignard
M. Neuropsychological Outcome of Children
Treated for Standard Risk Medulloblastoma
in the Hit-SIOP PNET4 European Randomised
Controlled Trial of Hyperfractionated (HFRT) versus
Standard Radiotherapy(STRT) and Maintenance
Chemotherapy. [2014] Neuro-Oncology (16) Suppl. 1
: i78-i78. Impact factor : 5.562
67. C
aniglia E.C., Cain L.E., Justice A., Tate J., Logan
R., Sabin C., Winston A., Van Sighem A., Miro J.M.,
Podzamczer D., Olson A., Arribas J.R., Moreno S.,
Meyer L., Del Romero J., Dabis F., Bucher H.C.,
Wandeler G., Vourli G., Skoutelis A., Lanoy E., Gasnault
J., Costagliola D., and Hernan M.A. Antiretroviral
penetration into the CNS and incidence of AIDSdefining neurologic conditions. [2014] Neurology
(83) 2 : 134-141. Impact factor : 8.286
68. C
assier P.A., Kantor G., Bonvalot S., Lavergne E.,
Stoeckle E., Le Péchoux C., Meeus P., Sunyach M.P.,
Vaz G., Coindre J.M., Linassier C., Labib A., Delcambre
C., Bay J.O., Leyvraz S., Dubergé T., Lagrange J.L.,
Duret A., and Blay J.Y. Adjuvant radiotherapy for
extremity and trunk wall atypical lipomatous tumor/
well-differentiated LPS (ALT/WD-LPS): A French
Sarcoma Group (GSF-GETO) Study. [2014] Annals of
69. C
assier P.A., Polivka V., Judson I., Soria J.C., Penel
N., Marsoni S., Verweij J., Schellens J.H., MoralesBarrera R., Schöffski P., Voest E.E., Gomez-Roca C.,
Evans T.R.J., Plummer R., Gallerani E., Kaye S.B.,
and Olmos D. Outcome of patients with sarcoma and
other mesenchymal tumours participating in phase
I trials: A subset analysis of a European phase I
database. [2014] Annals of Oncology (25) 6 : 12221228. Impact factor : 7.040
70. C
astel D., Debily M.A., Philippe C., Truffaux N., Taylor
K., Calmon R., Boddaert N., Le Dret L., Saulnier P.,
Lacroix L., Mackay A., Jones C., Puget S., SainteRose C., Blauwblomme T., Varlet P., and Grill J. The
Type of Histone H3 Variant with LYS27MET (K27M)
Change is a Prognostic Marker Associated with Two
Different Phenotypes of Diffuse Intrinsic Pontine
Gliomas (DIPG). [2014] Neuro-Oncology (16) Suppl. 1
: i47-i47. Impact factor : 5.562
71. C
astellsague X., Pawlita M., Roura E., Margall N.,
Waterboer T., Xavier Bosch F., de Sanjose S., Alberto
Gonzalez C., Dillner J., Gram I.T., Tjonneland A.,
Munk C., Pala V., Palli D., Khaw K.T., Barnabas R.V.,
Overvad K., Clavel-Chapelon F., Boutron-Ruault M.C.,
Fagherazzi G., Kaaks R., Lukanova A., Steffen A.,
Trichopoulou A., Trichopoulos D., Klinaki E., Tumino R.,
Sacerdote C., Mattiello A., Bueno-de-Mesquita H.B.,
Peeters P.H., Lund E., Weiderpass E., Ramon Quiros
J., Sanchez M.J., Navarro C., Barricarte A., Larranaga
N., Ekstrom J., Hortlund M., Lindquist D., Wareham N.,
Travis R.C., Rinaldi S., Tommasino M., Franceschi S.,
and Riboli E. Prospective seroepidemiologic study on
the role of Human Papillomavirus and other infections
in cervical carcinogenesis: Evidence from the EPIC
cohort. [2014] International Journal of Cancer (135) 2
: 440-452. Impact factor : 5.085
72. C
astro-Vega L.J., Buffet A., De Cubas A.A., Cascon A.,
Menara M., Khalifa E., Amar L., Azriel S., Bourdeau
I., Chabre O., Curras-Freixes M., Franco-Vidal V.,
Guillaud-Bataille M., Simian C., Morin A., Leton R.,
Gomez-Grana A., Pollard P.J., Rustin P., Robledo
M., Favier J., and Gimenez-Roqueplo A.P. Germline
mutations in FH confer predisposition to malignant
pheochromocytomas and paragangliomas. [2014]
Human Molecular Genetics (23) 9 : 2440-2446. Impact
factor : 6.393
73. C
hampiat S., Ileana E., Giaccone G., Besse B., Mountzios
G., Eggermont A., and Soria J.C. Incorporating
Immune-Checkpoint Inhibitors into Systemic Therapy
of NSCLC. [2014] Journal of Thoracic Oncology (9) 2 :
74. C
harbonneau H., Maillet J.M., Faron M., Mangin O.,
Puymirat E., Le Besnerais P., Du Puy-Montbrun L.,
Achouh P., Diehl J.L., Fagon J.Y., Mainardi J., and
Guerot E. Mediastinitis due to Gram-negative bacteria
is associated with increased mortality. [2014] Clinical
Microbiology and Infection (20) 3 : O197-O202. Impact
factor : 5.768
26
75. C
iardiello F., Arnold D., Casali P.G., Cervantes A.,
Douillard J.Y., Eggermont A., Eniu A., Mcgregor
K., Peters S., Piccart M., Popescu R., van Cutsem
E., Zielinski C., and Stahel R. Delivering precision
medicine in oncology today and in future-the promise
and challenges of personalised cancer medicine: A
position paper by the European Society for Medical
Oncology (ESMO). [2014] Annals of Oncology (25) 9 :
1673-1678. Impact factor : 7.040
76. C
ompanioni O., Bonet C., Munoz X., Weiderpass E.,
Panico S., Tumino R., Palli D., Agnoli C., Vineis P.,
Boutron-Ruault M.C., Racine A., Clavel-Chapelon F.,
Travis R.C., Khaw K.T., Riboli E., Murphy N., Vergnaud
A.C., Trichopoulou A., Benetou V., Trichopoulos D.,
Lund E., Johansen D., Lindkvist B., Johansson M.,
Sund M., Ardanaz E., Sanchez-Cantalejo E., Huerta
J.M., Dorronsoro M., Ramon Quiros J., Tjonneland
A., Mortensen L.M., Overvad K., Chang-Claude J.,
Rizzato C., Boeing H., De Mesquita H.B.B., Siersema
P., Peeters P.H.M., Numans M.E., Carneiro F.,
Licaj I., Freisling H., Sala N., and Gonzalez C.A.
Polymorphisms of Helicobacter pylori signaling
pathway genes and gastric cancer risk in the
European Prospective Investigation into CancerEurgast cohort. [2014] International Journal of
Cancer (134) 1 : 92-101. Impact factor : 5.085
77. C
onstant A.L., Montlahuc C., Grimaldi D., Pichon N.,
Mongardon N., Bordenave L., Soummer A., Sauneuf
B., Ricome S., Misset B., Schnell D., Dubuisson E.,
Brunet J., Lasocki S., Cronier P., Bouhemad B.,
Loriferne J.F., Begot E., Vandenbunder B., Dhonneur
G., Bedos J.P., Jullien P., Resche-Rigon M., and
Legriel S. Predictors of functional outcome after
intraoperative cardiac arrest. [2014] Anesthesiology
(121) 3 : 482-491. Impact factor : 5.879
78. C
ornelis G., Vernochet C., Malicorne S., Souquere S.,
Tzika A.C., Goodman S.M., Catzeflis F., Robinson T.J.,
Milinkovitch M.C., Pierron G., Heidmann O., Dupressoir
A., and Heidmann T. Retroviral envelope syncytin
capture in an ancestrally diverged mammalian clade
for placentation in the primitive Afrotherian tenrecs.
[2014] Proceedings of the National Academy of
Sciences of the United States of America (111) 41 :
E4332-E4341. Impact factor : 9.674
79. C
ouvé S., Ladroue C., Laine E., Mahtouk K., Guégan
J., Gad S., Le Jeune H., Le Gentil M., Nuel G., Kim
W.Y., Lecomte B., Pagès J.C., Collin C., Lasne F.,
Benusiglio P.R., Bressac-de Paillerets B., Feunteun
J., Lazar V., Gimenez-Roqueplo A.P., Mazure N.M.,
Dessen P., Tchertanov L., Mole D.R., Kaelin W.,
Ratcliffe P., Richard S., and Gardie B. Genetic
Evidence of a Precisely Tuned Dysregulation in the
Hypoxia Signaling Pathway during Oncogenesis.
[2014] Cancer research (74) 22 : 6554-6564. Impact
factor : 9.329
80. C
riscitiello C., André F., Thompson A.M., De
Laurentiis M., Esposito A., Gelao L., Fumagalli L.,
Locatelli M., Minchella I., Orsi F., Goldhirsch A., and
Curigliano G. Biopsy confirmation of metastatic sites
in breast cancer patients: Clinical impact and future
perspectives. [2014] Breast Cancer Research (16) 2.
81. D
avid C., Alfredo Z., Ramon S., Michel D., Tom W.,
Alexander S., Christophe T., Werner S., Alberto
S., Eric V.C., and Dirk A. The Randomized Phase 3
Impala Study : Immunomodulatory Maintenance
Therapy with TLR-9 Agonist MGN1703 in Patients
with Metastatic Colorectal Carcinoma. [2014] Annals
of Oncology (25) S2 : ii98-ii98. Impact factor : 7.040
82. D
avid M., Naudin C., Letourneur M., Polrot M.,
Renoir J.M., Lazar V., Dessen P., Roche S., Bertoglio
J., and Pierre J. Suppressor of cytokine signaling
1 modulates invasion and metastatic potential of
colorectal cancer cells. [2014] Molecular Oncology
(8) 5 : 942-955. Impact factor : 5.331
83. D
avid M., Naudin C., Letourneur M., Polrot M.,
Renoir J.M., Lazar V., Dessen P., Roche S., Bertoglio
J., and Pierre J. Suppressor of cytokine signaling
1 modulates invasion and metastatic potential of
colorectal cancer cells. [2014] Molecular Oncology
(8) 5 : 942-955. Impact factor : 5.331
84. D
avid M.D., Petit D., and Bertoglio J. The RhoGAP
ARHGAP19 controls cytokinesis and chromosome
segregation in T lymphocytes. [2014] Journal of Cell
Science (127) 2 : 400-410. Impact factor : 5.432
27
85. d
e Speville E.D., Dufour C., Bolle S., Giraudat K.,
Longaud A., Kieffer V., Grill J., Puget S., ValteauCouanet D., Hetz-Pannier L., and Noulhiane M.
EPISODIC MEMORY IMPAIRMENTS IN PAEDIATRIC
TEMPORAL BRAIN TUMORS. [2014] Neuro-Oncology
91. D
ianat N., Le Viet B., Gobbo E., Auger N., Bieche
I., Bennaceur-Griscelli A., and Griscelli F. Midkine
lacking its last 40 amino acids acts on endothelial
and neuroblastoma tumor cells and inhibits tumor
development. [2015] Molecular cancer therapeutics
(14) 1 : 213-224. Impact factor : 5.683
86. D
elaloge S. and Cullell-Young M. Reply to the letter to
the editor `Treating breast cancer with trabectedin:
a new arsenal’ by L. Malik. [2014] Annals of Oncology
(25) 10 : 2095-2095. Impact factor : 7.040
92. D
icheva B.M., Ten Hagen T.L.M., Schipper D., Seynhaeve
A.L.B., Van Rhoon G.C., Eggermont A.M.M., and Koning
G.A. Targeted and heat-triggered doxorubicin delivery
to tumors by dual targeted cationic thermosensitive
liposomes. [2014] Journal of Controlled Release
(195) : 37-48. Impact factor : 7.705
87. D
elaloge S., Wolp-Diniz R., Byrski T., Blum J.L.,
Gonçalves A., Campone M., Lardelli P., Kahatt C.,
Nieto A., Cullell-Young M., and Lubinski J. Activity of
trabectedin in germline BRCA1/2-mutated metastatic
breast cancer: Results of an international first-inclass phase II study. [2014] Annals of Oncology (25) 6 :
1152-1158. Impact factor : 7.040
88. D
elord J.P., Tabernero J., Garcia-Carbonero R.,
Cervantes A., Gomez-Roca C., Bergé Y., Capdevila
J., Paz-Ares L., Roda D., Delmar P., Oppenheim D.,
Brossard S.S., Farzaneh F., Manenti L., Passioukov
A., Ott M.G., and Soria J.C. Open-label, multicentre
expansion cohort to evaluate imgatuzumab in
pre-treated patients with KRAS-mutant advanced
colorectal carcinoma. [2014] European Journal of
89. D
enorme M., Yon L., Roux C., Gonzalez B.J., Baudin E.,
Anouar Y., and Dubessy C. Both sunitinib and sorafenib
are effective treatments for pheochromocytoma in a
xenograft model. [2014] Cancer Letters (352) 2 : 236244. Impact factor : 5.621
90. D
i Giannatale A., Dias-Gastellier N., Devos A., Mc Hugh
K., Boubaker A., Courbon F., Verschuur A., Ducassoul S.,
Malekzadeh K., Casanova M., Amoroso L., Chastagner
P., Zwaan C.M., Munzer C., Aerts I., Landman-Parker
J., Riccardi R., Le Deley M.C., Geoerger B., and Rubie
H. Phase II study of temozolomide in combination
with topotecan (TOTEM) in relapsed or refractory
neuroblastoma: A European Innovative Therapies for
Children with Cancer-SIOP-European Neuroblastoma
study. [2014] European Journal of Cancer (50) 1 : 170177. Impact factor : 5.417
93. D
ieci M.V., Criscitiello C., Goubar A., Viale G., Conte
P., Guarneri V., Ficarra G., Mathieu M.C., Delaloge S.,
Curigliano G., and Andre F. Prognostic value of tumorinfiltrating lymphocytes on residual disease after
primary chemotherapy for triple-negative breast
cancer: A retrospective multicenter study. [2014]
Annals of Oncology (25) 3 : 611-618. Impact factor :
7.040
94. D
ik V.K., Bueno-de-Mesquita H.B., Van Oijen M.G.H.,
Siersema P.D., Uiterwaal C.S.P.M., Van Gils C.H.,
Van Duijnhoven F.J.B., Cauchi S., Yengo L., Froguel
P., Overvad K., Bech B.H., Tjonneland A., Olsen A.,
Boutron-Ruault M.C., Racine A., Fagherazzi G., Kuhn
T., Campa D., Boeing H., Aleksandrova K., Trichopoulou
A., Peppa E., Oikonomou E., Palli D., Grioni S., Vineis
P., Tumino R., Panico S., Peeters P.H.M., Weiderpass
E., Engeset D., Braaten T., Dorronsoro M., Chirlaque
M.D., Sanchez M.J., Barricarte A., Zamora-Ros R.,
Arguelles M., Jirström K., Wallström P., Nilsson L.M.,
Ljuslinder I., Travis R.C., Khaw K.T., Wareham N.,
Freisling H., Licaj I., Jenab M., Gunter M.J., Murphy
N., Romaguera-Bosch D., and Riboli E. Coffee and
tea consumption, genotype-based CYP1A2 and NAT2
activity and colorectal cancer risk - Results from the
EPIC cohort study. [2014] International Journal of
95. D
omingues M.J., Rambow F., Job B., Papon L., Liu W.,
Larue L., and Bonaventure J. beta-Catenin Inhibitor
ICAT Modulates the Invasive Motility of Melanoma
Cells. [2014] Cancer research (74) 7 : 1983-1995.
28
96. D
ossus L., Boutron-Ruault M.C., Kaaks R., Gram I.T.,
Vilier A., Fervers B., Manjer J., Tjonneland A., Olsen
A., Overvad K., Chang-Claude J., Boeing H., Steffen
A., Trichopoulou A., Lagiou P., Sarantopoulou M.,
Palli D., Berrino F., Tumino R., Vineis P., Mattiello
A., Bueno-de-Mesquita H.B., van Duijnhoven F.J.B.,
Bakker M.F., Peeters P.H.M., Weiderpass E., Bjerkaas
E., Braaten T., Menendez V., Agudo A., Sanchez M.J.,
Amiano P., Tormo M.J., Barricarte A., Butt S., Khaw
K.T., Wareham N., Key T.J., Travis R.C., Rinaldi S.,
McCormack V., Romieu I., Cox D.G., Norat T., Riboli E.,
and Clavel-Chapelon F. Active and passive cigarette
smoking and breast cancer risk: Results from the
EPIC cohort. [2014] International Journal of Cancer
(134) 8 : 1871-1888. Impact factor : 5.085
97. D
uarte-Salles T., Fedirko V., Stepien M., Trichopoulou
A., Bamia C., Lagiou P., Lukanova A., Trepo E., Overvad
K., Tjonneland A., Halkjaer J., Boutron-Ruault M.C.,
Racine A., Cadeau C., Kuehn T., Aleksandrova K.,
Trichopoulos D., Tsiotas K., Boffetta P., Palli D., Pala
V., Tumino R., Sacerdote C., Panico S., Bueno-deMesquita H.B., Dik V.K., Peeters P.H., Weiderpass E.,
Gram I.T., Hjartaker A., Ramon Quiros J., FonsecaNunes A., Molina-Montes E., Dorronsoro M., Navarro
Sanchez C., Barricarte A., Lindkvist B., Sonestedt E.,
Johansson I., Wennberg M., Khaw K.T., Wareham N.,
Travis R.C., Romieu I., Riboli E., and Jenab M. Dairy
products and risk of hepatocellular carcinoma: The
European Prospective Investigation into Cancer and
Nutrition. [2014] International Journal of Cancer
(135) 7 : 1662-1672. Impact factor : 5.085
98. D
ubois J., Etienne G., Laroche-Clary A., Lascaux A.,
Bidet A., Lippert E., Ait-Ouferoukh S., Saada V., Micol
J.B., Bouabdallah K., and Robert J. Identification of
methylguanine methyltransferase polymorphisms
as genetic markers of individual susceptibility
to therapy-related myeloid neoplasms. [2014]
factor : 5.417
99. D
ucreux M., Dahan L., Smith D., O’Toole D., Lepère
C., Dromain C., Vilgrain V., Baudin E., LombardBohas C., Scoazec J.Y., Seitz J.F., Bitoun L., Koné
S., and Mitry E. Bevacizumab combined with 5-FU/
streptozocin in patients with progressive metastatic
well-differentiated pancreatic endocrine tumours
(BETTER trial)--a phase II non-randomised trial.
100. D
uplomb L., Duvet S., Picot D., Jego G., El
Chehadeh-Djebbar S., Marle N., Gigot N., Aral B.,
Carmignac V., Thevenon J., Lopez E., Riviere J.B.,
Klein A., Philippe C., Droin N., Blair E., Girodon
F., Donadieu J., Bellanne-Chantelot C., Delva L.,
Michalski J.C., Solary E., Faivre L., Foulquier F., and
Thauvin-Robinet C. Cohen syndrome is associated
with major glycosylation defects. [2014] Human
Molecular Genetics (23) 9 : 2391-2399. Impact
factor : 6.393
101. D
uraes C., Munoz X., Bonet C., Garcia N., Vencesla
A., Carneiro F., Peleteiro B., Lunet N., Barros
H., Lindkvist B., Boutron-Ruault M.C., Buenode-Mesquita H.B., Rizzato C., Trichopoulou A.,
Weiderpass E., Naccarati A., Travis R.C., Tjonneland
A., Gurrea A.B., Johansson M., Riboli E., Figueiredo
C., Gonzalez C., Capella G., MacHado J.C., and
Sala N. Genetic variants in the IL1A gene region
contribute to intestinal-type gastric carcinoma
susceptibility in European populations. [2014]
International Journal of Cancer (135) 6 : 13431355. Impact factor : 5.085
102. D
uvallet A., Duvallet E., Lhuissier F., Constantin P.,
and Beaudry M. Physiological heart rate profile of
hyperbaric underwater worker during an exercise
stress testing as a predictor of physical fitness.
[2014] FASEB Journal (28) S1. Impact factor : 5.043
103. E
ggermont A., Robert C., Soria J.C., and Zitvogel
L. Harnessing the immune system to provide
long-term survival in patients with melanoma and
other solid tumors. [2014] OncoImmunology (3) :
e27560-e27560. Impact factor : 6.266
104. E
ggermont A.M.M., Caldas C., Ringborg U., Medema
R., Tabernero J., and Wiestler O. Cancer Core
Europe: a consortium to address the cancer carecancer research continuum challenge. [2014]
European Journal of Cancer (50) 16 : 2745-2746.
29
105. E
kpe K., Novara A., Mainardi J.L., Fagon J.Y., and
Faisy C. Methicillin-resistant Staphylococcus
aureus bloodstream infections are associated with
a higher energy deficit than other ICU-acquired
bacteremia. [2014] Intensive care medicine (40) 12
: 1878-1887. Impact factor : 7.214
106. E
lias D., Goere D., Dumont F., Honore C., Dartigues
P., Stoclin A., Malka D., Boige V., and Ducreux M.
Role of hyperthermic intraoperative peritoneal
chemotherapy in the management of peritoneal
metastases. [2014] European Journal of Cancer
(50) 2 : 332-340. Impact factor : 5.417
107. E
lias D., Faron M., Iuga B.S., Honoré C., Dumont
F., Bourgain J.L., Dartigues P., Ducreux M., and
Goéré D. Prognostic Similarities and Differences
in Optimally Resected Liver Metastases and
Peritoneal Metastases From Colorectal Cancers.
[2014] Annals of Surgery. Impact factor : 8.327
108. E
lkhuizen P.H.M., van der Leij F., Lekberg T., Rivera
S., van den Bongard D., Vreeswijk S., Rutgers
E., and Bartelink H. First results of the PAPBI
trial (Preoperative Accelerated Partial Breast
Irradiation): Toxicity and cosmetic outcome. [2014]
European Journal of Cancer (50) S2 : S102-S102.
109. E
maus M.J., van Gils C.H., Bakker M.F., Bisschop
C.N.S., Monninkhof E.M., Bueno-de-Mesquita H.B.,
Travier N., Berentzen T.L., Overvad K., Tjonneland A.,
Romieu I., Rinaldi S., Chajes V., Gunter M.J., ClavelChapelon F., Fagherazzi G., Mesrine S., Chang-Claude
J., Kaaks R., Boeing H., Aleksandrova K., Trichopoulou
A., Naska A., Orfanos P., Palli D., Agnoli C., Tumino R.,
Vineis P., Mattiello A., Braaten T., Borch K.B., Lund
E., Menendez V., Sanchez M.J., Navarro C., Barricarte
A., Amiano P., Sund M., Andersson A., Borgquist S.,
Olsson A., Khaw K.T., Wareham N., Travis R.C., Riboli
E., Peeters P.H.M., and May A.M. Weight change in
middle adulthood and breast cancer risk in the
EPIC-PANACEA study. [2014] International Journal
of Cancer (135) 12 : 2887-2899. Impact factor : 5.085
110. E
scudier B., Porta C., Schmidinger M., Algaba F.,
Patard J.J., Khoo V., Eisen T., and Horwich A. Renal
cell carcinoma: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. [2014] Annals
of Oncology (25) suppl 3 : iii49-iii56. Impact factor :
7.040
111. E
scudier B., Grunwald V., Ravaud A., Ou Y.C.,
Castellano D., Lin C.C., Gschwend J.E., Harzstark A.,
Beall S., Pirotta N., Squires M., Shi M., and Angevin E.
Phase II results of dovitinib (TKI258) in patients with
metastatic renal cell cancer. [2014] Clinical Cancer
Research (20) 11 : 3012-3022. Impact factor : 8.722
112. E
spinosa-Parrilla Y., Munoz X., Bonet C., Garcia N.,
Vencesla A., Yiannakouris N., Naccarati A., Sieri S.,
Panico S., Huerta J.M., Barricarte A., Menendez
V., Sanchez-Cantalejo E., Dorronsoro M., Brennan
P., Duarte-Salles T., Bueno-de-Mesquita H.B.,
Weiderpass E., Lund E., Clavel-Chapelon F., BoutronRuault M.C., Racine A., Numans M.E., Tumino R.,
Canzian F., Campa D., Sund M., Johansson M.,
Ohlsson B., Lindkvist B., Overvad K., Tjonneland A.,
Palli D., Travis R.C., Khaw K.T., Wareham N., Boeing
H., Nesi G., Riboli E., Gonzalez C.A., and Sala N.
Genetic association of gastric cancer with miRNA
clusters including the cancer-related genes MIR29,
MIR25, MIR93 and MIR106: Results from the EPICEURGAST study. [2014] International Journal of
113. E
ven C., Pautier P., Duvillard P., Floquet A., Kerbrat
P., Troalen F., Rey A., Balleyguier C., Tazi Y., Leary
A., Augereau P., Morice P., Droz J.-P., Fizazi K., and
Lhomme C. Actinomycin D, cisplatin, and etoposide
regimen is associated with almost universal cure
in patients with high-risk gestational trophoblastic
neoplasia. [2014] European Journal of Cancer (50)
12 : 2082-2089. Impact factor : 5.417
114. E
zratty V., Guillossou G., Neukirch C., Dehoux M.,
Koscielny S., Bonay M., Cabanes P.A., Samet J.M.,
Mure P., Ropert L., Tokarek S., Lambrozo J., and
Aubier M. Repeated nitrogen dioxide exposures and
eosinophilic airway inflammation in asthmatics: a
randomized crossover study. [2014] Environmental
health perspectives (122) 8 : 850-855. Impact factor
: 7.977
30
115. F
agherazzi G., Vilier A., Lajous M., Boutron-Ruault M.C.,
Balkau B., Clavel-Chapelon F., and Bonnet F. Wine
consumption throughout life is inversely associated
with type 2 diabetes risk, but only in overweight
individuals: results from a large female French cohort
study. [2014] European Journal of Epidemiology (29) 11
: 831-839. Impact factor : 5.339
116. F
agherazzi G., Vilier A., Bonnet F., Lajous M., Balkau B.,
Boutron-Ruault M.C., and Clavel-Chapelon F. Dietary
acid load and risk of type 2 diabetes: the E3N-EPIC
cohort study. [2014] Diabetologia (57) 2 : 313-320.
117. F
aitot F., Faron M., Adam R., Elias D., Cimino M., Cherqui
D., Vibert E., Castaing D., Cunha A.S., and Goéré D. Twostage hepatectomy versus 1-stage resection combined
with radiofrequency for bilobar colorectal metastases:
a case-matched analysis of surgical and oncological
outcomes. [2014] Annals of Surgery (260) 5 : 822-828.
118. F
edirko V., Romieu I., Aleksandrova K., Pischon T.,
Trichopoulos D., Peeters P.H., Romaguera-Bosch D.,
Bueno-de-Mesquita H.B., Dahm C.C., Overvad K.,
Chirlaque M.D., Johansen C., Bidstrup P.E., Dalton S.O.,
Gunter M.J., Wark P.A., Norat T., Halkjaer J., Tjonneland
A., Dik V.K., Siersema P.D., Boutron-Ruault M.C., Dossus
L., Bastide N., Kuhn T., Kaaks R., Boeing H., Trichopoulou
A., Klinaki E., Katsoulis M., Pala V., Panico S., Tumino
R., Palli D., Vineis P., Weiderpass E., Skeie G., Gonzalez
C.A., Sanchez M.J., Barricarte A., Amiano P., Quiros
J.R., Manjer J.a., Jirström K., Ljuslinder I., Palmqvist
R., Khaw K.T., Wareham N., Bradbury K.E., Stepien M.,
Duarte-Salles T., Riboli E., and Jenab M. Pre-diagnostic
anthropometry and survival after colorectal cancer
diagnosis in Western European populations. [2014]
International Journal of Cancer (135) 8 : 1949-1960.
119. F
errari de Andrade L., Ngiow S.F., Stannard K.,
Rusakiewicz S., Kalimutho M., Khanna K.K., Tey S.K.,
Takeda K., Zitvogel L., Martinet L., and Smyth M.J.
Natural killer cells are essential for the ability of BRAF
inhibitors to control BRAFV600E-mutant metastatic
melanoma. [2014] Cancer research (74) 24 : 72987308. Impact factor : 9.329
120. F
erreboeuf M., Mariot V., Bessières B., Vasiljevic A.,
Attié-Bitach T., Collardeau S., Morere J., Roche S.,
Magdinier F., Robin-Ducellier J., Rameau P., Whalen
S., Desnuelle C., Sacconi S., Mouly V., ButlerBrowne G., and Dumonceaux J. DUX4 and DUX4
downstream target genes are expressed in fetal
FSHD muscles. [2014] Human Molecular Genetics
(23) 1 : 171-181. Impact factor : 6.393
121. F
erté C., Fernandez M., Hollebecque A., Koscielny
S., Levy A., Massard C., Balheda R., Bot B., GomezRoca C., Dromain C., Ammari S., and Soria J.C.
Tumor growth rate is an early indicator of antitumor
drug activity in phase I clinical trials. [2014] Clinical
Cancer Research (20) 1 : 246-252. Impact factor : 8.722
122. F
erté C., Koscielny S., and Soria J.C. TGR Analysis
in Phase I Clinical Trials-Response. [2014] Clinical
Cancer Research (20) 9 : 2497-2497. Impact factor : 8.722
123. F
igueroa J.D., Han S.S., Garcia-Closas M., Baris
D., Jacobs E.J., Kogevinas M., Schwenn M., Malats
N., Johnson A., Purdue M.P., Caporaso N., Landi
M.T., Prokunina-Olsson L., Wang Z., Hutchinson
A., Burdette L., Wheeler W., Vineis P., Siddiq
A., Cortessis V.K., Kooperberg C., Cussenot O.,
Benhamou S., Prescott J., Porru S., Bas Bueno-deMesquita H., Trichopoulos D., Ljungberg B., ClavelChapelon F., Weiderpass E., Krogh V.a., Dorronsoro
M., Travis R., Tjonneland A., Brenan P., ChangClaude J., Riboli E., Conti D., Gago-Dominguez
M., Stern M.C., Pike M.C., van den Berg D., Yuan
J.M., Hohensee C., Rodabough R., Cancel-Tassin
G., Roupret M., Comperat E., Chen C., de Vivo I.,
Giovannucci E., Hunter D.J., Kraft P., Lindstrom
S., Carta A., Pavanello S., Arici C., Mastrangelo G.,
Karagas M.R., Schned A., Armenti K.R., Monawar
Hosain G.M., Haiman C.A., Fraumeni J., Chanock
S.J., Chatterjee N., Rothman N., and Silverman D.T.
Genome-wide interaction study of smoking and
bladder cancer risk. [2014] Carcinogenesis (35) 8 :
1737-1744. Impact factor : 5.334
124. F
igueroa J.D., Ye Y., Siddiq A., Garcia-Closas M.,
Chatterjee N., Prokunina-Olsson L., Cortessis V.K.,
Kooperberg C., Cussenot O., Benhamou S., Prescott
J., Porru S., Dinney C.P., Malats N., Baris D., Purdue
31
M., Jacobs E.J., Albanes D., Wang Z., Deng X.,
Chung C.C., Tang W., Bas Bueno-de-Mesquita H.,
Trichopoulos D., Ljungberg B.a., Clavel-Chapelon F.,
Weiderpass E., Krogh V., Dorronsoro M., Travis R.,
Tjonneland A., Brenan P., Chang-Claude J., Riboli E.,
Conti D., Gago-Dominguez M., Stern M.C., Pike M.C.,
den berg D., Yuan J.a., Hohensee C., Rodabough R.,
Cancel-Tassin G., Roupret M., Comperat E., Chen
C., de Vivo I., Giovannucci E., Hunter D.J., Kraft
P., Lindstrom S., Carta A., Pavanello S.a., Arici C.,
Mastrangelo G., Kamat A.M., Lerner S.P., Barton
grossman H., Lin J., Gu J., Pu X., Hutchinson A.,
Burdette L., Wheeler W., Kogevinas M.a.a.a., Tardon
A., Serra C.b., Carrato A., Garcia-Closas R., Lloreta
J., Schwenn M., Karagas M.R., Johnson A., Schned
A., Armenti K.R., Hosain G.M., Andriole G., Grubb
R., Black A., Ryan Diver W., Gapstur S.M., Weinstein
S.J., Virtamo J., Haiman C.A., Landi M.T., Caporaso
N., Fraumeni J.F., Vineis P., Wu X., Silverman
D.T., Chanock S., and Rothman N. Genome-wide
association study identifies multiple loci associated
with bladder cancer risk. [2014] Human Molecular
Genetics (23) 5. Impact factor : 6.393
125. F
iore M., Coppola S., Cannell A.J., Colombo C.,
Bertagnolli M.M., George S., Le Cesne A., Gladdy
R.A., Casali P.G., Swallow C.J., Gronchi A., Bonvalot
S., and Raut C.P. Desmoid-type fibromatosis
and pregnancy: A multi-institutional analysis of
recurrence and obstetric risk. [2014] Annals of
Surgery (259) 5 : 973-978. Impact factor : 8.327
126. F
itzpatrick J.M., Bellmunt J., Fizazi K., Heidenreich
A., Sternberg C.N., Tombal B., Alcaraz A., Bahl A.,
Bracarda S., Di Lorenzo G., Efstathiou E., Finn S.P.,
Fossa S., Gillessen S., Kellokumpu-Lehtinen P.L.,
Lecouvet F.E., Oudard S., de Reijke T.M., Robson
C.N., De Santis M., Seruga B., and De Wit R. Optimal
management of metastatic castration-resistant
prostate cancer: Highlights from a European
Expert Consensus Panel. [2014] European Journal
127. F
izazi K., Gravis G., Flechon A., Geoffrois L., Chevreau
C., Laguerre B., Delva R., Eymard J.C., Rolland
F., Houede N., Laplanche A., Burcoveanu D., and
Culine S. Combining gemcitabine, cisplatin, and
ifosfamide (GIP) is active in patients with relapsed
metastatic germ-cell tumors (GCT): a prospective
multicenter GETUG phase II trial. [2014] Annals of
128. F
orouhi N.G., Koulman A., Sharp S.J., Imamura F.,
Kröger J., Schulze M.B., Crowe F.L., Huerta J.M.,
Guevara M., Beulens J.W.J., van Woudenbergh
G.J., Wang L., Summerhill K., Griffin J.L., Feskens
E.J.M., Amiano P., Boeing H., Clavel-Chapelon F.,
Dartois L., Fagherazzi G., Franks P.W., Gonzalez
C., Jakobsen M.U., Kaaks R., Key T.J., Khaw K.T.,
Kuhn T., Mattiello A., Nilsson P.M., Overvad K., Pala
V., Palli D., Quiros J.R., Rolandsson O., Roswall N.,
Sacerdote C., Sanchez M.J., Slimani N., Spijkerman
A.M.W., Tjonneland A., Tormo M.J., Tumino R.,
van d.A., van der Schouw Y.T., Langenberg C.,
Riboli E., and Wareham N.J. Differences in the
prospective association between individual plasma
phospholipid saturated fatty acids and incident
type 2 diabetes: The EPIC-InterAct case-cohort
study. [2014] Lancet Diabetes & Endocrinology (2)
10 : 810-818. Impact factor : 9.185
129. F
ouladi M., Bartels U., Warren K., Hassal T., Baugh
J., Kirkendall J., Doughman R., Leach J., Jones
B., Miles L., Hawkins C., Bouffet E., Hargrave D.,
Grill J., Jones C., Jacques T., Savage S., Goldman
S., Leary S., Packer R., Saunders D., Wesseling
P., Varlet P., and van Vuurden D. Establishment of
an International Diffuse Intrinsic Pontine Glioma
(DIPG) Registry. [2014] Neuro-Oncology (16) Suppl.
1 : i58-i58. Impact factor : 5.562
130. F
ournier A., Dossus L., Mesrine S., Vilier A., BoutronRuault M.C., Clavel-Chapelon F., and ChabbertBuffet N. Risks of Endometrial Cancer Associated
With Different Hormone Replacement Therapies
in the E3N Cohort, 1992-2008. [2014] American
Journal of Epidemiology (180) 5 : 508-517. Impact
factor : 5.230
131. F
ouyssac F., Gentet J.C., Frappaz D., Piguet C.,
Gorde-Grosjean S., Grill J., Schmitt E., PallKondolff S., and Chastagner P. Meningeal Sarcoma
in Children: A Survey from the French Society of
Pediatric Oncology (SFCE). [2014] Neuro-Oncology
32
132. G
albois A., Aegerter P., Martel-Samb P., Housset
C., Thabut D., Offenstadt G., Ait-Oufella H., Maury E.,
and Guidet B. Improved prognosis of septic shock in
patients with cirrhosis: a multicenter study. [2014]
Critical care medicine (42) 7 : 1666-1675. Impact
factor : 6.312
133. G
alluzzi L., Vitale I., Michels J., Brenner C., Szabadkai
G., Harel-Bellan A., Castedo M., and Kroemer G.
Systems biology of cisplatin resistance: past,
present and future. [2014] Cell Death & Disease (5)
: e1257-e1257. Impact factor : 5.014
134. G
alluzzi L., Vacchelli E., Bravo-San Pedro J.M., Buqué A., Senovilla L., Baracco E.E., Bloy N.,
Castoldi F., Abastado J.P., Agostinis P., Apte R.N.,
Aranda F., Ayyoub M., Beckhove P., Blay J.Y., Bracci
L., Caignard A., Castelli C., Cavallo F., Celis E.,
Cerundolo V., Clayton A., Colombo M.P., Coussens
L., Dhodapkar M.V., Eggermont A.M., Fearon D.T.,
Fridman W.H., Fucikova J., Gabrilovich D.I., Galon
J., Garg A., Ghiringhelli F., Giaccone G., Gilboa E.,
Gnjatic S., Hoos A., Hosmalin A., Jäger D., Kalinski
P., Kärre K., Kepp O., Kiessling R., Kirkwood J.M.,
Klein E., Knuth A., Lewis C.E., Liblau R., Lotze M.T.,
Lugli E., Mach J.P., Mattei F., Mavilio D., Melero
I., Melief C.J., Mittendorf E.A., Moretta L., Odunsi
A., Okada H., Palucka A.K., Peter M.E., Pienta
K.J., Porgador A., Prendergast G.C., Rabinovich
G.A., Restifo N.P., Rizvi N., Sautès-Fridman C.,
Schreiber H., Seliger B., Shiku H., Silva-Santos
B., Smyth M.J., Speiser D.E., Spisek R., Srivastava
P.K., Talmadge J.E., Tartour E., Van Der Burg S.H.,
Van Den Eynde B.J., Vile R., Wagner H., Weber J.S.,
Whiteside T.L., Wolchok J.D., Zitvogel L., Zou W., and
Kroemer G. Classification of current anticancer
immunotherapies. [2014] Oncotarget (5) 24 : 1247212508. Impact factor : 6.359
135. G
alluzzi L., Kepp O., Krautwald S., Kroemer G., and
Linkermann A. Molecular mechanisms of regulated
necrosis. [2014] Seminars in cell & developmental
biology (35) : 24-32. Impact factor : 6.265
136. G
arrec J., Monari A., Assfed X., Mir L.M., and
Tarek M. Lipid Peroxidation in Membranes: The
Peroxyl Radical Does Not «Float’’. [2014] Journal
of Physical Chemistry Letters (5) 10 : 1653-1658.
137. G
audin M., Krupovic M., Marguet E., Gauliard E.,
Cvirkaite-Krupovic V., Le Cam E., Oberto J., and
Forterre P. Extracellular membrane vesicles
harbouring viral genomes. [2014] Environmental
Microbiology (16) 4 : 1167-1175. Impact factor : 6.201
138. G
incul R., Palazzo M., Pujol B., Tubach F., Palazzo
L., Lefort C., Fumex F., Lombard A., Ribeiro D., Fabre
M., Hervieu V., Labadie M., Ponchon T., and Napoléon
B. Contrast-harmonic endoscopic ultrasound for
the diagnosis of pancreatic adenocarcinoma: a
prospective multicenter trial. [2014] Endoscopy
(46) 5 : 373-379. Impact factor : 5.053
139. G
irard N., Pichon E., Thomas P.A., Lena H., Dansin
E., Massard G., Zalcman G., Mazieres J., Thiberville
L., Westeel V., Fournel P., Clement-Duchene C.,
Quantin X., Bennouna J., Molina T.J., and Besse B.
RYTHMIC : Insights in the Management of Advanced
Thymic Epithelial Tumor. [2014] Journal of Thoracic
Oncology (9) 10 S4 : S223-S224. Impact factor : 5.282
140. G
iuliani M., Bennaceur-Griscelli A., Nanbakhsh
A., Oudrhiri N., Chouaib S., Azzarone B., Durrbach
A., and Lataillade J.J. TLR Ligands Stimulation
Protects MSC from NK Killing. [2014] Stem Cells
(32) 1 : 290-300. Impact factor : 6.523
141. G
lembotsky A.C., Bluteau D., Espasandin Y.R.,
Goette N.P., Marta R.F., Marin Oyarzun C.P., Korin
L., Lev P.R., Laguens R.P., Molinas F.C., Raslova
H., and Heller P.G. Mechanisms underlying
platelet function defect in a pedigree with familial
platelet disorder with a predisposition to acute
myelogenous leukemia: potential role for candidate
RUNX1 targets. [2014] Journal of Thrombosis and
Haemostasis (12) 5 : 761-772. Impact factor : 5.720
142. G
nekow A.K., Kandels D., Walker D.A., Perilongo G.,
Grill J., Stokland T., Sehested A.M., van Schouten
A.Y.N., de Paoli A., de Salvo G.L., and Grp S.L.G.G.W.
A Randomized Trial of Intensification of InductionChemotherapy within an 18 Months TreatmentStrategy on Tumor-Response at 24 Weeks and
33
Progression-Free-Survival in Pediatric Low Grade
Glioma (LGG) - Preliminary Results of the SIOPLGG-2004-Working-Group. [2014] Neuro-Oncology
(16) Suppl.1 : i64-i64. Impact factor : 5.562
143. G
oere D. and Elias D. Reply to Letter: «Prevention
of Peritoneal Carcinomatosis From Colorectal
Cancer: A Critical Issue». [2014] Annals of Surgery
(259) 3 : E52-E52. Impact factor : 8.327
144. G
omez-Sanchez R., Gegg M.E., Bravo-San
Pedro J.M., Niso-Santano M., Alvarez-Erviti L.,
Pizarro-Estrella E., Gutierrez-Martin Y., AlvarezBarrientos A., Fuentes J.M., Ana Gonzalez-Polo
R., and Schapira A.H.V. Mitochondrial impairment
increases FL-PINK1 levels by calcium-dependent
gene expression. [2014] Neurobiology of Disease
(62) : 426-440. Impact factor : 5.078
145. G
ore M.E., Bellmunt J., Eisen T., Escudier B.,
Mickisch G., Patard J., Porta C., Ravaud A.,
Schmidinger M., Schöffski P., Sternberg C.N.,
Szczylik C., Lewis S., and Kirpekar S. Assessing the
impact of evolving evidence in renal cell carcinoma
treatment: an update of the Renal Cell Carcinoma
Appropriateness-based
Treatment
Toolkit
(ReCATT). [2014] European Journal of Cancer (50)
18 : 3153-3160. Impact factor : 5.417
146. G
rasso C., Truffaux N., Berlow N., Liu L., Debily M.A.,
Davis L., Huang E., Woo P., Tang Y., Ponnuswami
A., Chen S., Huang Y., Huett-Cabezas M., Warren
K., Dret L., Meltzer P., Mao H., Quezado M., van
Vuurden D., Abraham J., Fouladi M., Svalina M.N.,
Wang N., Hawkins C., Raabe E., Hulleman E., Li X.N.,
Keller C., Spellman P.T., Pal R., Grill J., and Monje
M. Functionally-Defined Therapeutic Targets
in Diffuse Intrinsic Pontine Glioma: A Report of
the Children’s Oncology group DIPG Preclinical
Consortium. [2014] Neuro-Oncology (16) Suppl.1 :
147. G
ravis G., Marino P., Joly F., Oudard S., Priou F.,
Esterni B., Latorzeff I., Delva R., Krakowski I.,
Laguerre B., Rolland F., Theodore C., Deplanque
G., Ferrero J.M., Pouessel D., Mourey L., Beuzeboc
P., Zanetta S., Habibian M., Berdah J.F., Dauba J.,
Baciuchka M., Platini C., Linassier C., Labourey
J.L., Machiels J.P., El Kouri C., Ravaud A., Suc E.,
Eymard J.C., Hasbini A., Bousquet G., Soulie M.,
and Fizazi K. Patients’ self-assessment versus
investigators’ evaluation in a phase III trial in noncastrate metastatic prostate cancer (GETUG-AFU
15). [2014] European Journal of Cancer (50) 5 : 953962. Impact factor : 5.417
148. G
rimaldi D., Le Bourhis L., Sauneuf B., Dechartres A.,
Rousseau C., Ouaaz F., Milder M., Louis D., Chiche
J.D., Mira J.P., Lantz O., and Pène F. Specific MAIT
cell behaviour among innate-like T lymphocytes in
critically ill patients with severe infections. [2014]
Intensive care medicine (40) 2 : 192-201. Impact
factor : 7.214
149. G
ronchi A., Colombo C., Le Péchoux C., Dei Tos A.P.,
Le Cesne A., Marrari A., Penel N., Grignani G., Blay
J.Y., Casali P.G., Stoeckle E., Gherlinzoni F., Meeus
P., Mussi C., Gouin F., Duffaud F., Fiore M., and
Bonvalot S. Sporadic desmoid-type fibromatosis:
A stepwise approach to a non-metastasising
neoplasm-A position paper from the Italian and the
French Sarcoma Group. [2014] Annals of Oncology
(25) 3 : 578-583. Impact factor : 7.040
150. G
uerin E., Orabona M., Raquil M.A., Giraudeau B.,
Bellier R., Gibot S., Bene M.C., Lacombe F., Droin
N., Solary E., Vignon P., Feuillard J., and Francois
B. Circulating Immature Granulocytes With T-Cell
Killing Functions Predict Sepsis Deterioration.
[2014] Critical care medicine (42) 9 : 2007-2018.
151. G
uerrini-Rousseau L., Dufour C., Pujet S., KiefferRenaux V., Raquin M.A., Varlet P., Longaud A.,
Sainte-Rose C., Valteau-Couanet D., and Grill J.
Benefits and Risks of Neoadjuvant Chemotherapy
in Metastatic Medulloblastoma: A Comparative
Study in 71 Patients. [2014] Neuro-Oncology (16)
Suppl. 1 : i83-i83. Impact factor : 5.562
152. G
uinney J., Ferte C., Dry J., McEwen R., Manceau
G., Kao K.J., Chang K.M., Bendtsen C., Hudson K.,
Huang E., Dougherty B., Ducreux M., Soria J.C.,
Friend S., Derry J., and Laurent-Puig P. Modeling
34
RAS Phenotype in Colorectal Cancer Uncovers
Novel Molecular Traits of RAS Dependency and
Improves Prediction of Response to Targeted
Agents in Patients. [2014] Clinical Cancer Research
(20) 1 : 265-272. Impact factor : 8.722
153. G
upta R.K., Goodall R.L., Ranopa M., Kityo C., Munderi
P., Lyagoba F., Mugarura L., Gilks C.F., Kaleebu P.,
and Pillay D. High rate of HIV resuppression after
viral failure on first-line antiretroviral therapy
in the absence of switch to second-line therapy.
[2014] Clinical infectious diseases (58) 7 : 10231026. Impact factor : 8.886
154. G
upta S., Munster P., Hollebecque A., Argiles G.,
Guren T., Cheng J., Wang R., Swift A., Tosolini A.,
and Piha-Paul S. Safety and Efficacy of MK-8669
(Ridaforolimus) + MK-2206 (AKT Inhibitor) in
Patients with Advanced Breast Cancer with PI3K
Pathway Dependence. [2014] Annals of Oncology
(25) suppl 1 : i25-i25. Impact factor : 7.040
155. G
yorffy B., Bottai G., Lehmann-Che J., Kéri G., Orfi L.,
Iwamoto T., Desmedt C., Bianchini G., Turner N.C.,
de Thè H., André F., Sotiriou C., Hortobagyi G.N., Di
Leo A., Pusztai L., and Santarpia L. TP53 mutationcorrelated genes predict the risk of tumor relapse
and identify MPS1 as a potential therapeutic kinase
in TP53-mutated breast cancers. [2014] Molecular
156. H
addy N., Tartier L., Koscielny S., Adjadj E., Rubino C.,
Brugières L., Pacquement H., Diallo I., De Vathaire
F., Averbeck D., Hall J., and Benhamou S. Repair of
ionizing radiation-induced DNA damage and risk
of second cancer in childhood cancer survivors.
[2014] Carcinogenesis (35) 8 : 1745-1749. Impact
factor : 5.334
157. H
adoux J., Favier J., Scoazec J.Y., Leboulleux S., Al
Ghuzlan A., Caramella C., Déandreis D., Borget I.,
Loriot C., Chougnet C., Letouzé E., Young J., Amar
L., Bertherat J., Libé R., Dumont F., Deschamps
F., Schlumberger M., Gimenez-Roqueplo A.P.,
and Baudin E. SDHB mutations are associated
with response to temozolomide in patients with
metastatic pheochromocytoma or paraganglioma.
[2014] International Journal of Cancer (135) 11 :
2711-2720. Impact factor : 5.085
158. H
annani D., Locher C., Yamazaki T., Colin-Minard
V., Vetizou M., Aymeric L., Viaud S., Sanchez D.,
Smyth M.J., Bruhns P., Kroemer G., and Zitvogel
L. Contribution of humoral immune responses to
the antitumor effects mediated by anthracyclines.
[2014] Cell death and differentiation (21) 1 : 50-58.
159. H
eijnen H.F., van Wijk R., Pereboom T.C., Goos Y.J.,
Seinen C.W., van Oirschot B.A., van Dooren R., Gastou
M., Giles R.H., van Solinge W., Kuijpers T.W., Gazda
H.T., Bierings M.B., Da Costa L., and MacInnes A.W.
Ribosomal protein mutations induce autophagy
through S6 kinase inhibition of the insulin pathway.
[2014] PLoS genetics (10) 5 : e1004371-e1004371.
160. H
einemann V., Reni M., Ychou M., Richel D.J.,
Macarulla T., and Ducreux M. Tumour-stroma
interactions in pancreatic ductal adenocarcinoma:
Rationale and current evidence for new therapeutic
strategies. [2014] Cancer Treatment Reviews (40) 1
: 118-128. Impact factor : 7.588
161. H
ilpert M., Legrand C., Bluteau D., Balayn N.,
Betems A., Bluteau O., Villeval J.L., Louache F.,
Plo I., Vainchenker W., Gilles L., and Raslova H.
P19INK4D Controls Hematopoietic Stem Cells
Through Microenvironment at Basal State and
Through Apoptosis at Hematopoietic Stress. [2014]
Haematologica (99) S1 : 241-242. Impact factor :
5.814
162. H
ochart A., Maurage C.A., Rocourt N., Vinchon M.,
Kerdraon O., Escande F., Grill J., Pick V.K., and
Leblond P. Spontaneous Malignant Transformation
of a Cervical Spinal Cord Pilocytic Astrocytoma into
Glioblastoma in a Child. [2014] Neuro-Oncology
(16) Suppl.1 : i43-i43. Impact factor : 5.562
163. H
olderfield M., Lorenzana E., Weisburd B.,
Lomovasky L., Boussemart L., Lacroix L., Tomasic
G., Favre M., Vagner S., Robert C., Ghoddusi M.,
Daniel D., Pryer N., McCormick F., and Stuart D.
35
Vemurafenib cooperates with HPV to promote
initiation of cutaneous tumors. [2014] Cancer
research (74) 8 : 2238-2245. Impact factor : 9.329
164. H
ollebecque A., Houédé N., Cohen E.E.W., Massard
C., Italiano A., Westwood P., Bumgardner W., Miller
J., Brail L.H., Benhadji K.A., and Soria J.C. A phase
Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in
combination with erlotinib or everolimus in patients
with solid tumours. [2014] European Journal of
165. H
ouvenaeghel G., Goncalves A., Classe J.M., Garbay
J.R., Giard S., Charytensky H., Cohen M., Belichard
C., Faure C., Uzan S., Hudry D., Azuar P., Villet R.,
Gimbergues P., de Lara C., Martino M., Lambaudie E.,
Coutant C., Dravet F., Chauvet M.P., Chéreau Ewald E.,
Penault-Llorca F., and Esterni B. Characteristics and
clinical outcome of T1 breast cancer: A multicenter
retrospective cohort study. [2014]
Annals of
166. H
u M.I., Glezerman I.G., Leboulleux S., Insogna K.,
Gucalp R., Misiorowski W., Yu B., Zorsky P., Tosi D.,
Bessudo A., Jaccard A., Tonini G., Ying W., Braun
A., and Jain R.K. Denosumab for treatment of
hypercalcemia of malignancy. [2014] Journal of
Clinical Endocrinology and Metabolism (99) 9 : 31443152. Impact factor : 6.204
167. H
ua C., Zehou O., Ducassou S., Minard-Colin V., HamelTeillac D., Wolkenstein P., and Valeyrie-Allanore L.
Sirolimus improves pain in NF1 patients with severe
plexiform neurofibromas. [2014] Pediatrics (133) 6 :
e1792-e1797. Impact factor : 5.473
168. Iglesias M.J.L., Riet F.G., Dhermain F.D., Canale
S., Dufour C., San Rose C., Puget S., Grill J., and
Bolle S. RE-IRRADIATION FOR RECURRENT
EPENDYMOMAS: TUMOR CONTROL WITHOUT CSI
Re-irradiation for Recurrent Ependynomas: Tumor
Control without CSI. [2014] Neuro-Oncology (16)
Suppl.1 : i24-i24. Impact factor : 5.562
169. Ignatiadis M., Riethdorf S., Bidard F.C., Vaucher I.,
Khazour M., Rothé F., Metallo J., Rouas G., Payne R.E.,
Coombes R., Teufel I., Andergassen U., Apostolaki S.,
Politaki E., Mavroudis D., Bessi S., Pestrin M., Di Leo
A., Campion M., Reinholz M., Perez E., Piccart M.,
Borgen E., Naume B., Jimenez J., Aura C., Zorzino
L., Cassatella M., Sandri M., Mostert B., Sleijfer S.,
Kraan J., Janni W., Fehm T., Rack B., Terstappen
L., Repollet M., Pierga J.Y., Miller C., Sotiriou C.,
Michiels S., and Pantel K. International study on
inter-reader variability for circulating tumor cells in
breast cancer. [2014] Breast Cancer Research (16) 2
: R43-R43. Impact factor : 5.490
170. Isambert N., Ray-Coquard I., Italiano A., Rios M.,
Kerbrat P., Gauthier M., Blouet A., Chaigneau
L., Duffaud F., Piperno-Neumann S., Kurtz J.E.,
Girard N., Collard O., Bompas E., Penel N., Bay
J.O., Guillemet C., Collin F., Blay J.Y., Le Cesne
A., and Thariat J. Primary cardiac sarcomas: A
retrospective study of the French Sarcoma Group.
[2014] European Journal of Cancer (50) 1 : 128-136.
171. Izzedine H., Mangier M., Ory V., Zhang S.Y., Sendeyo
K., Bouachi K., Audard V., Le Péchoux C., Soria
J.C., Massard C., Bahleda R., Bourry E., Khayat D.,
Baumelou A., Lang P., Ollero M., Pawlak A., and
Sahali D. Expression patterns of RelA and c-mip
are associated with different glomerular diseases
following anti-VEGF therapy. [2014] Kidney
International (85) 2 : 457-470. Impact factor : 8.563
172. Izzedine H., Escudier B., Lhomme C., Pautier P.,
Rouvier P., Gueutin V., Baumelou A., Derosa L.,
Bahleda R., Hollebecque A., Sahali D., and Soria J.C.
Kidney Diseases Associated With Anti-Vascular
Endothelial Growth Factor (VEGF): An 8-year
Observational Study at a Single Center. [2014]
Medicine (93) 24 : 333-339. Impact factor : 5.723
173. J acobs S., De Vathaire F., Diallo I., Llanas D., Verez
C., Diop F., Kahlouche A., Grill J., Puget S., ValteauCouanet D., and Dufour C. Second Tumors in
Children with Medulloblastoma Treated Between
1964 and 2007: A Single Center Retrospective
Study. [2014] Neuro-Oncology (16) Suppl. 1 :
174. J erusalem G., Bachelot T., Barrios C., Andre F.,
Neven P., Di Leo A., Janni W., and de Boer R. A
36
new era of improving progression-free survival in
HR+, HER2(-) advanced breast cancer with dual
blockade. [2014] European Journal of Cancer (50)
S2 : S185-S185. Impact factor : 5.417
175. J oshi A.D., Lindstrom S., Husing A., Barrdahl M.,
VanderWeele T.J., Campa D., Canzian F., Gaudet
M.M., Figueroa J.D., Baglietto L., Berg C.D., Buring
J.E., Chanock S.J., Chirlaque M.D., Diver W.R.,
Dossus L., Giles G.G., Haiman C.A., Hankinson S.E.,
Henderson B.E., Hoover R.N., Hunter D.J., Isaacs C.,
Kaaks R., Kolonel L.N., Krogh V., Le Marchand L.,
Lee I.M., Lund E., McCarty C.A., Overvad K., Peeters
P.H., Riboli E., Schumacher F., Severi G., Stram
D.O., Sund M., Thun M.J., Travis R.C., Trichopoulos
D., Willett W.C., Zhang S., Ziegler R.G., Kraft P.,
and Marchand L.L. Additive Interactions Between
Susceptibility Single-Nucleotide Polymorphisms
Identified in Genome-Wide Association Studies
and Breast Cancer Risk Factors in the Breast
and Prostate Cancer Cohort Consortium. [2014]
American Journal of Epidemiology (180) 10 : 10181027. Impact factor : 5.230
176. K
aaks R., Tikk K., Sookthai D., Schock H., Johnson T.,
Tjonneland A., Olsen A., Overvad K., Clavel-Chapelon
F., Dossus L., Baglietto L., Rinaldi S., Chajes V.,
Romieu I., Boeing H., Schuetze M., Trichopoulou A.,
Lagiou P., Trichopoulos D., Palli D., Sieri S., Tumino
R., Ricceri F., Mattiello A., Buckland G., Ramon
Quiros J., Sanchez M.J., Amiano P., Chirlaque
M.D., Barricarte A., Bas Bueno-de-Mesquita H.,
van Gils C.H., Peeters P.H., Andersson A., Sund M.,
Weiderpass E., Khaw K.T., Wareham N., Key T.J.,
Travis R.C., Merritt M.A., Gunter M.J., Riboli E., and
Lukanova A. Premenopausal serum sex hormone
levels in relation to breast cancer risk, overall and
by hormone receptor status-Results from the EPIC
cohort. [2014] International Journal of Cancer
(134) 8 : 1947-1957. Impact factor : 5.085
177. K
aaks R., Johnson T., Tikk K., Sookthai D., Tjonneland
A., Roswall N., Overvad K., Clavel-Chapelon F.,
Boutron-Ruault M.C., Dossus L., Rinaldi S., Romieu
I., Boeing H., Schuetze M., Trichopoulou A., Lagiou
P., Trichopoulos D., Palli D., Grioni S., Tumino R.,
Sacerdote C., Panico S., Buckland G., Arguelles M.,
Sanchez M.J., Amiano P., Chirlaque M.D., Ardanaz
E., Bueno-de-Mesquita H.B., van Gils C.H., Peeters
P.H., Andersson A., Sund M., Weiderpass E., Gram
I.T., Lund E., Khaw K.T., Wareham N., Key T.J.,
Travis R.C., Merritt M.A., Gunter M.J., Riboli E., and
Lukanova A. Insulin- like growth factor I and risk of
breast cancer by age and hormone receptor statusA prospective study within the EPIC cohort. [2014]
178. K
arayan-Tapon L., Cortes U., Rivet P., Jermidi C.,
Vassal G., Wager M., and Taillandier L. Lack of
GOPC-ROS1 (FIG-ROS1) rearrangement in adult
human gliomas. [2014] European Journal of Cancer
(50) 13 : 2364-2366. Impact factor : 5.417
179. K
epp O., Senovilla L., Vitale I., Vacchelli E., Adjemian
S., Agostinis P., Apetoh L., Aranda F., Barnaba V.,
Bloy N., Bracci L., Breckpot K., Brough D., Buqué
A., Castro M.G., Cirone M., Colombo M.I., Cremer
I., Demaria S., Dini L., Eliopoulos A.G., Faggioni
A., Formenti S.C., Fucikova J., Gabriele L., Gaipl
U.S., Galon J., Garg A., Ghiringhelli F., Giese N.A.,
Guo Z.S., Hemminki A., Herrmann M., Hodge J.W.,
Holdenrieder S., Honeychurch J., Hu H.M., Huang X.,
Illidge T.M., Kono K., Korbelik M., Krysko D.V., Loi S.,
Lowenstein P.R., Lugli E., Ma Y., Madeo F., Manfredi
A.A., Martins I., Mavilio D., Menger L., Merendino
N., Michaud M., Mignot G., Mossman K.L., Multhoff
G., Oehler R., Palombo F., Panaretakis T., Pol J.,
Proietti E., Ricci J.E., Riganti C., Rovere-Querini P.,
Rubartelli A., Sistigu A., Smyth M.J., Sonnemann
J., Spisek R., Stagg J., Sukkurwala A.Q., Tartour E.,
Thorburn A., Thorne S.H., Vandenabeele P., Velotti
F., Workenhe S.T., Yang H., Zong W.X., Zitvogel L.,
Kroemer G., and Galluzzi L. Consensus guidelines
for the detection of immunogenic cell death. [2014]
OncoImmunology (3) 9 : e955691-e955691. Impact
factor : 6.266
180. K
err K.M., Bubendorf L., Edelman M.J., Marchetti
A., Mok T., Novello S., O’Byrne K., Stahel R., Peters
S., Felip E., Besse B., Vansteenkiste J., Eberhardt
W., Baas P., Reck M., Syrigos K., Paz-Ares L., Smit
E.F., Meldgaard P., Adjei A., Nicolson M., Crino
L., Schil P.V., Senan S., Faivre-Finn C., Rocco G.,
Veronesi G., Douillard J.Y., Lim E., Dooms C., Weder
W., de Ruysscher D., Le Pechoux C., de Leyn P., and
37
Westeel V. Second ESMO consensus conference on
lung cancer: Pathology and molecular biomarkers
for non-small-cell lung cancer. [2014] Annals of
181. K
hosrotehrani K., Van Der Ploeg A.P.T., Siskind
V., Hughes M.C., Wright A., Thomas J., Barbour
A., Allan C., Bayley G., Eggermont A., Verhoef C.,
Smithers B.M., and Green A.C. Nomograms to
predict recurrence and survival in stage IIIB and IIIC
melanoma after therapeutic lymphadenectomy.
182. K
o A., Kanehisa A., Martins I., Senovilla L., Chargari
C., Dugue D., Marino G., Kepp O., Michaud M.,
Perfettini J.L., Kroemer G., and Deutsch E.
Autophagy inhibition radiosensitizes in vitro, yet
reduces radioresponses in vivo due to deficient
immunogenic signalling. [2014] Cell death and
differentiation (21) 1 : 92-99. Impact factor : 8.184
183. K
owalczyk J.R., Samardakiewicz M., Fitzgerald E.,
Essiaf S., Ladenstein R., Vassal G., Kienesberger
A., and Pritchard-Jones K. Towards reducing
inequalities: European Standards of Care for
Children with Cancer. [2014] European Journal of
184. K
usamura S., Moran B.J., Sugarbaker P.H., Levine
E.A., Elias D., Baratti D., Morris D.L., Sardi A.,
Glehen O., Deraco M., Gilly F.N., Barrios P., Quenet
F., Loggie B.W., Gomez Portilla A., De Hingh I.H.J.T.,
Ceelen W.P., Pelz J.O.W., Piso P., Gonzalez-Moreno
S., Van Der Speeten K., Chua T.C., Yan T.D., and Liauw
W. Multicentre study of the learning curve and
surgical performance of cytoreductive surgery with
intraperitoneal chemotherapy for pseudomyxoma
peritonei. [2014] British Journal of Surgery (101)
13 : 1758-1765. Impact factor : 5.542
185. K
vaskoff M., Han J., Qureshi A.A., and Missmer S.A.
Pigmentary traits, family history of melanoma
and the risk of endometriosis: a cohort study
of US women. [2014] International Journal of
Epidemiology (43) 1 : 255-263. Impact factor : 9.176
186. L
acroix L., Boichard A., Andre F., and Soria J.C.
Genomes in the clinic: the Gustave Roussy Cancer
Center experience. [2014] Current Opinion in
Genetics & Development (24) : 99-106. Impact
factor : 7.574
187. L
adoire S., Hannani D., Vetizou M., Locher C., Aymeric
L., Apetoh L., Kepp O., Kroemer G., Ghiringhelli F.,
and Zitvogel L. Cell-death-associated molecular
patterns as determinants of cancer immunogenicity.
[2014] Antioxidants and Redox Signaling (20) 7 :
1098-1116. Impact factor : 7.407
188. L
adoire S., Dalban C., Roché H., Spielmann M.,
Fumoleau P., Levy C., Martin A.L., Ecarnot F.,
Bonnetain F., and Ghiringhelli F. Effect of obesity
on disease-free and overall survival in nodepositive breast cancer patients in a large French
population: A pooled analysis of two randomised
trials. [2014] European Journal of Cancer (50) 3 :
189. L
ajous M., Bijon A., Fagherazzi G., Rossignol E.,
Boutron-Ruault M.C., and Clavel-Chapelon F.
Processed and unprocessed red meat consumption
and hypertension in women. [2014] American
Journal of Clinical Nutrition (100) 3 : 948-952.
190. L
ajous M., Bijon A., Fagherazzi G., Boutron-Ruault
M.C., Balkau B., Clavel-Chapelon F., and Hernan M.A.
Body mass index, diabetes, and mortality in French
women: explaining away a «paradox». [2014]
191. L
amora A., Talbot J., Bougras G., Amiaud J., Leduc M.,
Chesneau J., Taurelle J., Stresing V., Le Deley M.C.,
Heymann M.F., Heymann D., Redini F., and Verrecchia
F. Overexpression of Smad7 blocks primary tumor
growth and lung metastasis development in
osteosarcoma. [2014] Clinical Cancer Research (20)
19 : 5097-5112. Impact factor : 8.722
192. L
anglois T., Da Costa Reis Monte-Mor, Lenglet G.,
Droin N., Marty C., Le Couédic J.P., Almire C., Auger
N., Mercher T., Delhommeau F., Christensen J.,
Helin K., Debili N., Fuks F., Bernard O.A., Solary E.,
38
Vainchenker W., and Plo I. TET2 deficiency inhibits
mesoderm and hematopoietic differentiation in
human embryonic stem cells. [2014] Stem Cells
(32) 8 : 2084-2097. Impact factor : 6.523
193. L
avaud P. and Andre F. Strategies to overcome
trastuzumab resistance in HER2-overexpressing
breast cancers: focus on new data from clinical
trials. [2014] BMC Medicine (12) 1 : 132-132.
194. L
e Guellec S., Chibon F., Ouali M., Perot G.,
Decouvelaere A.V., Robin Y.M., Larousserie F., Terrier
P., Coindre J.M., and Neuville A. Are Peripheral Purely
Undifferentiated Pleomorphic Sarcomas With MDM2
Amplification
Dedifferentiated
Liposarcomas?
[2014] American Journal of Surgical Pathology (38)
3 : 293-304. Impact factor : 5.145
195. L
eary A., Evans A., Johnston S.R.D., A’Hern R.,
Bliss J.M., Sahoo R., Detre S., Haynes B.P., Hills M.,
Harper-Wynne C., Bundred N., Coombes G., Smith I.,
and Dowsett M. Antiproliferative Effect of Lapatinib
in HER2-Positive and HER2-Negative/HER3High Breast Cancer: Results of the Presurgical
Randomized MAPLE Trial (CRUK E/06/039). [2014]
Clinical Cancer Research. Impact factor : 8.722
196. L
educ C. and Besse B. Clinical benefit of continuing
ALK inhibition with crizotinib beyond initial disease
progression in patients with advanced ALK-positive
NSCLC. [2014] Annals of Oncology (25) 10 : 20922092. Impact factor : 7.040
197. L
educ C., Moussa N., Faivre L., Biondani P., Pignon
J., Caramella C., and Besse B. Tumor Burden
and Tyrosine Kinase Inhibitors (TKI) Benefit in
Advanded Non-Small Cell Lung Cancer (NSCLC)
Patients with EGFR Sensitizing Mutations (EGFRM)
and ALK Rearrnagement (ALK Plus). [2014]
Journal of Thoracic Oncology (9) 4 S1 : S37-S37.
198. L
eenders M., Boshuizen H.C., Ferrari P., Siersema
P.D., Overvad K., Tjonneland A., Olsen A., BoutronRuault M.C., Dossus L., Dartois L., Kaaks R., Li K.,
Boeing H., Bergmann M.M., Trichopoulou A., Lagiou
P., Trichopoulos D., Palli D., Krogh V., Panico S.,
Tumino R., Vineis P., Peeters P.H.M., Weiderpass
E., Engeset D., Braaten T., Redondo M.L., Agudo
A., Sanchez M.J., Amiano P., Huerta J.M., Ardanaz
E., Drake I., Sonestedt E., Johansson I., Winkvist
A., Khaw K.T., Wareham N.J., Key T.J., Bradbury
K.E., Johansson M., Licaj I., Gunter M.J., Murphy
N., Riboli E., and Bueno-de-Mesquita H.B. Fruit
and vegetable intake and cause-specific mortality
in the EPIC study. [2014] European Journal of
199. L
eenders M., Leufkens A.M., Siersema P.D., Van
Duijnhoven F.J.B., Vrieling A., Hulshof P.J.M.,
Van Gils C.H., Overvad K., Roswall N., Kyro C.,
Boutron-Ruault M.C., Fagerhazzi G., Cadeau C.,
Kuhn T., Johnson T., Boeing H., Aleksandrova K.,
Trichopoulou A., Klinaki E., Androulidaki A., Palli D.,
Grioni S., Sacerdote C., Tumino R., Panico S., Bakker
M.F., Skeie G., Weiderpass E., Jakszyn P., Barricarte
A., Huerta J.M., Molina-Montes E., Arguelles M.,
Johansson I., Ljuslinder I., Key T.J., Bradbury K.E.,
Khaw K.T., Wareham N.J., Ferrari P., Duarte-Salles
T., Jenab M., Gunter M.J., Vergnaud A.C., Wark P.A.,
and Bueno-de-Mesquita H.B. Plasma and dietary
carotenoids and vitamins A, C and e and risk of
colon and rectal cancer in the European Prospective
Investigation into Cancer and Nutrition. [2014]
200. L
esueur L.L., Mir L.M., Ragot T., and Andre F.M.
In Vitro Electrotransfer of Large Plasmids. [2014]
Molecular Therapy (22) S1 : S129-S129. Impact
factor : 6.227
201. L
i L., Ten Hagen T.L.M., Haeri A., Soullié T., Scholten
C., Seynhaeve A.L.B., Eggermont A.M.M., and
Koning G.A. A novel two-step mild hyperthermia for
advanced liposomal chemotherapy. [2014] Journal
of Controlled Release (174) : 202-208. Impact
factor : 7.705
202. L
issa D., Senovilla L., Rello-Varona S., Vitale I.,
Michaud M., Pietrocola F., Boilève A., Obrist F.,
Bordenave C., Garcia P., Michels J., Jemaa M., Kepp
O., Castedo M., and Kroemer G. Resveratrol and
aspirin eliminate tetraploid cells for anticancer
39
chemoprevention. [2014] Proceedings of the
National Academy of Sciences of the United States
of America (111) 8 : 3020-3025. Impact factor : 9.674
203. L
oi S., Michiels S., Salgado R., Sirtaine N., Jose V.,
Fumagalli D., Kellokumpu-Lehtinen P.L., Bono P.,
Kataja V., Desmedt C., Piccart M.J., Loibl S., Denkert
C., Smyth M.J., Joensuu H., and Sotiriou C. Tumor
infiltrating lymphocytes are prognostic in triple
negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: results from the
FinHER trial. [2014] Annals of Oncology (25) 8 : 15441550. Impact factor : 7.040
204. L
ondon J., Grados A., Fermé C., Charmillon A., Maurier
F., Deau B., Crickx E., Brice P., Chapelon-Abric C.,
Haioun C., Burroni B., Alifano M., Le Jeunne C., Guillevin
L., Costedoat-Chalumeau N., Schleinitz N., Mouthon L.,
and Terrier B. Sarcoidosis occurring after lymphoma:
report of 14 patients and review of the literature. [2014]
Medicine (93) 21 : e121-e121. Impact factor : 5.723
205. L
ongaud-Vales A., Chevignard M., Dufour C., Grill J.,
Pujet S., Sainte-Rose C., Valteau-Couanet D., and
Dellatolas G. Assessment of Executive Functioning in
Children and Young Adults Treated for Frontal Lobe
Tumours Using Ecologically Valid Tests. [2014] NeuroOncology (16) Suppl.1 : i101-i101. Impact factor : 5.562
206. L
opez-Terrada D., Alaggio R., De Davila M.T., Czauderna
P., Hiyama E., Katzenstein H., Leuschner I., Malogolowkin
M., Meyers R., Ranganathan S., Tanaka Y., Tomlinson G.,
Fabrè M., Zimmermann A., and Finegold M.J. Towards
an international pediatric liver tumor consensus
classification: Proceedings of the Los Angeles COG
liver tumors symposium. [2014] Modern Pathology (27)
3 : 472-491. Impact factor : 6.187
207. L
oriot Y., Mordant P., Dugue D., Geneste O., Gombos
A., Opolon P., Guegan J., Perfettini J.L., Pierre A.,
Berthier L.K., Kroemer G., Soria J.C., Depil S., and
Deutsch E. Radiosensitization by a novel Bcl-2 and
Bcl-X-L inhibitor S44563 in small-cell lung cancer.
[2014] Cell Death & Disease (5) 9 : e1423-e1423.
208. L
ortholary O., Renaudat C., Sitbon K., Madec Y.,
Denoeud-Ndam L., Wolff M., Fontanet A., Bretagne
S., Dromer F., Bouges-Michel C., Poilane I., Dunan J.,
Galeazzi G., Alanio A., Foulet F., Fauchet N., Forget E.,
Lawrence C., Angoulvant A., Bonnal C., Hennequin C.,
Botterel F., Eloy O., David M.F., Khassis N., Milhaila
L., Chachaty E., Chochillon C., Lesle F., Paugam A.,
Baixench M.T., Escande M.C., Cornet M., Bougnoux
M.E., Sterckers Y., Challier S., Dannaoui E., Lavarde
V., Datry A., Mimouni B.L., Brun S., Fekkar A., Guitard
J., Poirot J.L., Lacroix C., Moissenet D., Develoux M.,
Mariani P., Bonacorsi S., Desnos-Ollivier M., GarciaHermoso D., Hoinard D., and Raoux D. Worrisome
trends in incidence and mortality of candidemia in
intensive care units (Paris area, 2002-2010). [2014]
Intensive care medicine (40) 9 : 1303-1312. Impact
factor : 7.214
209. L
oupy A., Lefaucheur C., Vernerey D., Chang J.,
Hidalgo L.G., Beuscart T., Verine J., Aubert O.,
Dubleumortier S., Duong van Huyen J.-P., Jouven X.,
Glotz D., Legendre C., and Halloran P.F. Molecular
microscope strategy to improve risk stratification in
early antibody-mediated kidney allograft rejection.
[2014] Journal of the American Society of Nephrology
(JASN) (25) 10 : 2267-2277. Impact factor : 9.343
210. L
ueza B., Le Pechoux C., and Pignon J.-P. Phase III
trial of concurrent thoracic radiotherapy with either
first- or third-cycle chemotherapy for limiteddisease small-cell lung cancer. [2014] Annals of
211. L
ukanova A., Becker S., Husing A., Schock H., Fedirko
V., Trepo E., Trichopoulou A., Bamia C., Lagiou P.,
Benetou V., Trichopoulos D., Nöthlings U., Tjonneland
A., Overvad K., Dossus L., Teucher B., Boeing H.,
Aleksandrova K., Palli D., Pala V., Panico S., Tumino
R., Ricceri F., Bueno-de-Mesquita H.B., Siersema
P.D., Peeters P.H.M., Quiros J.R., Duell E.J., MolinaMontes E., Chirlaque M.D., Gurrea A.B., Dorronsoro
M., Lindkvist B., Johansen D., Werner M., Sund M.,
Khaw K.T., Wareham N., Key T.J., Travis R.C., Rinaldi
S., Romieu I., Gunter M.J., Riboli E., Jenab M., and
Kaaks R. Prediagnostic plasma testosterone, sex
hormone-binding globulin, IGF-I and hepatocellular
carcinoma: Etiological factors or risk markers?
[2014] International Journal of Cancer (134) 1 : 164173. Impact factor : 5.085
40
212. M
a X., Rousseau V., Sun H., Lantuejoul S., Filipits
M., Pirker R., Popper H., Mendiboure J., Vataire A.L.,
Le Chevalier T., Soria J.C., Brambilla E., Dunant A.,
and Hainaut P. Significance of TP53 mutations as
predictive markers of adjuvant cisplatin-based
chemotherapy in completely resected non-smallcell lung cancer. [2014] Molecular Oncology (8) 3 :
214. M
a Y., Adjemian S., Galluzzi L., Zitvogel L., and Kroemer
G. Chemokines and chemokine receptors required
for optimal responses to anticancer chemotherapy.
[2014] OncoImmunology (3) : e27663-e27663. Impact
factor : 6.266
219. M
arivin A., Berthelet J., Cartier J., Paul C., Gemble S.,
Morizot A., Boireau W., Saleh M., Bertoglio J., Solary
E., and Dubrez L. cIAP1 regulates TNF-mediated
cdc42 activation and filopodia formation. [2014]
Oncogene (33) 48 : 5534-5545. Impact factor : 8.459
216. M
alouf G.G., Su X., Yao H., Gao J., Xiong L., He Q.,
Compérat E., Couturier J., Molinié V., Escudier B.,
Camparo P., Doss D.J., Thompson E.J., Khayat D.,
Wood C.G., Yu W., Teh B.T., Weinstein J., and Tannir
N.M. Next-generation sequencing of translocation
renal cell carcinoma reveals novel RNA splicing
partners and frequent mutations of chromatinremodeling Genes. [2014] Clinical Cancer Research
(20) 15 : 4129-4140. Impact factor : 8.722
221. M
ary F., Zaanan A., Malka D., Artru P., Boubaya M.,
Samalin E., Coriat R., Bachet J.B., Tougeron D.,
Benallaoua M., Afchain P., Locher C., Baumgaertner
I., Lecaille C., and Aparicio T. Perioperative
Chemotherapy with Folfox in Resectable
Gastro-oesophageal Adenocarcinoma: An Ageo
Multicentric Retrospective Study. [2014] Annals of
Oncology (25) S2 : ii27-ii28 . Impact factor : 7.040
213. M
a Y., Mattarollo S.R., Adjemian S., Yang H., Aymeric L.,
Hannani D., Catani J.P.P., Duret H., Teng M.W.L., Kepp
O., Wang Y., Sistigu A., Schultze J.L., Stoll G., Galluzzi
L., Zitvogel L., Smyth M.J., and Kroemer G. CCL2/
CCR2-dependent recruitment of functional antigenpresenting cells into tumors upon chemotherapy.
[2014] Cancer research (74) 2 : 436-445. Impact
factor : 9.329
215. M
agdalou I., Lopez B.S., Pasero P., and Lambert
S.A.E. The causes of replication stress and their
consequences on genome stability and cell fate.
[2014] Seminars in cell & developmental biology (30)
: 154-164. Impact factor : 6.265
217. M
amez A.C., Levy V., Chevallier P., Vigouroux S.,
Xhaard A., Contentin N., Mohty M., Yakoubagha
I., Bulabois C.E., Deconink E., Lamy T., Huynh A.,
Fegueux N., Turlure P., Maury S., Suarez F., Beguin
Y., Jubert C., Rialland F., Maillard N., Guillerm
G., Bilger K., Bourhis J.H., Bay J.O., and Quoc
S.N. Effect of Immunomodulation for Peripheral
T-Cell Lymphoma in Relapse after Allogeneic
Hematopoietic Stem Cell Transplant: A SFGM-TC
Study on 64 Patients. [2014] Haematologica (99) S1
: 506-506. Impact factor : 5.814
218. M
anceau G., Imbeaud S., Thiébaut R., Liébaert F.,
Fontaine K., Rousseau F., Génin B., Le Corre D.,
Didelot A., Vincent M., Bachet J.B., Chibaudel B.,
Bouché O., Landi B., Bibeau F., Leroy K., PenaultLlorca F., Van Laethem J.L., Demetter P., Tejpar S.,
Rossi S., Mosakhani N., Osterlund P., Ristamäki
R., Sarhadi V., Knuutila S., Boige V., André T., and
Laurent-Puig P. Hsa-miR-31-3p expression is linked
to progression-free survival in patients with KRAS
wild-type metastatic colorectal cancer treated with
anti-EGFR therapy. [2014] Clinical Cancer Research
(20) 12 : 3338-3347. Impact factor : 8.722
220. M
artins I., Wang Y., Michaud M., Ma Y., Sukkurwala
A.Q., Shen S., Kepp O., Métivier D., Galluzzi L.,
Perfettini J.L., Zitvogel L., and Kroemer G. Molecular
mechanisms of ATP secretion during immunogenic
cell death. [2014] Cell death and differentiation
(21) 1 : 79-91. Impact factor : 8.184
222. M
erks J.H.M., de Salvo G.L., Bergeron C., Bisogno G., de
Paoli A., Ferrari A., Rey A., Oberlin O., Stevens M.C.G.,
Kelsey A., Michalski J., Hawkins D.S., and Anderson
J.R. Parameningeal rhabdomyosarcoma in pediatric
age: Results of a pooled analysis from North American
and European cooperative groups. [2014] Annals of
41
223. M
esnard C., Mazouni C., Amabille M.I., Bentivegna E.,
Garbay J.R., and Rimareix F. Mastectomy padding:
A technical procedure to reduce post-operative
seroma and punction. [2014] European Journal of
Cancer (50) S2 : S158-S158. Impact factor : 5.417
224. M
essai Y., Noman M.Z., Hasmim M., Janji B., Tittarelli
A., Boutet M., Baud V., Viry E., Billot K., Nanbakhsh
A., Ben Safta T., Richon C., Ferlicot S., Donnadieu
E., Couve S., Gardie B., Orlanducci F., Albiges L.,
Thiery J., Olive D., Escudier B., and Chouaib S.
ITPR1 protects renal cancer cells against natural
killer cells by inducing autophagy. [2014] Cancer
225. M
essaoudene M., Fregni G., Fourmentraux-Neves E.,
Chanal J., Maubec E., Mazouz-Dorval S., Couturaud
B., Girod A., Sastre-Garau X., Albert S., Guédon C.,
Deschamps L., Mitilian D., Cremer I., Jacquelot N.,
Rusakiewicz S., Zitvogel L., Avril M.F., and Caignard
A. Mature Cytotoxic CD56bright/CD16+ Natural
Killer Cells Can Infiltrate Lymph Nodes Adjacent to
Metastatic Melanoma. [2014] Cancer research (74)
1 : 81-92. Impact factor : 9.329
226. M
ichaud M., Sukkurwala A.Q., Di Sano F., Zitvogel
L., Kepp O., and Kroemer G. Synthetic induction
of immunogenic cell death by genetic stimulation
of endoplasmic reticulum stress. [2014]
OncoImmunology (3) : e28276-e28276. Impact
factor : 6.266
227. M
ichaud M., Xie X., Bravo-San Pedro J.M., Zitvogel L.,
White E., and Kroemer G. An autophagy-dependent
anticancer immune response determines the
efficacy of melanoma chemotherapy. [2014]
OncoImmunology (3) 7 : e944047-e944047. Impact
factor : 6.266
228. M
ichels J., Obrist F., Castedo M., Vitale I., and
Kroemer G. PARP and other prospective targets
for poisoning cancer cell metabolism. [2014]
Biochemical pharmacology (92) 1 : 164-171. Impact
factor : 5.009
229. M
ichels J., Vitale I., Saparbaev M., Castedo M.,
and Kroemer G. Predictive biomarkers for cancer
therapy with PARP inhibitors. [2014] Oncogene (33)
30 : 3894-3907. Impact factor : 8.459
230. M
ichels J., Obrist F., Vitale I., Lissa D., Garcia P.,
Behnam-Motlagh P., Kohno K., Wu G.S., Brenner C.,
Castedo M., and Kroemer G. MCL-1 dependency of
cisplatin-resistant cancer cells. [2014] Biochemical
pharmacology (92) 1 : 55-61. Impact factor : 5.009
231. M
icol J.B., Chahine C., Woerther P.L., Ghez D.,
Netzer F., Dufour C., Merad M., Blot F., Chachaty
E., De Botton S., and Gachot B. Discontinuation of
empirical antibiotic therapy in neutropenic acute
myeloid leukaemia patients with fever of unknown
origin: is it ethical? [2014] Clinical Microbiology and
Infection (20) 7 : O453-O455. Impact factor : 5.768
232. M
icol J.B. and Abdel-Wahab O. Collaborating
constitutive and somatic genetic events in myeloid
malignancies: ASXL1 mutations in patients with
germline GATA2 mutations. [2014] Haematologica
(99) 2 : 201-203. Impact factor : 5.814
233. M
iquel C., Delisle M.B., Dufour C., Lafon D.,
Sevenet N., Pierron G., Delattre O., and Bourdeaut
F. Divergence and Convergence of Morphology,
,Immunohistochemistry and Molecular Profiling to
Determine SHH Type Medulloblastoma in Children
< 5 years. [2014] Neuro-Oncology (16) Suppl.1 :
234. M
irghani H., Amen F., Moreau F., Guigay J., Hartl
D.M., and Lacau St.Guily J. Oropharyngeal cancers:
Relationship between epidermal growth factor
receptor alterations and human papillomavirus
status. [2014] European Journal of Cancer (50) 6 :
1100-1111. Impact factor : 5.417
235. M
itry E., Walter T., Baudin E., Kurtz J.E., Ruszniewski
P., Dominguez-Tinajero S., Bengrine-Lefevre
L., Cadiot G., Dromain C., Farace F., Rougier P.,
and Ducreux M. Bevacizumab plus capecitabine
in patients with progressive advanced welldifferentiated neuroendocrine tumors of the gastrointestinal (GI-NETs) tract (BETTER trial)--a phase II
non-randomised trial. [2014] European Journal of
42
236. M
olina T.J., Chalabreysse L., De Montpreville V.T., De
Muret A., Hofman V., Lantuejoul S., Parrens M., Payan
M.J., Rouquette I., Secq V., Girard N., Besse B., and
Marx A. Impact of the ITMIG Criteria on Diagnosis in
the French Network of Thymic Epihelial Tumours.
[2014] Journal of Thoracic Oncology (9) 10 S4 :
S217-S217. Impact factor : 5.282
237. M
oreno Garcia V., Olmos D., Gomez-Roca C., Cassier
P.A., Morales-Barrera R., Del Conte G., Gallerani E.,
Brunetto A.T., Schöffski P., Marsoni S., Schellens
J.H.M., Penel N., Voest E., Evans J., Plummer R.,
Wilson R.H., Soria J.C., Tabernero J., Verweij J., and
Kaye S.B. Dose-response relationship in phase
i clinical trials: a European Drug Development
Network (EDDN) Collaboration Study. [2014]
Clinical Cancer Research (20) 22 : 5663-5671.
238. M
orin S., Uro-Coste E., Munzer C., Gambart M.,
Puget S., Miquel C., Maurage C.A., Dufour C.,
Leblond P., Andre N., Kanold J., Icher C., Bertozzi
A., and Isabelle A French Retrospective Study on
Choroid Plexus Tumors in Children. [2014] NeuroOncology (16) Suppl.1 : i128-i128. Impact factor :
5.562
239. M
ounier N., Brice P., Bologna S., Briere J., Gaillard
I., Heczko M., Gabarre J., Casasnovas O., Jaubert J.,
Colin P., Delmer A., Devidas A., Bachy E., NicolasVirelizier E., Aoudjhane A., Humbrecht C., Andre M.,
Carde P., Divine M., Fenaux P., Coiffier B., Reman O.,
Aoudjhane M., Blaise A.M., Bordessoule D., Bosly A.,
Morschhauser F., Caillot D., Gonzalez H., Lederlin
P., Bouabdallah R., Van Hoof A., Boulat O., Bauduer
F., Tournilhac O., Decaudin D., Sebban C., Janvier
M., Kentos A., Voillat L., Fabbro M., Eisenmann
J.C., Martin C., Christian B., Ferrant A., Salanoubat
C., Varet B., Bouabdallah K., de Prijck B., Levaltier
X., Castaigne S., Audhuy B., Frenkiel N., Rose C.,
Fitoussi O., Orfeuvre H., and Pignon J.M. ABVD (8
cycles) versus BEACOPP (4 escalated cycles >=
4 baseline): Final results in stage III-IV low-risk
Hodgkin lymphoma (IPS 0-2) of the LYSA H34
randomized trial. [2014] Annals of Oncology (25) 8 :
1622-1628. Impact factor : 7.040
240. M
uller D.C., Fanidi A., Midttun O., Steffen A., Dossus
L., Boutron-Ruault M.C., Severi G., Kuehn T.,
Katzke V., de la Torreon R., Gonzalez C.A., Sanchez
M.J., Dorronsoro M., Santiuste C., Barricarte A.,
Khaw K.T., Wareham N., Travis R.C., Trichopoulou
A., Giotaki M., Trichopoulos D., Palli D., Krogh
V., Tumino R., Vineis P., Panico S., Tjonneland A.,
Olsen A., Bueno-de-Mesquita H.B., Peeters P.H.,
Ljungberg B., Wennberg M., Weiderpass E., Murphy
N., Riboli E., Ueland P.M., Boeing H., Brennan P.,
and Johansson M. Circulating 25-Hydroxyvitamin
D-3 in Relation to Renal Cell Carcinoma Incidence
and Survival in the EPIC Cohort. [2014] American
Journal of Epidemiology (180) 8 : 810-820. Impact
factor : 5.230
241. N
euville A., Decouvelaere A.V., Ranchere-Vince
D., Terrier P., Collin F., and Coindre J.M. Impacts
of a Systematic Histological Review for Desmoid
Tumors: About a Series of 735 Cases Reviewed in 42
Months. [2014] Modern Pathology (27) S2 : 23A-23A.
242. N
euville A., Collin F., Bruneval P., Parrens M., Thivolet
F., Gomez-Brouchet A., Terrier P., De Montpreville V.T.,
Le Gall F., Hostein I., Lagarde P., Chibon F., and Coindre
J.M. Intimal sarcoma is the most frequent primary
cardiac sarcoma: Clinicopathologic and molecular
retrospective analysis of 100 primary cardiac
sarcomas. [2014] American Journal of Surgical
Pathology (38) 4 : 461-469. Impact factor : 5.145
243. N
itter M., Norgard B., de Vogel S., Eussen S.J.P.M.,
Meyer K., Ulvik A., Ueland P.M., Nygard O., Vollset
S.E., Bjorge T., Tjonneland A., Hansen L., BoutronRuault M., Racine A., Cottet V., Kaaks R., Kuehn T.,
Trichopoulou A., Bamia C., Naska A., Grioni S., Palli D.,
Panico S., Tumino R., Vineis P., Bueno-de-Mesquita
H.B., van Kranen H., Peeters P.H., Weiderpass E.,
Dorronsoro M., Jakszyn P., Sanchez M., Arguelles M.,
Huerta J.M., Barricarte A., Johansson M., Ljuslinder
I., Khaw K., Wareham N., Freisling H., Duarte-Salles
T., Stepien M., Gunter M.J., and Riboli E. Plasma
methionine, choline, betaine, and dimethylglycine
in relation to colorectal cancer risk in the European
Prospective Investigation into Cancer and Nutrition
(EPIC). [2014] Annals of Oncology (25) 8 : 16091615. Impact factor : 7.040
43
244. O
pletalova K., Bourillon A., Yang W., Pouvelle
C., Armier J., Despras E., Martin L., Mateus C.,
Robert C., Kannouche P., Soufir N., and Sarasin A.
Correlation of Phenotype/Genotype in a Cohort
of 23 Xeroderma Pigmentosum-Variant Patients
Reveals 12 New Disease-Causing POLH Mutations.
[2014] Human Mutation (35) 1 : 117-128. Impact
factor : 5.144
245. P
aci A., Veal G., Bardin C., Levêque D., Widmer
N., Beijnen J., Astier A., and Chatelut E. Review of
therapeutic drug monitoring of anticancer drugs
part 1--cytotoxics. [2014] European Journal of
246. P
alazzo A., Bluteau O., Messaoudi K., Ali A., Baylin
N., Rameau P., Lecluse Y., Solary E., Chang Y.,
Raslova H., Vainchenker W., and Debili N. CDC42
Regulates Proplatelet Formation Not By Wasp But
Via N-Wasp. [2014] Haematologica (99) S1 : 477477. Impact factor : 5.814
247. P
aoletti X., Le Tourneau C., Verweij J., Siu L.L.,
Seymour L., Postel-Vinay S., Collette L., Rizzo E.,
Ivy P., Olmos D., Massard C., Lacombe D., Kaye
S.B., and Soria J.C. Defining dose-limiting toxicity
for phase 1 trials of molecularly targeted agents:
Results of a DLT-TARGETT international survey.
248. P
eeters M., Oliner K., Price T., Cervantes A., Sobrero
A., Ducreux M., Hotko Y., Andre T., Chan E., Lordick F.,
Punt C., Strickland A., Wilson G., Ciuleanu T., Roman
L., van Cutsem E., Yu H., Jung A.S., Sidhu R., and
Patterson S. KRAS/NRAS AND BRAF MUTATIONS
IN THE 20050181 STUDY OF PANITUMUMAB plus
FOLFIRI FOR THE 2ND-LINE TREATMENT OF
METASTATIC COLORECTAL CANCER: UPDATED
ANALYSIS. [2014] Annals of Oncology (25) S2 : ii5ii5. Impact factor : 7.040
249. P
eeters M., Price T.J., Cervantes A., Sobrero A.F.,
Ducreux M., Hotko Y., André T., Chan E., Lordick F.,
Punt C.J.A., Strickland A.H., Wilson G., Ciuleanu
T.E., Roman L., van Cutsem E., Tian Y., and Sidhu R.
Final results from a randomized phase 3 study of
FOLFIRI Â± panitumumab for second-line treatment
of metastatic colorectal cancer. [2014] Annals of
250. P
eterlin P., Renneville A., Ben Abdelali R., Nibourel
O., Thomas X., Pautas C.Ã., De Botton S., Raffoux
E., Cayuela J.M., Boissel N., Terré C., Celli-Lebras
K., Castaigne S., Preudhomme C., Gardin C., and
Dombret H. Impact of additional genetic alterations
on the outcome of patients with NPM1-mutated
cytogenetically normal acute myeloid leukemia.
[2014] Haematologica. Impact factor : 5.814
251. P
érot G., Mendiboure J., Brouste V., Velasco V.,
Terrier P., Bonvalot S., Guillou L., Ranchèe-Vince
D., Aurias A., Coindre J.M., and Chibon F. Smooth
muscle differentiation identifies two classes of
poorly differentiated pleomorphic sarcomas with
distinct outcome. [2014] Modern Pathology (27) 6 :
252. P
hillips G.D.L., Fields C.T., Li G., Dowbenko D.,
Schaefer G., Miller K., Andre F., Burris III H.A.,
Albain K.S., Harbeck N., Dieras V., Crivellari D.,
Fang L., Guardino E., Olsen S.R., Crocker L.M.,
and Sliwkowski M.X. Dual targeting of HER2positive cancer with trastuzumab emtansine and
pertuzumab: Critical role for neuregulin blockade
in antitumor response to combination therapy.
[2014] Clinical Cancer Research (20) 2 : 456-468.
253. P
ol J., Bloy N., Obrist F., Eggermont A., Galon J.,
Fridman W.H., Cremer I., Zitvogel L., Kroemer G.,
and Galluzzi L. Trial Watch DNA vaccines for cancer
therapy. [2014] OncoImmunology (3). Impact factor
: 6.266
254. P
ol J., Bloy N., Obrist F., Eggermont A., Galon
J., Cremer I., Erbs P., Limacher J.M., Preville
X., Zitvogel L., Kroemer G., and Galluzzi L. Trial
Watch: Oncolytic viruses for cancer therapy. [2014]
factor : 6.266
255. P
olo V. and Besse B. Maintenance strategies in
stage IV non-small-cell lung cancer (NSCLC): in
44
which patients, with which drugs? [2014] Annals of
256. P
ostel-Vinay S., Collette L., Paoletti X., Rizzo E.,
Massard C., Olmos D., Fowst C., Levy B., Mancini P.,
Lacombe D., Ivy P., Seymour L., Le Tourneau C., Siu
L.L., Kaye S.B., Verweij J., and Soria J.C. Towards
new methods for the determination of dose limiting
toxicities and the assessment of the recommended
dose for further studies of molecularly targeted
agents - Dose-Limiting Toxicity and Toxicity
Assessment Recommendation Group for Early
Trials of T. [2014] European Journal of Cancer (50)
12 : 2040-2049. Impact factor : 5.417
257. P
ropper D., Davidenko I., Bridgewater J., Kupcinskas
L., Fittipaldo A., Hillenbach C., Klughammer B.,
and Ducreux M. Phase II, randomized, biomarker
identification trial (MARK) for erlotinib in patients
with advanced pancreatic carcinoma. [2014] Annals
of Oncology (25) 7 : 1384-1390. Impact factor : 7.040
258. Q
uilot P., Molina T.J., Chalabreysse L., De Muret A.,
Hofman V., Lantuejoul S., Parrens M., Payan M.J.,
Rouquette I., Secq V., Girard N., Marx A., Besse B., and
De Montpreville V.T. Glut-1 Immunohistochemical
Expression in Thymic Epithelial Tumors According
To Who Histological Type. [2014] Journal of
Thoracic Oncology (9) 10 S4 : S220-S220. Impact
factor : 5.282
259. R
enaudin X., Guervilly J.H., Aoufouchi S., and Rosselli
F. Proteomic analysis reveals a FANCA-modulated
neddylation pathway involved in CXCR5 membrane
targeting and cell mobility. [2014] Journal of Cell
Science (127) 16 : 3546-3554. Impact factor : 5.432
260. R
epunte-Canonigo V., Lefebvre C., George O.,
Kawamura T., Morales M., Koob G.F., Califano A.,
Masliah E., and Sanna P.P. Gene expression changes
consistent with neuroAIDS and impaired working
memory in HIV-1 transgenic rats. [2014] Molecular
Neurodegeneration (9) 1. Impact factor : 6.563
261. R
epunte-Canonigo V., Chen J., Lefebvre C.,
Kawamura T., Kreifeldt M., Basson O., Roberts A.J.,
and Sanna P.P. MeCP2 regulates ethanol sensitivity
and intake. [2014] Addiction biology (19) 5 : 791799. Impact factor : 5.359
262. R
eyes-Botero G., Dehais C., Idbaih A., MartinDuverneuil N., Lahutte M., Carpentier C., Letouzé
E., Chinot O., Loiseau H., Honnorat J., Ramirez
C., Moyal E., Figarella-Branger D., and Ducray
F. Contrast enhancement in 1p/19q-codeleted
anaplastic oligodendrogliomas is associated with
9p loss, genomic instability, and angiogenic gene
expression. [2014] Neuro-Oncology (16) 5 : 662670. Impact factor : 5.562
263. R
ibrag V., Dupuis J., Tilly H., Morschhauser F., Laine
F., Houot R., Haioun C., Copie C., Varga A., Lambert
J., Hatteville L., Ziti-Ljajic S., Caron A., Payrard S.,
and Coiffier B. A dose-escalation study of SAR3419,
an anti-CD19 antibody maytansinoid conjugate,
administered by intravenous infusion once weekly
in patients with relapsed/refractory B-cell nonhodgkin lymphoma. [2014] Clinical Cancer Research
(20) 1 : 213-220. Impact factor : 8.722
264. R
ogers K. and Lenoir G.M. Cancer research in
France. [2014] International Journal of Cancer
(135) 10 : 2235-2236. Impact factor : 5.085
265. R
omero A.I., Chaput N., Poirier-Colame V.,
Rusakiewicz S., Jacquelot N., Chaba K., Mortier E.,
Jacques Y., Caillat-Zucman S., Flament C., Caignard
A., Messaoudene M., Aupérin A., Vielh P., Dessen
P., Porta C., Mateus C., Ayyoub M., Valmori D.,
Eggermont A., Robert C., and Zitvogel L. Regulation
of CD4+NKG2D+ Th1 cells in patients with
metastatic melanoma treated with sorafenib: Role
of IL-15R& and NKG2D triggering. [2014] Cancer
266. R
oswall N., Freisling H., Bueno-de-Mesquita H.B.,
Ros M., Christensen J., Overvad K., Boutron-Ruault
M.C., Severi G., Fagherazzi G., Chang-Claude J.,
Kaaks R., Steffen A., Boeing H., Arguelles M., Agudo
A., Sanchez M.J., Chirlaque M.D., Barricarte Gurrea
A., Amiano P., Wareham N., Khaw K.T., Bradbury
K.E., Trichopoulou A., Papatesta H.M., Trichopoulos
D., Palli D., Pala V., Tumino R., Sacerdote C.,
Mattiello A., Peeters P.H., Ehrnstrom R., Brennan P.,
45
Ferrari P., Ljungberg B., Norat T., Gunter M., Riboli
E., Weiderpass E., and Halkjaer J. Anthropometric
measures and bladder cancer risk: A prospective
study in the EPIC cohort. [2014] International
Journal of Cancer (135) 12 : 2918-2929. Impact
factor : 5.085
267. R
othé F., Laes J.F., Lambrechts D., Smeets D.,
Vincent D., Maetens M., Fumagalli D., Michiels S.,
Drisis S., Moerman C., Detiffe J.P., Larsimont D.,
Awada A., Piccart M., Sotiriou C., and Ignatiadis M.
Plasma circulating tumor DNA as an alternative
to metastatic biopsies for mutational analysis in
breast cancer. [2014] Annals of Oncology (25) 10 :
1959-1965. Impact factor : 7.040
268. R
otolo F., Dunant A., Le Chevalier T., Pignon
J.P., and Arriagada R. Adjuvant cisplatin-based
chemotherapy in nonsmall-cell lung cancer:
new insights into the effect on failure type via a
multistate approach. [2014] Annals of Oncology
(25) 11 : 2162-2166. Impact factor : 7.040
269. R
oura E., Castellsague X., Pawlita M., Travier N.,
Waterboer T., Margall N., Xavier Bosch F., de Sanjose
S., Dillner J., Gram I.T., Tjonneland A., Munk C.,
Pala V., Palli D., Khaw K.T., Barnabas R.V., Overvad
K., Clavel-Chapelon F., Boutron-Ruault M.C.,
Fagherazzi G., Kaaks R., Lukanova A., Steffen A.,
Trichopoulou A., Trichopoulos D., Klinaki E., Tumino
R., Sacerdote C., Panico S., Bueno-de-Mesquita
H.B., Peeters P.H., Lund E., Weiderpass E., Luisa
Redondo M., Sanchez M.J., Tormo M.J., Barricarte
A., Larranaga N., Ekstrom J., Hortlund M., Lindquist
D., Wareham N., Travis R.C., Rinaldi S., Tommasino
M., Franceschi S., and Riboli E. Smoking as a major
risk factor for cervical cancer and pre-cancer:
Results from the EPIC cohort. [2014] International
Journal of Cancer (135) 2 : 453-466. Impact factor
: 5.085
270. R
uckenstuhl C., Netzberger C., Entfellner I.,
Carmona-Gutierrez D., Kickenweiz T., Stekovic S.,
Gleixner C., Schmid C., Klug L., Sorgo A.G., Eisenberg
T., Buttner S., Marino G., Koziel R., Jansen-Durr P.,
Fröhlich K.U., Kroemer G., and Madeo F. Lifespan
extension by methionine restriction requires
autophagy-dependent
vacuolar
acidification.
[2014] PLoS genetics (10) 5 : e1004347-e1004347.
271. S
anda N., Heran F., Daly-Schveitzer N., Sahel J.A., and
Safran A.B. Increased Optic Nerve Radiosensitivity
Following Optic Neuritis. [2014] Neurology (82) 16 :
1474-1475. Impact factor : 8.286
272. S
chadendorf D., Amonkar M.M., Milhem M.,
Grotzinger K., Demidov L.V., Rutkowski P., Garbe
C., Dummer R., Hassel J.C., Wolter P., Mohr P.,
Trefzer U., Lefeuvre-Plesse C., Rutten A., Steven N.,
Ullenhag G., Sherman L., Wu F.S., Patel K., Casey
M., and Robert C. Functional and symptom impact
of trametinib versus chemotherapy in BRAF V600E
advanced or metastatic melanoma: Quality-of-life
analyses of the METRIC study. [2014] Annals of
273. S
chlumberger M., Brose M., Elisei R., Leboulleux
S., Luster M., Pitoia F., and Pacini F. Definition
and management of radioactive iodine-refractory
differentiated thyroid cancer.
[2014] Lancet
Diabetes & Endocrinology (2) 5 : 356-358. Impact
factor : 9.185
274. S
chrey D., Malietzis G., Chi S., Dufour C., LafayCousin L., Marshall L., Carceller F., Moreno L., and
Zacharoulis S. Impact Of High Dose Chemotherapy
On Survival Of Newly Diagnosed Patients With
Atypical Teratoid Rhabdoid Tumour (ATRT) - A
Systematic Review And Re-Analysis Of Multimodal
Therapy. [2014] Neuro-Oncology (16) Suppl.1 : i4i4. Impact factor : 5.562
275. S
culier J.P., Besse B., and Van Schil P. Challenges
and controversies in thoracic oncology: A new ERJ
series. [2014] European Respiratory Journal (43) 6
: 1571-1572. Impact factor : 7.636
276. S
elle F., Wittnebel S., Biron P., Gravis G., Roubaud G.,
Bui B.N., Delva R., Bay J.O., Flechon A., Geoffrois L.,
Caty A., Soares D.G., de Revel T., Fizazi K., Gligorov
J., Micléa J.M., Dubot C., Provent S., Temby I., Gaulet
M., Horn E., Brindel I., and Lotz J.P. A phase II trial
of high-dose chemotherapy (HDCT) supported by
hematopoietic stem-cell transplantation (HSCT) in
46
germ-cell tumors (GCTs) patients failing cisplatinbased chemotherapy: The multicentric TAXIF II
study. [2014] Annals of Oncology (25) 9 : 1775-1782.
277. S
emeraro M. and Galluzzi L. Novel insights into
the mechanism of action of lenalidomide. [2014]
factor : 6.266
278. S
enovilla L., Aranda F., Galluzzi L., and Kroemer
G. Impact of myeloid cells on the efficacy of
anticancer chemotherapy. [2014] Current Opinion
in Immunology (30) : 24-31. Impact factor : 7.478
279. S
iegfried A., Bertozzi A.I., Sevely A., Loukh N.,
Munzer C., Miquel C., Bourdeaut F., Pietsch T.,
Dufour C., and Delisle M.B. Desmoplastic/Nodular
Medulloblastoma
And
Hit-SKK
Treatment.
Clinicopathological Data From A French Series.
[2014] Neuro-Oncology (16) Suppl.1 : i76-i76.
280. S
oares M., Toffart A.-C., Timsit J.-F., Burghi G.,
Irrazabal C., Pattison N., Tobar E., Almeida B.F.C.,
Silva U.V.A., Azevedo L.C.P., Rabbat A., Lamer C.,
Parrot A., Souza-Dantas V.C., Wallet F., Blot F.,
Bourdin G., Piras C., Delemazure J., Durand M.,
Tejera D., Salluh J.I.F., Azoulay E., and Care L.C.C.
Intensive care in patients with lung cancer: a
multinational study. [2014] Annals of Oncology (25)
9 : 1829-1835. Impact factor : 7.040
281. S
oria J.C. Annals of Oncology: an editorial
perspective. [2014] Annals of Oncology (25) 1 : 5-6.
282. S
ourisseau T., Hassan K.A., Wistuba I., PenaultLlorca F., Adam J., Deutsch E., and Soria J.C. Lung
Cancer Stem Cell Fancy Conceptual Model of
Tumor Biology or Cornerstone of a Forthcoming
Therapeutic Breakthrough? [2014] Journal of
Thoracic Oncology (9) 1 : 7-17. Impact factor : 5.282
283. S
teins Bisschop C.N., van Gils C.H., Emaus M.J.,
Bueno-de-Mesquita H.B., Monninkhof E.M., Boeing
H., Aleksandrova K., Jenab M., Norat T., Riboli E.,
Boutron-Ruault M.C., Fagherazzi G., Racine A., Palli
D., Krogh V., Tumino R., Naccarati A., Mattiello A.,
Arguelles M.V., Sanchez M.J., Tormo M.J., Ardanaz
E., Dorronsoro M., Bonet C., Khaw K.T., Key T.,
Trichopoulou A., Orfanos P., Naska A., Kaaks R.R.,
Lukanova A., Pischon T., Ljuslinder I., Jirström K.,
Ohlsson B., Overvad K., Landsvig Berentzen T.,
Halkjaer J., Tjonneland A., Weiderpass E., Skeie G.,
Braaten T., Siersema P.D., Freisling H., Ferrari P.,
Peeters P.H.M., May A.M., Bisschop C.N.S., Vicente
Argueeles M., Jose Sanchez M., Jose Tormo M.,
Jirstrom K., and Berentzen T.L. Weight change
later in life and colon and rectal cancer risk in
participants in the EPIC-PANACEA study. [2014]
American Journal of Clinical Nutrition (99) 1 : 139147. Impact factor : 6.770
284. S
ternberg C.N., De Bono J.S., Chi K.N., Fizazi K.,
Mulders P., Cerbone L., Hirmand M., Forer D., and
Scher H.I. Improved outcomes in elderly patients
cancer treated with the androgen receptor inhibitor
enzalutamide: results from the phase III AFFIRM
trial. [2014] Annals of Oncology (25) 2 : 429-434.
285. S
toll G., Enot D., Mlecnik B., Galon J., Zitvogel L.,
and Kroemer G. Immune-related gene signatures
predict the outcome of neoadjuvant chemotherapy.
[2014] OncoImmunology (3) 3 : e27884-e27884.
286. S
ukkurwala A.Q., Martins I., Wang Y., Schlemmer
F., Ruckenstuhl C., Durchschlag M., Michaud M.,
Senovilla L., Sistigu A., Ma Y., Vacchelli E., Sulpice
E., Gidrol X., Zitvogel L., Madeo F., Galluzzi L., Kepp
O., and Kroemer G. Immunogenic calreticulin
exposure occurs through a phylogenetically
conserved stress pathway involving the chemokine
CXCL8. [2014] Cell death and differentiation (21) 1 :
287. S
ukkurwala A.Q., Adjemian S., Senovilla L., Michaud
M., Spaggiari S., Vacchelli E., Baracco E.E., Galluzzi
L., Zitvogel L., Kepp O., and Kroemer G. Screening
of novel immunogenic cell death inducers
within the NCI Mechanistic Diversity Set. [2014]
OncoImmunology (3). Impact factor : 6.266
47
288. T
alhaoui I., Couve S., Gros L., Ishchenko A.A.,
Matkarimov B., and Saparbaev M.K. Aberrant
repair initiated by mismatch-specific thymineDNA glycosylases provides a mechanism for the
mutational bias observed in CpG islands. [2014]
Nucleic Acids Research (42) 10 : 6300-6313. Impact
factor : 9.112
289. T
hibault C., Fizazi K., Barrios D., Massard C., Albiges
L., Baumert, Patard J.J., Escudier B., and Loriot Y.
Compliance with guidelines and correlation with
outcome in patients with advanced germ-cell
tumours. [2014] European Journal of Cancer (50) 7
: 1284-1290. Impact factor : 5.417
290. T
ikk K., Sookthai D., Johnson T., Rinaldi S., Romieu I.,
Tjonneland A., Olsen A., Overvad K., Clavel-Chapelon
F., Baglietto L., Boeing H., Trichopoulou A., Lagiou P.,
Trichopoulos D., Palli D., Pala V., Tumino R., Rosso
S., Panico S., Agudo A., Menendez V., Sanchez M.-J.,
Amiano P., Huerta Castano J.M., Ardanaz E., Buenode-Mesquita H.B., Monninkhof E., Onland-Moret C.,
Andersson A., Sund M., Weiderpass E., Khaw K.-T.,
Key T.J., Travis R.C., Gunter M.J., Riboli E., Dossus
L., and Kaaks R. Circulating prolactin and breast
cancer risk among pre- and postmenopausal
women in the EPIC cohort. [2014] Annals of
291. T
oulmonde M., Bonvalot S., Ray-Coquard I., Stoeckle
E., Riou O., Isambert N., Bompas E., Penel N.,
Delcambre-Lair C., Saada E., Lecesne A., Le Péchoux
C., Blay J.Y., Piperno-Neumann S., Chevreau C.,
Bay J.O., Brouste V., Terrier P., Ranchère-Vince
D., Neuville A., and Italiano A. Retroperitoneal
sarcomas: Patterns of care in advanced stages,
prognostic factors and focus on main histological
subtypes: A multicenter analysis of the French
Sarcoma Group. [2014] Annals of Oncology (25) 3 :
292. T
oulmonde M., Bonvalot S., Méeus P., Stoeckle E., Riou
O., Isambert N., Bompas E., Jafari M., DelcambreLair C., Saada E., Le Cesne A., Le Péchoux C., Blay
J.Y., Piperno-Neumann S., Chevreau C., Bay J.O.,
Brouste V., Terrier P., Ranchère-Vince D., Neuville A.,
and Italiano A. Retroperitoneal sarcomas: Patterns
of care at diagnosis, prognostic factors and focus on
main histological subtypes: A multicenter analysis
of the French Sarcoma Group. [2014] Annals of
293. T
ournier I., Marlin R., Walton K., Charbonnier F.,
Coutant S., Théry J.C., Charbonnier C., Spurrell
C., Vezain M., Ippolito L., Bougeard G., Roman H.,
Tinat J., Sabourin J.C., Stoppa-Lyonnet D., Caron
O., Bressac-De Paillerets B., Vaur D., King M.C.,
Harrison C., and Frebourg T. Germline mutations of
inhibins in early-onset ovarian epithelial tumors.
[2014] Human Mutation (35) 3 : 294-297. Impact
factor : 5.144
294. T
rocoli A., Bensadoun P., Richard E., Labrunie G.,
Merhi F., Schlaaefli A.M., Brigger D., Souquere
S., Pierron G., Pasquet J.M., Soubeyran P.,
Reiffers J., Ségal-Bendirdjian E., Tschan M.P., and
Djavaheri-Mergny M. p62/SQSTM1 upregulation
constitutes a survival mechanism that occurs
during granulocytic differentiation of acute
myeloid leukemia cells. [2014] Cell death and
differentiation (21) 12 : 1852-1861. Impact factor
: 8.184
295. T
rouilloud I., Dupont-Gossard A.C., Malka D.,
Artru P., Gauthier M., Lecomte T., Aparicio T.,
Thirot-Bidault A., Lobry C., Asnacios A., ManetLacombe S., Fein F., Dubreuil O., Landi B., Zaanan
A., Bonnetain F., and Taïeb J. Fixed-dose rate
gemcitabine alone or alternating with FOLFIRI.3
(irinotecan, leucovorin and fluorouracil) in the
first-line treatment of patients with metastatic
pancreatic adenocarcinoma: an AGEO randomised
phase II study (FIRGEM). [2014] European Journal
of Cancer (50) 18 : 3116-3124. Impact factor :
5.417
296. T
ruffaux N., Philippe C., Paulsson J., Andreiuolo
F., Guerrini-Rousseau L., Cornilleau G., Le Dret L.,
Richon C., Lacroix L., Puget S., Geoerger B., Vassal
G., Ostman A., and Grill J. Preclinical evaluation
of dasatinib alone and in combination with
cabozantinib for the treatment of diffuse intrinsic
pontine glioma. [2014] Neuro-Oncology (16) supplt
1 - HG-061 : 55-55. Impact factor : 5.562
48
297. T
selikas L., Souillard-Scemama R., Naggara O.,
Mellerio C., Varlet P., Dezamis E., Domont J.,
Dhermain F., Devaux B., Chrétien F., Meder J.F.,
Pallud J., and Oppenheim C. Imaging of gliomas
at 1.5 and 3 Tesla - A comparative study. [2014]
Neuro-Oncology. Impact factor : 5.562
298. T
ufo G., Jones A.W.E., Wang Z., Hamelin J.,
Tajeddine N., Esposti D.D., Martel C., Boursier
C., Gallerne C., Migdal C., Lemaire C., Szabadkai
G., Lemoine A., Kroemer G., and Brenner C. The
protein disulfide isomerases PDIA4 and PDIA6
mediate resistance to cisplatin-induced cell death
in lung adenocarcinoma. [2014] Cell death and
differentiation (21) 5 : 685-695. Impact factor :
8.184
299. U
zan C., Nikpayam M., Ribassin-Majed L., Gouy S.,
Bendifallah S., Cortez A., Rey A., Duvillard P., Darai
E., and Morice P. Influence of histological subtypes
on the risk of an invasive recurrence in a large
series of stage I borderline ovarian tumor including
191 conservative treatments. [2014] Annals of
300. U
zan C., Muller E., Kane A., Rey A., Gouy S.,
Bendiffallah S., Duvillard P., Fauvet R., Darai E., and
Morice P. Prognostic factors for recurrence after
conservative treatment in a series of 119 patients
with stage I serous borderline tumors of the ovary.
factor : 7.040
301. V
acchelli E., Aranda F., Eggermont A., Galon
J., Sautes-Fridman C., Zitvogel L., Kroemer G.,
and Galluzzi L. Trial Watch Tumor-targeting
monoclonal antibodies in cancer therapy. [2014]
factor : 6.266
302. V
acchelli E., Aranda F., Eggermont A., Galon J.,
Sautes-Fridman C., Cremer I., Zitvogel L., Kroemer
G., and Galluzzi L. Trial Watch Chemotherapy
with immunogenic cell death inducers. [2014]
factor : 6.266
303. V
acchelli E., Aranda F., Eggermont A., SautèsFridman C., Tartour E., Kennedy E.P., Platten
M., Zitvogel L., Kroemer G., and Galluzzi L. Trial
watch: IDO inhibitors in cancer therapy. [2014]
OncoImmunology
(3) 10 : e957994-e957994.
304. V
acchelli E., Aranda F., Obrist F., Eggermont A., Galon
J., Cremer I., Zitvogel L., Kroemer G., and Galluzzi L.
Trial watch Immunostimulatory cytokines in cancer
therapy. [2014] OncoImmunology (3). Impact factor
: 6.266
305. V
alent A., Mathieu M.C., Bernheim A., Arnould L.,
MacGrogan G., Guinebretiere J.M., Chibon F., PenaultLlorca F., and Lacroix-Triki M. Genetic Analysis
of HER2 Equivocal Heterogeneous Tumors: How
Genetic Categories Can Help in the Final Decision
for HER2 Gene Status? [2014] Modern Pathology
(27) S2 : 85A-86A. Impact factor : 6.187
306. V
an Broekhoven D.L.M., Deroose J.P., Bonvalot S.,
Gronchi A., Grünhagen D.J., Eggermont A.M.M., and
Verhoef C. Isolated limb perfusion using tumour
necrosis factor & and melphalan in patients with
advanced aggressive fibromatosis. [2014] British
Journal of Surgery (101) 13 : 1674-1680. Impact
factor : 5.542
307. v an der Ploeg A.P.T., van Akkooi A.C.J., Haydu L.E.,
Scolyer R.A., Murali R., Verhoef C., Thompson J.F.,
and Eggermont A.M.M. The prognostic significance
of sentinel node tumour burden in melanoma
patients: An international, multicenter study of 1539
sentinel node-positive melanoma patients. [2014]
factor : 5.417
308. V
annucchi A.M., Heidel F.H., Ribrag V., Kiladjian J.J.,
Passamonti F., Hayat A., Conneally E., Kindler T.,
Martino B., Lipka D.B., Acharyya S., Gopalakrishna P.,
Loechner S., Mu S., and Harrison C.N. Ruxolitinib Plus
Panoninostat In Patients With Primary Myelofibrosis,
Post-Polycythemia Vera Myelofibrosis Or PostEssential Thrombocythemia Myelofibrosis: A Phase
1B Dose-Finding Study. [2014] Haematologica (99)
S1 : 129-130. Impact factor : 5.814
49
309. V
ansteenkiste J., Crino L., Dooms C., Douillard J.Y.,
Faivre-Finn C., Lim E., Rocco G., Senan S., Van Schil
P., Veronesi G., Stahel R., Peters S., Felip E., Kerr K.,
Besse B., Eberhardt W., Edelman M., Mok T., O’Byrne
K., Novello S., Bubendorf L., Marchetti A., Baas P.,
Reck M., Syrigos K., Paz-Ares L., Smit E., Meldgaard
P., Adjei A., Nicolson M., Weder W., de Ruysscher D.,
Le Pechoux C., de Leyn P., and Westeel V. 2nd ESMO
consensus conference on lung cancer: Earlystage non-small-cell lung cancer consensus on
diagnosis, treatment and follow-up. [2014] Annals
of Oncology (25) 8 : 1462-1474. Impact factor : 7.040
310. V
asen H.F.A., Ghorbanoghli Z., Bourdeaut F.,
Cabaret O., Caron O., Duval A., Entz-Werle N.,
Goldberg Y., Ilencikova D., Kratz C.P., Lavoine
N., Loeffen J., F.H.m M., Muleris M., Sebille G.,
Colas C., Burkhardt B., Brugières L., and Wimmer
K. Guidelines for surveillance of individuals
with constitutional mismatch repair-deficiency
proposed by the European Consortium «Care for
CMMR-D»(C4CMMR-D). [2014] Journal of Medical
311. V
erlingue L., Koscielny S., and Ferte C. Should we resist
to including tumour growth patterns in Response
Evaluation Criteria in Solid Tumours evaluation?
(Response to Litiere et al.). [2014] European Journal
312. V
iaud S., Daillère R., Boneca I.G., Lepage P., Pittet M.J.,
Ghiringhelli F., Trinchieri G., Goldszmid R., and Zitvogel
L. Harnessing the intestinal microbiome for optimal
therapeutic immunomodulation. [2014] Cancer
313. V
iaud S., Daillere R., Yamazaki T., Lepage P., Boneca
I., Goldszmid R., Trinchieri G., and Zitvogel L. Why
should we need the gut microbiota to respond to
cancer therapies? [2014] OncoImmunology (3) 1 :
e27574-e27574. Impact factor : 6.266
314. V
icier C., Dieci M.V., Arnedos M., Delaloge S., Viens P.,
and Andre F. Clinical development of mTOR inhibitors
in breast cancer. [2014] Breast Cancer Research (16)
1. Impact factor : 5.490
315. V
oit C.A., Gooskens S.L.M., Siegel P., Schaefer G.,
Schoengen A., Röwert J., van Akkooi A.C.J., and
Eggermont A.M.M. Ultrasound-guided fine needle
aspiration cytology as an addendum to sentinel
lymph node biopsy can perfect the staging strategy
in melanoma patients. [2014] European Journal of
316. v on Hoff K., Pizer B., Dufour C., van Vuurden D.G.,
Garami M., Massimino M., Fangusaro J., Davidson
T.B., da Costa M.J., Sterba J., Benesch M., Gerber
N.U., Mynarek M., Kwiecien R., Clifford S.C.,
Kool M., Pietsch T., Finlay J.L., and Rutkowski S.
Prognostic Factors In Childhood CNS-PNET And
Pineoblastoma: An International Meta-Analysis Of
Original Clinical Data. [2014] Neuro-Oncology (16)
S1 : i91-i91. Impact factor : 5.562
317. W
ang M., Beelen R., Stafoggia M., Raaschou-Nielsen
O., Andersen Z.J., Hoffmann B., Fischer P., Houthuijs
D., Nieuwenhuijsen M., Weinmayr G., Vineis P., Xun
W.W., Dimakopoulou K., Samoli E., Laatikainen T.,
Lanki T., Turunen A.W., Oftedal B., Schwarze P.,
Aamodt G., Penell J., De Faire U., Korek M., Leander
K., Pershagen G., Pedersen N.L., Ostenson C.G.,
Fratiglioni L., Eriksen K.T., Sorensen M., Tjonneland
A., Bueno-de-Mesquita B., Eeftens M., Bots M.L.,
Meliefste K., Kraemer U., Heinrich J., Sugiri D.,
Key T., de Hoogh K., Wolf K., Peters A., Cyrys J.,
Jaensch A., Concin H., Nagel G., Tsai M.Y., Phuleria
H., Ineichen A., Kuenzli N., Probst-Hensch N.,
Schaffner E., Vilier A., Clavel-Chapelon F., Declerq
C., Ricceri F., Sacerdote C., Marcon A., Galassi
C., Migliore E., Ranzi A., Cesaroni G., Badaloni C.,
Forastiere F., Katsoulis M., Trichopoulou A., Keuken
M., Jedynska A., Kooter I.M., Kukkonen J., Sokhi
R.S., Brunekreef B., Katsouyanni K., and Hoek G.
Long-term exposure to elemental constituents of
particulate matter and cardiovascular mortality
in 19 European cohorts: Results from the ESCAPE
and TRANSPHORM projects. [2014] Environment
International (66) : 97-106. Impact factor : 5.559
318. W
etzler M., Mrozek K., Kohlschmidt J., Dombret H.,
Dôhner H., Pilorge S., Krug U., Carroll A.J., Larson
R.A., Marcucci G., Hiddemann W., Büchner T., and
Bloomfield C.D. Intensive induction is effective in
selected octogenarian acute myeloid leukemia
50
patients: Prognostic significance of karyotype and
selected molecular markers used in the European
LeukemiaNet classification. [2014] Haematologica
(99) 2 : 308-313. Impact factor : 5.814
319. W
idmer N., Bardin C., Chatelut E., Paci A., Beijnen
J., Levêque D., Veal G., and Astier A. Review of
therapeutic drug monitoring of anticancer drugs
part two--targeted therapies. [2014] European
Journal of Cancer (50) 12 : 2020-2036. Impact
factor : 5.417
320. W
ilhelm T., Magdalou I., Barascu A., Techer H.,
Debatisse M., and Lopez B.S. Spontaneous slow
replication fork progression elicits mitosis
alterations in homologous recombination-deficient
mammalian cells. [2014] Proceedings of the
National Academy of Sciences of the United States
of America (111) 2 : 763-768. Impact factor : 9.674
321. W
immer K., Kratz C.P., Vasen H.F., Caron O., Colas C.,
Entz-Werle N., Gerdes A.M., Goldberg Y., Ilencikova
D., Muleris M., Duval A., Lavoine N., Ruiz-Ponte C.,
Slavc I., Burkhardt B., and Brugières L. Diagnostic
criteria for constitutional mismatch repair
deficiency syndrome: Suggestions of the European
consortium ‘Care for CMMRD’ (C4CMMRD). [2014]
Journal of Medical Genetics (51) 6 : 355-365. Impact
factor : 6.335
322. X
haard C., Rubino C., Cléro E., Maillard S., Ren Y.,
Borson-Chazot F., Sassolas G., Schvartz C., Colonna
M., Lacour B., Danzon A., Velten M., Buemi A.,
Bailly L., Barjoan E.M., Schlumberger M., Orgiazzi
J., Adjadj E., and De Vathaire F. Menstrual and
reproductive factors in the risk of differentiated
thyroid carcinoma in young women in France:
A population-based case-control study. [2014]
American Journal of Epidemiology (180) 10 : 10071017. Impact factor : 5.230
323. Y amazaki T., Hannani D., Poirier-Colame V., Ladoire
S., Locher C., Sistigu A., Prada N., Adjemian
S., Catani J.P.P., Freudenberg M., Galanos C.,
André F., Kroemer G., and Zitvogel L. Defective
immunogenic cell death of HMGB1-deficient
tumors: compensatory therapy with TLR4 agonists.
[2014] Cell death and differentiation (21) 1 : 69-78.
324. Z
amora-Ros R., Lujan-Barroso L., Bueno-deMesquita H.B., Dik V.K., Boeing H., Steffen A.,
Tjonneland A., Olsen A., Bech B.H., Overvad K.,
Boutron-Ruault M.C., Racine A., Fagherazzi G., Kuhn
T., Katzke V., Trichopoulou A., Lagiou P., Trichopoulos
D., Tumino R., Panico S., Vineis P., Grioni S., Palli D.,
Weiderpass E., Skeie G., Maria Huerta J., Sanchez
M.J., Arguelles M., Amiano P., Ardanaz E., Nilsson
L., Wallner B., Lindkvist B., Wallstrom P., Peeters
P.H.M., Key T.J., Khaw K.T., Wareham N.J., Freisling
H., Stepien M., Ferrari P., Gunter M.J., Murphy
N., Riboli E., and Gonzalez C.A. Tea and coffee
consumption and risk of esophageal cancer: The
European prospective investigation into cancer
and nutrition study. [2014] International Journal of
/ GUSTAVE ROUSSY
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
www.gustaveroussy.fr

rapport annuel - les annexes

Transcription

Similar documents

omnicanalita` e mercato del lavoro

e,iurt£.e,u aaii) aan) iAia JAOL m

Front Matter

donor report - American-Italian Cancer Foundation

ZEBs impact on the energy system

TUMOR LAMBUNG

Immunotherapy meets Lung Cancer: New treatments for

DeFlora - Tumori_professionali

Donor Report - American-Italian Cancer Foundation

Trattamento delle metastasi ossee

Diapositiva 1

ROAD MAP PILOT PROJECT PENGEMBANGAN INDUSTRI OBAT

Proposta di linee guida per la valutazione di